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Abstract
Magnetic nanoparticles are effective in a range of biomedical applications including mag-
netic resonance imaging (MRI) contrast enhancement. The efficacy of nanoparticles as
contrast agents depends mainly on the surface chemistry and magnetic properties of the
particles, with a large magnetic moment inducing efficient transverse (T2) relaxation of
protons. This results in improved negative enhancement of MRI contrast on T2 weighted
sequences. Iron oxide nanoparticles (FeOx NPs) have been used in MRI for 20 years and
are the only commercially available T2 contrast agents. A significantly larger magnetic
moment can potentially be achieved with iron nanoparticles (Fe NPs), but development
has been hampered by difficulty in preparing stable particles. In this study, stable Fe NP
were prepared by a novel, simple, synthesis and compared with FeOx NP as T2 contrast
agents in a range of MRI-based biomedical applications.
The effectiveness of Fe NPs versus FeOx NPs to negatively enhance MRI contrast on
T2 weighted sequences was first examined in vitro. The Fe NPs and FeOx NPs were
characterised by electron microscopy and found to be of similar size (16nm). The Fe NPs
possessed a core of highly magnetic α-Fe inside a 3nm shell of FeOx of the same crystal
structure as the pure FeOx NPs. Both types of NP were coated with the same molecule,
DMSA, to produce aqueous dispersions with similar hydrodynamic particle sizes and
pharmacokinetics. When dispersed in gels and examined by MRI, the Fe NPs were found
to produce more than twice the amount of T2 contrast change per unit concentration
relative to FeOx NPs. When cells were labelled in vitro, Fe NPs produced greater T2
contrast enhancement in all cell types tested, whilst there was no significant difference in
the uptake of iron or the cytotoxicity between cells labelled with Fe or FeOx NPs.
To assess the clinical applicability of the nanoparticles in vivo, FeOx NPs and Fe NPs
were administered to mice and MRI experiments were performed at 1.5 T. Contrast ef-
fects of the NPs were examined in the liver, spleen and lymph nodes, as tissues in these
organs are rich in phagocytic cells and have a strong tendency to take up circulating
NPs. In all three organs studied, the Fe NPs produced noticeably darker contrast than
the FeOx NPs, providing twice the contrast improvement.
One of the most intensely researched applications of magnetic nanoparticles in MRI is
improving detection of cancer in the lymph nodes. To model the size and NP uptake of
small lymph node metastases in humans, a mouse model was developed by injecting 4T1
breast cancer cells directly into the mouse spleen. Analysis of mice bearing 4T1 tumours
performed at 1.5 T showed that Fe NPs produced better contrast than FeOx NPs and
improved the detection of small tumours in the spleen as determined by two blinded
radiologists. Indeed, the heightened sensitivity and specificity improved the threshold of
cancer detection on previous studies performed at 1.5 T.
It was then examined whether the improved T2 contrast could enable new MRI appli-
cations in vivo. A novel assay to detect induced immune responses following dendritic
cell-based vaccination using MRI was developed. By tracking cells labelled with iron
nanoparticles, a difference in contrast could be detected between nave mice and those
that had developed a strong immune response after vaccination. This assay only reached
statistical significance with Fe NPs and not with FeOx NPs.
As a consequence of these studies, another MRI-based technique for assessing induction
of an immune response was developed, based on the simple observation that lymph nodes
draining the injection site became enlarged. This enlargement was seen as early as 12
hours after vaccination and was caused by a cellular infiltrate dominated by lymphoid
cells. In experiments where vaccination was performed multiple times using different tu-
mours as a source of antigen, incremental increases in lymph node size were detectable
by MRI, which was shown to be a highly antigen-specific response. In the vaccine model
studied, the increase in lymph node size was associated with protection from a tumour
challenge.
Thus, Fe NPs produce a significant improvement of T2 contrast over FeOx NPs in a range
of applications without any differences found in uptake or cytotoxicity. These findings
are substantial enough to justify further investigations into the application of Fe NPs in
a variety of clinical settings.
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Chapter 1
General introduction
Magnetic Resonance Imaging (MRI) is a powerful and versatile technique that has pro-
duced significant benefits for medical imaging. It has several key advantages over other
imaging modalities. In contrast to computed tomography and positron emission tomogra-
phy, MRI produces excellent soft-tissue contrast resolution without exposing the patient
to ionizing radiation1–3. Unlike ultrasound or fluorescent imaging techniques, MRI can
be used effectively to assess deep tissues4–6. Several biomedical applications of MRI can
be further improved with the use of magnetic nanoparticles (NPs) as contrast agents.
These include imaging small tumors in the liver and lymph nodes and tracking cells in
vivo. Improving cancer imaging can result in more effective clinical treatment whereas
enhanced cell tracking can lead to advances in emerging cellular therapies, such as cancer
immunotherapy with cell-based vaccines.
This chapter introduces the key concepts involved in producing a diagnostic image with
MRI and how this can be improved with the use of magnetic NPs as contrast agents.
The clinical applications of magnetic NPs are reviewed followed by a basic introduction
to the principles of cancer immunotherapy with cell-based vaccines. These concepts form
the foundation of the experimental work presented in this thesis.
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1.1 Basic principles of nuclear magnetic
resonance
The basic principles of nuclear magnetic resonance (NMR) have been well covered in
the scientific literature and several excellent sources were used in the preparation of this
chapter7–11. The purpose of this section is to provide the non-specialist with an
introduction to the principles of NMR, which underpin the magnetic resonance imaging
(MRI) experiments described in this thesis. This section covers the key concepts of how
an NMR response can be produced and manipulated such that information collected
from the response can be used to generate an image. Different tissues and pathology
can be distinguished with MRI contrast, which can be improved with the use of
contrast agents.
1.1.1 Nuclear spin and the Zeeman interaction
Atomic nuclei possess an intrinsic, quantum mechanical property called spin7. Nuclear
spin angular momentum ml is quantised and is related to the nuclear magnetic moment
µ by the magnetogyric ratio γ:
µ = γ~ml (Equation 1)
where ~ is the modified Plancks constant h
2pi
. The 1H nucleus is often termed a proton
as it consists of just a single proton. Protons have a positive magnetogyric ratio, which
means that the direction of their spin angular momentum and magnetic moment are the
same. The vast majority of imaging experiments are done with protons because they
produce the best signal to noise ratio. This is due to their large magnetogyric ratio and
natural abundance both as an isotope (nearly 100%)12 and in water molecules in
biological tissue (human adults are up to 60% water by mass). Although an increasing
amount of MRI research is performed on atomic nuclei other than 1H (such as 23Na, 31P
and 19F), discussion of other nuclei is beyond the scope of this thesis.
In the absence of an applied magnetic field, the proton spins in a sample are randomly
oriented in all directions and no energy difference exists between different orientations.
When an external magnetic field (B0) is applied, there are two important effects on the
nuclear spins in a sample. Firstly, a difference is created between the two allowed energy
states of those spins that are aligned parallel and those that are aligned antiparallel to
the direction of B0. Quantum mechanics has determined that the projection of the spin
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Figure 1.1: Zeeman splitting. Before an external magnetic field B0 is applied, the
directions of the magnetic dipole moments of the nuclear spins have an isotropic distribu-
tion (a). After B0 is applied (b), the proton spins precess at their Larmor frequency and
there is net spin polarisation in the direction of B0 with the population of aligned spins
exaggerated for illustration. The application of B0 splits the two different spin states
(ml = ±12) into two different energy levels (c).




. The splitting of these energy states is called Zeeman splitting and is
illustrated in Figure 1-1. The second important effect is that the nuclear spins precess
about the axis of the applied field, B0, at a frequency relative to the strength of B0 and
the magnetogyric ratio γ of the nuclei. The Larmor equation defines this relationship:
∆E = γ~B0 = hνL (Equation 2)
∆E is the difference between in energy between the two spin eigenstates and νL is the
frequency of precession, known as the Larmor frequency. The result is that the energy
state of the spin polarization can take only one of two discrete values for protons at a
given B0 (Figure 1-1).
The energy difference between the two spin alignments is small compared to thermal
energy even at large applied fields. For example, at 9.4T (the largest B0 employed in
this thesis), the difference in energy for a single 1H proton aligned with (ml = −12)
versus against (ml = +
1
2
) B0 is 2.5x10
−25J compared to the thermal energy available at
room temperature of 4.1x10−21J. As a result, at thermal equilibrium, there is a
fractional population difference between the spins that are aligned with B0 (and hence
at a lower energy state) and those that are aligned against it. At 9.4T there is
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approximately 0.007% excess in the populations of proton spins aligned with B0.
Although it is a relatively small proportion, the difference in the alignment of the
proton spin populations forms a net magnetisation vector aligned with B0, precessing at
the Larmor frequency. Manipulation of this nuclear magnetisation vector (NMV) is the
basis of NMR experiments. The remainder of this chapter uses a descriptive approach
with semiclassical mechanics, as opposed to quantum mechanics, to explain how
manipulation of the NMV results can produce an image.
1.1.2 Generation of the free induction decay
The nuclear magnetic vector (NMV) is difficult to detect at thermal equilibrium when it
is aligned along B0, as it is many orders of magnitude smaller than B0. However, the
NMV can be measured when it is disturbed away from its equilibrium orientation along
B0. An electromagnetic pulse applied perpendicular to B0 at the same frequency as the
frequency of precession (the Larmor frequency) can disturb the equilibrium and rotate
the NMV. This is a simple result of the torque felt by the NMV resulting from the
applied electromagnetic pulse.
The Larmor frequencies of protons at B0 fields used for imaging are in the
radio-frequency (RF) range. Therefore if an RF pulse is at the Larmor frequency and
perpendicular to B0, it can rotate the NMV towards the transverse plane. If the RF
pulse is of adequate strength and duration, the NMV can be rotated 90◦ so that it
precesses entirely in the transverse plane (Figure 1-2). Such an RF pulse is termed a
90◦ pulse. The precessing of the NMV in the transverse plane induces an electromotive
force, producing an electric current in an RF receiver coil. This signal known as free
induction decay (FID), is the measurable basis of NMR.
1.1.3 Relaxation processes cause decay of the MR signal
After the NMV is rotated into the transverse plane by a 90◦ RF pulse, the NMV loses
its transverse component and is restored to its original precession about B0. This is
caused by relaxation which indicates a return of the nuclear spins to thermal
equilibrium. In a non-homogenous sample, nuclear spins in different regions of a sample
may have different rates of relaxation according to their local environment. This is a
fundamental concept that is exploited in MRI to produce image contrast.
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Figure 1.2: Generation of the Free Induction Decay. The application of a 90◦ RF
pulse about the x-axis (B1) rotates the net magnetization of the spins into the transverse
plane (a) where they precess at their Larmor frequency (b). The rotating frame rotates
in the plane perpendicular to B0 at the Larmor frequency, so that the precession of the
NMV about B0 is not apparent (a). The laboratory frame represents the fixed space in
which the FID is recorded, and thus shows the precession of the NMV around B0 (b).
Over time, the magnetisation vector decays in the transverse plane (c), as shown in the
laboratory frame. The precession and decay can both be seen in the induced signal (d),
called the free induction decay (FID). Note that the rate of decay relative to the number
of precessions in the transverse plane has been exaggerated for illustrative purposes.
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As spins precess together, their magnetic fields interact which makes a slight change to
their rate of precession. These spin-spin interactions are temporary and random and
they result in a loss of phase coherence. This process is called transverse or T2
relaxation and it causes irreversible decay of the NMV in the transverse plane (Figure
1-2). The rate of T2 relaxation is dependent on the local environment of the proton
nuclei and is related to the NMR signal S at time t by:
S(t) = S0exp(−t/T2) (Equation 3)
S0 is the (maximum) signal at time= 0, immediately after the 90
◦ pulse is applied as
seen in Figure 1-3. The T2 time is when 63% (
1
e
) of the signal has decayed.
After removal of a 90◦ RF pulse, thermal equilibrium will be gradually restored and the
slight population surplus of nuclear spins aligned with B0 will be re-established. As this
happens, the NMV returns to its thermodynamic equilibrium along the z-axis in the
laboratory frame (Figure 1-2). This process is called longitudinal or T1 relaxation. The
effects of these relaxation processes on image contrast are discussed in section 1.1.8
below.
It has been shown in Equation 2 that the Larmor frequency of spin precession is
dependent on the strength of the applied magnetic field B0. B0 is never perfectly
homogenous which results in macroscopic variations in the magnetic field as experienced
by nuclear spins within the sample. Also non-homogeneous samples may have regions
with different magnetic susceptibility that also cause magnetic field variations
experienced by spins within the sample. The inhomogeneity in B0 and within the
sample causes nuclear spins to precess at different Larmor frequencies, which in turn
cause the NMV to lose coherence and its transverse magnetization to decay. This
process is called loss of spin coherence due to magnetic inhomogeneity and spin-spin
relaxation (T2*). T2* relaxation can be reversed by application of an RF pulse to rotate
the NMV by 180◦. After the 180◦ pulse is applied, the nuclear spins will come back into
coherence generating an echo signal in the RF receiver (Figure 1-3). The echo time is
the time between the application of the 90◦ pulse and the generation of an echo.
Further echoes can be generated by applying successive 180◦ pulses, one echo time
apart. T2 relaxation causes the signal in each successive echo to diminish. The basic
concept of this pulse sequence is called a spin echo and it often used to produce images
with T2 contrast that have not been degraded by T2* effects. All of the imaging
performed in this thesis incorporates the spin echo technique.
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Figure 1.3: T2 and T2* relaxation. As shown in the rotating frame, a 90
◦ pulse about
B1 brings the nuclear magnetization vector into the transverse plane (a). Due to magnetic
field inhomogeneity, different spins in the sample precess at different Larmor frequencies
in the transverse plane shown in the laboratory frame (b) higher frequencies in grey,
lower frequencies in black). This causes T2* decay of the FID (g). A 180
◦ pulse is applied
to flip the magnetisation vectors about the x-axis (c), which reverses the effects of the
magnetic field inhomogeneity (d,e) such that phase coherence occurs (e) and produces
an echo detectable in the transverse plane. Each successive echo has less signal and due
to irreversible T2 relaxation (g). The RF pulse sequence (f) is shown in synchrony with
the echoes produced (g).
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1.1.4 Image formation: slice selection
In the absence of externally applied magnetic field gradients, a 90◦ pulse will cause the
nuclear spins distributed across the whole sample to rotate into the transverse plane
and contribute to the FID. For imaging applications, it is often desirable to examine
only part of the sample. This can be done by selectively rotating the nuclear spins from
only a slice of the sample by applying a magnetic field gradient in combination with an
appropriate RF pulse.
If a homogenous magnetic field gradient is applied along the axis of B0, the nuclear
spins will experience a different magnetic field according to their position along the
axis. Therefore they will precess at a different Larmor frequency according to their
position along B0 (Figure 1-4). If an RF pulse is applied transverse to B0 in the
presence of such a gradient, only the proton spins in the sample that are precessing at
the same frequency as the RF pulse will be rotated towards the transverse plane. This
technique is called slice selection and is used to examine the NMV of select regions of
the sample according to their position along B0. The thickness of the slice is
determined by the bandwidth of the RF pulse and the strength of the magnetic field




Therefore to achieve selection of a thinner slice, a larger gradient can be applied or the
width of the RF bandwidth can be reduced.
1.1.5 Image formation: frequency and phase encoding
By the slice selection technique, the NMV from protons in the region of interest along
the B0 axis (defined as the z-axis by convention) can be rotated into the transverse
plane. After slice selection, if a magnetic field gradient is applied along one of the
transverse axes, such as the x axis, the frequency of the precessing spins will vary along
the x-axis according to position. An echo recorded whilst the gradient is applied will
contain information about the position of spins along the x-axis, as encoded by
frequency along the gradient (Figure 1-5). This is known as the read, or frequency
encoding gradient.
To produce a 2D image, information about spins along the y-axis is required. After a
90◦ slice selection pulse, a gradient is applied across the y-axis. Once the gradient is
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Figure 1.4: Slice selection by application of a magnetic field gradient. When
a magnetic field gradient is applied along the z-axis (a), proton spins in the sample will
precess at different Larmor frequencies νL corresponding to their position along the axis.
Regions of the sample can be selected by applying a 90◦ pulse at a frequency corresponding
to the region of interest along the z-axis (a). In this example, only spins in a slice in the
middle of the patient (grey rectangle) at z = 0 would be rotated into the transverse plane
by a 90◦ pulse at frequency νL (c). To select spins in a slice corresponding to the head or
the feet, a RF pulse of lower or higher frequency would be required, respectively. Note
that for a fixed bandwidth, increasing the strength of the gradient (G) would reduce the
slice thickness (Equation 4).
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removed the spins will return to precessing at the Larmor frequency but with a phase
shift relative to their position along the y-axis. This is known as the phase encoding
gradient. The echo is then recorded in the presence of the frequency encoding gradient
(along the x-axis). This sequence is repeated for a number of steps changing the
strength of the phase encoding gradient (along the y-axis) by the same increment each
time (Figure 1-5). The resulting data set contains a series of echoes containing
information about the nuclear spins in the sample according to their position in the
z-axis (slice selection), x-axis (frequency encoding) and y-axis (phase encoding). It is
important to note that MRI is completely flexible as to which method of encoding is
used along which axis. Many alternative strategies exist such as in 3D imaging where
no slice selection and three different phase encoding gradients or one frequency and two
phase encoding gradients can be used.
1.1.6 Image formation: Fourier transformation of k-space
How is a series of FIDs, generated under conditions such as those seen in Figure 1-5,
used to form an image? To convert the raw signal into an image, the recorded FIDs are
first converted into a digital signal and stored in a matrix, containing what is known as
k-space data. K-space is known as a reciprocal space because it maps directly to the
spin density ρ of the sample in real space, by a Fourier transform:
ρ(x, y) =
∫
S(kx, ky)exp[−i2pi(kxx+ kyy)]dkxdkx (Equation 5)
A Fourier transform is an operation that decomposes a signal into its complex
constituent frequencies with their respective amplitudes. Therefore, by performing a 2D
Fourier transform on k-space, an image is produced with the number of pixels
equivalent to the number of points acquired in k-space. In two dimensions, k-space has
two axes, kx and ky corresponding to the frequency encoding gradient (GF ) and the
phase encoding gradient (GP ) as follows:
kx = kF = (γGFn∆t)/2pi (Equation 6)
ky = kP = γ(Gmin +m∆GP )τ/2pi (Equation 7)
GF is the strength of the frequency encoding gradient, n is sample number along the kx
axis and ∆t is the sampling time (or reciprocal of the sampling frequency) of the FID as
the GF is applied. ∆GP is the difference between increments in the phase encoding
gradient, Gmin is the minimum strength of the phase encoding gradient, m is the sample
number along the ky axis and τ is the duration of the GP in a given direction along the
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Figure 1.5: Frequency and phase encoding. After slice selection, by application of
the Gz gradient during a 90
◦ pulse, frequency and phase encoding are performed to obtain
spatial information about the specimen along its x- and y- axis respectively. Frequency
encoding is performed by applying a constant gradient GF whilst recording the echo at n
intervals of increasing duration ∆t. Phase encoding is performed by varying the strength
of the GP gradient by m intervals, each applied once per echo for a fixed time period τ .
Note that n steps of ∆t are obtained for every echo, whereas for each step of GP , this
pulse sequence is repeated a total of m times.
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phase encoding axis. Figure 1-6 illustrates how the axes of k-space can be filled by
incrementing ∆t for each value of m in m∆GP .
There are two key properties of k space worth noting here. Firstly, every point in
k-space contains information from an FID with signal contributions drawn from the
entire 2D slice. Secondly, at the centre of k-space ((kx, ky) = (0, 0)) is data of low
spatial frequency related to signal to noise ratio and contrast (Figure 1-6). The data at
this point represents the MR signal that is unaffected by the phase or frequency
encoding gradients. Conversely, data with higher spatial frequency relating to resolution
is found towards the periphery.
1.1.7 Image formation: resolution
Given that the number of points in k-space determines the number of pixels in the final
image, what determines the pixel size? The pixel size is determined by the physical field
of view (FOV) and the number of points acquired across the field of view. For example,




Nx represents the number of points acquired across the x-axis. The spatial resolution
1
∆x
can be improved by increasing Nx through an increase in the strength of gradient
applied along the kx-axis (e.g. GF ). There are potential drawbacks with increasing
resolution, including increased imaging time and decreased signal to noise ratio. If
resolution is increased along the frequency encoding gradient then there will not be an
increase in imaging time required because the increase in Nx, corresponding to an
increase in the number of points along the kx-axis, is made by increasing the strength of
GF (see Equation 6). However, as is often the case, if a corresponding increase in
resolution is required across the phase encoding axis, this will increase the number of
acquisitions required, as each change in GP requires a separate acquisition (see
Equation 7 and Figure 1-5). As a consequence, imaging time will be lengthened in
direct proportion to the increase in resolution across the phase encoding gradient.
Therefore, to double the resolution with the same FOV along the phase encoding
gradient, twice the time is required.
Another drawback and one of the ultimate limitations in increasing the image resolution
is the associated decrease in signal to noise ratio (SNR). The SNR decreases in
proportion to the voxel volume. A voxel is the 3D volume element from which the MRI
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Figure 1.6: Filling k-space. A spin echo pulse sequence is shown with slice selection,
frequency and phase encoding steps (a) with the echo signal and frequency and phase
encoding steps enlarged (b). A line of k-space is filled along the kx axis by incrementing
the time duration of signal capture ∆t by n steps (c,d). This is done during a single echo
whilst keeping the frequency encoding gradient GF constant. To fill a new line of k-space
with a different value along the ky axis, the process is repeated with the strength of the
phase encoding gradient modified by an increment ∆GP (e). Note that the intersection
of the axes (c-e in red) represents the center of k-space, where kx = ky = 0.
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signal was drawn, in other words it is product of the area of a pixel and the slice
thickness. Therefore by halving the slice thickness, the SNR will be approximately
halved. One strategy to increase the SNR is to increase the number of signals acquired
to average the signal, which increases it relative to the noise. The SNR is proportional
to the square root of the number of echoes acquired, so by doubling the number of FIDs
acquired (and hence the imaging time), SNR can be improved a factor of
√
2. Another
strategy to improve the SNR is to decrease the size of the RF probe. SNR is
proportional to voxel volume/probe volume so that the closer the probe is to volume of
the sample, the larger the SNR. This principle was applied in this thesis by using a
wrist coil to image mice rather than the integrated RF coils in the body of the magnet,
improving SNR by a factor of approximately 65.
A balance exists between image resolution, signal to noise and the amount of time taken
to acquire the image. If the image resolution is too low, significant volume averaging
can occur where volume elements (i.e. collections of nuclear spins) with different signal
intensities within a voxel become averaged. If the SNR is too low, the image will be of
poor quality with limited sensitivity. In a clinical setting, strong pressure on MRI
scanner time makes the duration of each image sequence a key consideration.
Understanding the balance of these basic principles is key to designing an imaging
sequence appropriate for the specific needs of the operator.
1.1.8 Image contrast: introduction
Magnetic resonance imaging provides an excellent tool for clinical diagnosis. The
advantages of MRI over other imaging modalities include its excellent spatial resolution
and the degree of tissue characterisation possible without exposure to ionizing
radiation13. There are five different variables that can be used to characterise different
tissues with MRI. These include the proton density, longitudinal or spin-lattice
relaxation (T1) and transverse or spin-spin relaxation (T2) relaxation times, diffusion
and chemical shifts14. This section will describe how MRI contrast is produced and how
it can be augmented with the use of contrast agents.
The three intrinsic characteristics of biological tissue that are exploited most commonly
in clinical MRI are the proton density, the T1 and the T2 relaxation times. Two further
characteristics include chemical shift and diffusion. Chemical shift imaging can produce
spectral information about the chemical content of each voxel. An example of its use is
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in studies of tissue metabolites15. Diffusion based imaging techniques are used
predominantly in neurological studies and can provide information about tissue
physiology, microvascular circulation and advanced anatomical pathways16. Although
the latter two techniques are used increasingly in the clinical setting17, their detailed
description is outside the scope of this thesis. The experimental work that follows is
concerned primarily with contrast produced by enhancing T2 relaxation, but T1
relaxation and proton density will also be explored in this chapter.
1.1.9 Image contrast: T1 relaxation
T1 or longitudinal relaxation is the return of the nuclear magnetization vector to
alignment with the applied magnetic field B0, as discussed in section 1.1.3. The T1 time
is defined as the time at which 63% (1
e
) of the longitudinal magnetization is restored
after being disturbed from thermal equilibrium. Therefore, the faster the rate of T1
relaxation in a given tissue, the shorter its T1 time.
So what causes variation in the rates of T1 relaxation? T1 relaxation is affected by
thermal interactions between the precessing 1H nuclear spins and other magnetic nuclei
in the surrounding magnetic environment. These interactions allow the energy absorbed
by the nuclei during the application of the RF pulse to be dispersed to other nuclei in
the environment. T1 relaxation therefore reflects the rate of energy dispersal from the
proton spins to their environment.
The rate of energy dispersal from protons spins is related to their speed of molecular
motion and their Larmor frequency. When the Larmor frequency is close to the speed of
molecular motion of water protons, their dispersal of energy becomes more efficient
which increases the rate of T1 relaxation and decreases the T1 time
14. Protons in water
molecules move rapidly with a frequency that is greater then the Larmor frequency of
their spin at the strength of B0 used for clinical imaging. Therefore bulk aqueous fluid
such as cerebrospinal fluid (CSF) has a long T1 time as seen in Table 1-1.
When the movement of water molecules is constrained, their frequency of motion is
reduced. This occurs if water molecules are bound in hydration layers such as in
proteinaceous fluids (i.e. abscesses) or around myelin protein (i.e. periventricular
oedema)18. In these cases the frequency of protons moving in water molecules is
reduced so that it is closer to the Larmor frequency, resulting in increased energy
dissipation and a shorter T1 time.
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In addition to the frequency of molecular motion, T1 relaxation is also affected by the
presence of paramagnetic substances. Paramagnetic substances have magnetism that is
induced in the presence of a magnetic field. They produce T1 shortening by an
interaction between their unpaired electrons and the proton in the 1H nucleus. An
important example is the iron-containing haemoglobin molecule. When haemoglobin is
oxygenated as oxyhaemoglobin, it is not paramagnetic and does not enhance T1
contrast. When it becomes deoxygenated as deoxyhaemoglobin, it becomes
paramagnetic and is able to produce T1 shortening. This is exploited in functional MRI
(fMRI) where the difference in contrast between oxyhaemoglobin and deoxyhaemoglobin
gives information about oxygen consumption of specific regions of the brain19.
Another important paramagnetic substance that enhances T1 relaxation is gadolinium.
Gadolinium is a lanthanide rare-earth metal with seven unpaired electrons, which
bestow it with a large magnetic moment. Free gadolinium ions are a similar size to
calcium ions and act as calcium antagonists in the body, producing toxic effects which
impair cellular metabolism, muscle contraction and blood clotting11. For this reason,
gadolinium is administered clinically only as a chelated ion. Chelated gadolinium
complexes have a low rate of dissociation of free gadolinium, the log of the dissociation
constant measured in vitro is between 16-2620 for various chelation agents. Therefore
the administration of gadolinium chelates was long thought to be safe21 and up to 2007
they were used to enhance an estimated total of 130 million MRI scans worldwide22.
The popularity of gadolinium based contrast agents (GBCA) is due to their
effectiveness as extracellular contrast agents that remain intravascular except in regions
of abnormal vascular permeability, such as breakdown of the blood-brain barrier such as
in tumours20. Other central nervous system pathology can be identified on MRI with
GBCA including active demyelination plaques in multiple sclerosis versus chronic
quiescent ones23, early ischaemia24, parenchymal and meningeal brain infections25.
Gadolinium based contrast agents can be used for dynamic imaging whereby a series of
images is taken within the first few minutes of administration of the contrast agent.
This type of imaging is useful for distinguishing lesions such as breast cancer vs benign
fibroadenoma; hepatic hemangiomas vs hepatocellular carcinoma. The overall utility of
GBCAs means they are used in approximately one third of MRI scans26. An aspersion
has been cast recently on the safety profile of GBCAs, as they have been found to be
strongly associated with a multi-organ fibrotic disorder called nephrogenic systemic
fibrosis27 in patients with renal impairment. The implications of this finding to the
clinical use of GBCAs will be discussed in Chapter 7.
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1.1.10 Image contrast: T2 relaxation
T2 or ”transverse” relaxation time occurs simultaneously with T1 relaxation but they are
distinct processes. T2 relaxation is a measure of how long the transverse magnetization
of the nuclear magnetization vector persists after a 90◦ RF pulse, which is equivalent to
how long the precessing nuclear spins remain in phase. T2 relaxation is a result of the
magnetic interactions that occur between precessing nuclear spins. Unlike T1 relaxation,
T2 relaxation does not involve energy transfer
28 but instead a change in the phase of
precessing spins, which leads to a loss of their coherence. T2 relaxation is accelerated by
static magnetic fields in the local environment. In substances such as bulk water, the
rapid motion of 1H nuclei tends to average out the magnetic fields producing a more
uniform magnetic environment, which slows down the rate of T2 relaxation.
Coated nanocrystals of iron oxides, are a type of magnetic nanoparticle that can
produce enhanced T2*, T2 and to a lesser extent, T1 relaxation
29. All iron oxide based
nanoparticle systems will be referred to in this thesis as iron oxide nanoparticles (FeOx
NPs). FeOx NPs have been used as contrast agents in clinical MRI for over 20 years28
and remain the focus of a highly active field of research30,31.
FeOx NPs can cause a rapid loss of coherence by producing strong inhomogeneities in
the local magnetic field. This causes increased T2* relaxation, which is a direct result of
the magnetic field inhomogeneity and is reversible by a spin-echo technique as seen in
Figure 1-3. FeOx NPs enhance T2 relaxation by a mechanism known as the outer sphere
theory32. This theory states that the refocusing 180◦ RF pulse in a spin-echo pulse
sequence (see Figure 1-3) will reverse the decay of transverse magnetisation due to
static magnetic fields as long as no proton spins have encountered FeOx NPs between
RF pulses33. If water protons have diffused across the magnetic field associated with a
FeOx NP, this will result in a phase change in their rate of precession. If this phase
change was not present when the 90◦ RF pulse was applied, then the 180◦ RF pulse will
not bring them back into coherence with the other proton spins in the sample, resulting
in irreversible decay of transverse magnetization. The relationship between the physical
and chemical characteristics of FeOx NPs and the enhancement of T2 contrast will be
discussed in detail in Chapter 3.
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Table 1.1: Proton density, T1 and T2 times of different tissues and lesions at
1.5T. This table illustrates the variation in proton density, T1 and T2 relaxation times
between different tissues and disease processes, compiled from multiple sources11,14,34–37.
Incomplete or inconsistent data is replaced by “/”.
Tissue/lesion Proton density T1 (ms) T2 (ms)
Aqueous liquid (e.g. CSF) 100 > 4000 > 2000
Fat 100 260 80
Air 0 0 0
Skeletal muscle 80 760 30
Grey matter 85 920 100
White matter 70 780 90
Multiple sclerosis lesions / 1200-1800 110-150
Cerebral infarction 100 / 120
Meningioma 90 400 80
Metastasis 85 1800 85
1.1.11 Image contrast: weighting an image to emphasize
different MR characteristics
Different tissues and disease processes have different rates of T1 and T2 relaxation, as
seen in Table 1-1. How are these differences exploited to produce contrast in an image?
The amplitude of signal intensity on an MR image is related to both the proton density
and the relaxation rates of the protons in the region imaged. Differences in proton
density, T1 or T2 relaxation can be emphasized through the use of different pulse
sequences and by varying the echo (TE) and repetition time (TR).
The echo time (TE) is the interval between the application of the excitatory 90◦ RF
pulse and the collection of the MR signal. The TE determines the degree to which T2
relaxation affects image contrast. To illustrate this concept, an example of three
different tissues, each with a different T2 relaxation rate, is shown in Figure 1-7. The
graph shows the MR signal intensity versus time following a spin echo pulse sequence.
The tissues all had the same initial signal intensity, which has been normalized. The T2
time of each of the tissues can be taken from the graph where the signal intensity has
decayed to 63% (= 1
e
) of the original (Figure 1-7b, solid grey horizontal line), and it is
apparent that the T2 time of tissue 1 > 2 > 3. A more accurate way of determining the
T2 time of a tissue is to extract the value from the mono exponential fit of the graph
shown in Figure 1-7b. The former method was used throughout this thesis for in vivo
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imaging at 1.5T, where T2 mapping was not available. The latter method of producing a
value of T2 from a fit of the exponential signal decay was used in all other circumstances.
Consider the signal remaining in each of the tissues if a short TE of 1ms was used, for
example. There would be less than a 10% difference in the MR signal from any of the
tissues. In this case, the tissues would all appear bright as less than 10% of their
original signal had decayed by T2 relaxation. As can be seen in the image (Figure 1-7a,
far left), there is little contrast between the tissues. Now consider a longer TE of 8ms
(Figure 1-7b, dotted vertical line). At this echo time there is ≈45% difference in the
MR signal between tissue 1 and 2 and ≈30% difference between tissue 2 and 3. The
resulting images captured at this echo time are shown in Figure 1-7c. The MR image
with a TE of 8ms can be said to have more T2 weighting than the image with a TE of
1ms. A shorter TE produces less T2 weighting and a longer TE increases the T2
weighting. Another way of expressing this is that a T2 weighted image has a TE greater
than or equal to the tissue specific T2. Therefore, by selecting the TE, the degree of T2
weighting in the resulting MR image can be modified.
Consider again the simulated image at the far left of Figure 1-7a, where a TE of 1ms
was modeled. In this case, differences in the image contrast would be mostly due to
differences in the density of the protons in the tissues, as not enough time has passed
(relative to the T2 values of the tissues) for significant signal decay to have occurred by
T2 relaxation. This type of weighting is called proton density weighting and it can be
used to distinguish between tissues that have low proton density (i.e. lung) and those
that have T2 times that are very short (i.e. liver). These tissues would both appear dark
on an image that had a TE > T2 time of liver (as can be seen in many of the images in
chapter 4).
MR images can also be weighted so that their contrast emphasizes differences in T1
relaxation rates. This can be achieved by shortening the repeat time (TR). The TR is
the interval between two successive 90◦ RF pulses. Application of a 90◦ pulse rotates
the NMV 90◦ from the longitudinal into the transverse orientation, and as a result the
longitudinal component of the NMV is totally lost. The longitudinal component of the
NMV must be allowed to recover before another signal can be generated. The amount
of longitudinal magnetization that is recovered depends on the T1 relaxation rate and
the time allowed for recovery to occur, which is the TR. Tissues with a shorter T1 time
will recover their longitudinal magnetization faster and will have a larger longitudinal
component of their NMV available to rotate into the transverse plane at an earlier time
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Figure 1.7: The effect of echo time (TE) on T2 contrast. The transverse relaxation
of three different tissues (1% agar gels containing FeOx NPs in tissue 2, and Fe NPs in
tissue 3) were analysed at 9.4T using a spin-echo sequence (b,c). Each point represents
the signal intensity at a given echo time relative to the initial signal intensity (at t =
0). Curves were fitted by using a monoexponential decay. The point where each curve
intercepts the line drawn at signal = 1
e
(b, solid horizontal line), represents the T2 time
of the tissue. The line drawn at 8 ms (b, dashed vertical line) represents the echo time
(TE) used for imaging the tissues shown in (c). A simulation shows the contrast of each
tissue at different echo times (a). (This figure contains data from Figure 3-8b and 3-9c,
which is used here for illustrative purposes).
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Table 1.2: The effect of TE and TR on image weighting.
Weighting TE TR
Proton density short (≤ T2 time) long ( T1 time)
T1 short (≥ T2 time) short (≤ T1 time)
T2 long (≤ T2 time) long (≤ T1 time)
point compared to another tissue with a longer T1 time. If the TR is set to be equal or
less than the T1 time of the tissue of interest, any tissues with a longer T1 time will have
less signal rotated into the transverse plane by the second 90◦ pulse and will appear
darker in the MR image. This is called T1 weighting and can be defined by the use of a
TR T1 time of the tissue of interest. Table 1-2 summarises the differences in TE and
TR used to weight image contrast for proton density, T1 or T2 relaxation.
1.1.12 Summary
MRI is versatile in its ability to distinguish different tissue types and disease processes
with image contrast. Image contrast can be weighted to emphasize different tissue
characteristics, such as T1 and T2 relaxation rates, by varying the echo time (TE) and
the repeat time (TR) of the pulse sequence. Further image contrast can be produced
with the use of contrast agents. Gadolinium based contrast agents enhance T1 contrast
and are the most widely used contrast agent, although concerns with their toxicity have
emerged in recent years. T2 contrast can be enhanced with the use of magnetic
nanoparticles, which are the main focus of this thesis. In summary, these principles
form the basis of MRI contrast and they are applied throughout this thesis.
1.2 Magnetic nanoparticles as T2 contrast agents
Magnetic NPs play a significant role in many biomedical applications of magnetic
resonance imaging (MRI), including liver imaging28, detection of lymph node
metastases38, tracking of therapeutic cells39 and imaging macrophages in diverse
processes from strokes40,41 to organ graft rejections42,43. The only commercially
available T2 contrast agents are FeOx NPs, due to their biocompatibility
44, ease of
synthesis45 and adaptability by alteration of their surface coating46. Owing to a
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significantly larger magnetic moment, Fe NPs have the potential to be more effective T2
contrast agents but have proven very difficult to synthesize47.
Each Fe NP contains a single crystal of Fe that is superparamagnetic, which refers to its
large magnetic moment in the presence of an external magnetic field.
Superparamagnetic NPs possess a large magnetic susceptibility, which is the ability to
align with and strengthen the external magnetic field they are exposed to. This is
because the entire NP crystal aligns with the external magnetic field, due to its single
crystal nature. Superparamagnetism can exist when the size of the single crystal NP is
less than its ferromagnetic domain. For Fe NPs, this superparamagnetic size limit is less
than 30nm30. This is in contrast to paramagnetic materials, in which each atom aligns
their individual magnetic dipoles with an external magnetic field, resulting in small
magnetic susceptibilities with random orientations when there is no magnetic field
present.
Through their large magnetic moments, Fe NPs can produce large changes in the local
magnetic field, which causes a rapid dephasing of the spins of neighbouring protons,
resulting in more efficient transverse relaxation. This can be seen as areas of signal
hypointensity (i.e. dark region) on a T2 weighted scan, as discussed in section 1.1. It is
worth noting that superparamagnetic NPs do not directly cause a change in MRI
contrast, rather they influence the MRI signal produced by proton spins in their
vicinity. Although they are also able to affect longitudinal relaxation and produce T1
contrast, superparamagnetic NPs are primarily applied for their effects on T2 contrast
48.
The characterization of Fe NPs, including their size, crystal pattern, and effects on T2
contrast are examined and contrasted with those of FeOx NPs in chapter 3.
1.2.1 Clinical applications of magnetic NPs
FeOx NPs that are clinically approved as intravenous MRI contrast agents in Europe or
the US are shown in Table 1-3. Some FeOx NPs in later stages of clinical development
are shown for comparison as are the Fe NPs and the FeOx NPs examined in this thesis.
Note that the FeOx NPs used for lymph node imaging, Sinerem, have a size of less than
50nm (although the size of their FeOx core without the coating is only 6nm49).
Sinerem’s smaller size facilitates a longer circulation time in the blood, enabling them
to reach macrophages in the lymph nodes, whereas the larger NPs are rapidly taken up
in the liver and spleen, which are both rich in macrophages and have more permeable
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Table 1.3: FeOx NPs developed for clinical applications (adapted from
sources49,52)
Name Approval Application T2 relaxivity size(nm)
Endorem/Feridex US liver/spleen 120 120-180
Sinerem clinical lymph nodes 65 15-30
Resovist clinical liver/cell labelling 189 60
FeOx NPs preclinical all of the above 145 65-75
Fe NPs preclinical all of the above 324 60-70
blood vessels50. Despite this characteristic, Sinerem recently failed to gain approval for
use in imaging lymph nodes from the European Medicines Agency following a large
clinical trial due in part to its failure to improve the sensitivity of detecting cancer in
lymph nodes by MRI51.
Early and accurate detection of lymph node involvement can improve the outcomes in a
number of different cancers53–55, and one of the most intensely researched applications
of magnetic nanoparticles is in improving the MRI detection of cancer in the lymph
nodes56,57. FeOx NPs have been shown to improve the MRI diagnosis of metastatic
tumours in the lymph nodes when the tumours are greater than 5mm57,58 or cause
lymph node enlargement59. However the sensitivity of detecting tumours that are
smaller than 5mm with FeOx NPs decreases from 96% to 41%. Fe NPs, with a greater
magnetic moment, have the potential to improve the sensitivity of MRI detection of
smaller tumours in the macrophage-rich tissues of the liver, spleen and lymph nodes.
The ability of Fe NPs to improve the MRI detection of small tumors above that of FeOx
NPs is examined in chapter 4.
1.2.2 Tracking dendritic cells with Fe NPs
When applied to track therapeutic cells, MRI can provide important information to
assist the development of novel cellular therapies. With their relatively long half life
and low toxicity in labelled cells60,61, FeOx NPs have been applied to track many
42 General introduction
different cell types, including stem cells62,63 and immune cells64,65 involved in
regenerative medicine and cellular immunotherapy respectively.
Cancer immunotherapy with dendritic cell (DC)-based vaccines has demonstrated
tumour regression and prolonged survival in a modest number of patients with
metastatic cancer66,67. Evaluating the generation of specific immune responses following
DC-based immunotherapy has proved challenging and potentially limits the
development of more effective vaccines68. In chapter 5, a novel in vivo strategy is
developed which employs Fe NPs to assist DC tracking by MRI in order to detect an
induced antigen-specific immune response to a DC-based vaccine.
1.2.3 The role of dendritic cells in cancer immunotherapy
DCs are immune cells present throughout the body that are critical for the induction of
powerful and enduring immune responses by the adaptive immune system69. DCs
belong to a subset of cells called antigen presenting cells that are able to effectively take
up and process molecules from the extracellular environment, migrate to lymphoid
tissues and present them to cells of the adaptive immune system in a manner that can
stimulate immunity70. Collectively, the acquired molecules are known as antigens. The
adaptive immune system has the ability to recognize and respond to specific antigens,
then form long lasting memory that can enables a rapid immune response on
re-exposure to the antigen.
The adaptive immune system evolved to protect the host from infectious pathogens
through the generation of a diverse repertoire of antigen-specific cells that can respond
to almost any antigen to which they are exposed. Two major divisions of the adaptive
immune system correspond to the type of immune response that they produce.
Cytotoxic T lymphocytes (CTL), which are a specialised subset of CD8+ T cells, can
directly eliminate cells infected with intracellular pathogens or tumour cells through a
cytotoxic immune response. B cells can generate antibodies that recognise
pathogen-associated antigens and promote the removal of the pathogen. These
processes both require the participation of CD4+ T cells, also known as T helper cells,
which produce cytokines that can support CTL71 and or B cell72 differentiation and
proliferation. Furthermore, CD4+ T cells can produce effector responses in their own
right73.
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Virtually all nucleated cells can process intracellular proteins, break them into peptides,
and display them on their surface complexed to major histocompatability complex
(MHC) (MHC) class I molecules74. DCs, and other antigen presenting cells such as B
cells, can process extracellular proteins in their environment and present them as
peptides on MHC class II molecules. DCs can also present exogenous antigens on MHC
class I molecules, which is known as cross-presentation75. CTLs can recognize infected
or malignant cells through binding between their T cell receptor (TCR) and specific
peptide molecules presented on MHC class I molecules on the target cell. CD4+ T cells
bind specific peptides that are presented on MHC class II molecules by antigen
presenting cells. These binding events are assisted by the CD8 and CD4 co-receptors,
respectively76. Depending upon the co-stimulatory signals from the environment,
including DCs, antigen recognition by TCRs can result in a cascade of signaling events
that can ultimately differentiate T and B cells to produce cytotoxic and humoral
immune responses, proliferate, and form long lasting memory cells77,78.
The hazard of having an adaptive immune system that can recognize and eliminate
diverse antigens is that the antigen-specific T and B cell repertoire contains cells that
recognize self-antigens and could potentially attack the host’s own tissues. Control
mechanisms exist to prevent immune responses to self-antigens and DCs are at the
center of controlling the regulation and promotion of antigen-specific adaptive immune
responses. Tissue-resident DCs that process pathogen-associated antigens are activated
by ”danger signals” associated with infection79 (e.g. bacterial cell wall components) or
tissue damage80 (e.g. uric acid). When DCs become activated, they change from being
benign regulators of immune homeostasis to pro-inflammatory cells with the ability to
induce differentiation and proliferation of antigen-specific T cells. Activated DCs
change their expression of surface molecules such as CD86, which have the ability to
”co-stimulate” T cells that bind to the antigen presented on MHC molecules on the
surface of the DC. This second signal is important in translating the danger signal to
potent activation of antigen-specific T cells81. There are also positive feedback
mechanisms whereby molecules expressed on stimulated T cells can produce further DC
activation and release of cytokines that support T cell differentiation82. Activated DCs
migrate from the tissues to draining lymph nodes, where they encounter a high
concentration of lymphocytes. This facilitates the interaction of DCs with lymphocytes
expressing receptors specific for the MHC molecules and antigen expressed on the
surface of the DC. This migration of activated DCs from the tissues to the draining
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lymph nodes is tracked using MRI assisted with Fe NPs in chapter 5.
Tumours can become targets for T cells when they express mutated proteins, known as
tumour antigens, that the immune system regards as ”foreign”83. Unlike infectious
pathogens however, tumours do not usually produce the correct ”danger signals”
required to activate DCs84, resulting in an ineffective immune response85. DC-based
vaccines can overcome this obstacle through the administration of DCs that have been
loaded with tumour antigen(s) and activation molecules in vitro. These DCs can
produce potent immunostimulatory effects in vivo, resulting in antigen-specific CTLs
that are able to eliminate tumour cells67,86. The source of tumour antigens can consist
of single peptides from defined tumour-associated proteins, whole tumour-associated
proteins, tumour lysates or antibody complexes with proteins or cellular material87.
The goal of vaccination in cancer immunotherapy is to induce immunity against
tumours through selectively stimulating antigen-specific CTLs and CD4+ T cells. DCs
have been used as the basis of cellular vaccines against metastatic cancer for over a
decade88 in more than 1000 patients and 100 published studies89. However, further
testing is required to improve the response rate to beyond 10%90. To address this need,
two novel, MRI-based assays are presented in chapter 5 and 6 to detect the presence of
an antigen specific response following DC vaccination.
1.2.4 Summary
The effectiveness of MRI in detecting small tumors and tracking therapeutic cells can
be augmented with the use of magnetic nanoparticles as T2 contrast agents. Fe NPs,
with their larger magnetic moment, have the potential to further improve these
applications beyond FeOx NPs, which are the current commercial standard. The
application of Fe NPs to enhance T2 contrast, cancer detection, cell tracking and the
detection of immune responses following DC-based vaccination comprises the four
experimental chapters which form the body of this thesis.
Chapter 2
Materials and methods
This chapter provides further details regarding the materials and methods used in this
thesis. The information is presented in the order of its appearance in the figures from
the results chapters 3, 4, 5 and 6. The methods are not repeated in later chapters unless
there are modifications. A justification is given for the MRI sequences and statistical
methods used in this thesis. As this was a multidisciplinary body of work with a large
degree of variation in content between chapters, a discussion structure modelled on
Docherty and Smith91 was applied to the results chapters in an attempt to maintain a
cohesive structure throughout the thesis.
2.1 MRI scanning
The comparison between imaging at 9.4T and 1.5T was limited by the fact that in vivo
scanning was not possible at 9.4 T, and T2 mapping was not possible at 1.5T. These
measurements are perfectly feasible in general but they were not possible in this study
for logistical reasons concerning the access arrangements to the 9.4T NMR spectrometer
and the 1.5T clinical MRI scanner. Comparisons were still able to made between T2
weighted images, and this explains why the in vivo data is presented as % reduction in
T2 contrast as opposed to a % reduction in T2 time.
MRI pulse sequences used in this study were all weighted for T2 contrast, using
spin-echo based sequences. The question may be raised why T2* contrast, such as can
be produced with a gradient echo pulse sequence, was not used. Magnetic nanoparticles
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are known to produce strong T2* contrast through their magnetic susceptibility
92.
When gradient echo pulse sequences were applied at 1.5T, the contrast to noise ratio
was significantly reduced compared to spin-echo sequences with the same resolution.
Reduced contrast to noise ratio is an expected feature of T2* versus T2 weighted
sequences as there is accelerated decay of the transverse magnetization with T2* (as
seen in Figure 1-3). The result was that the T2* weighted images were too poor for any
gains in contrast sensitivity to be of benefit. A further reason for using T2
measurements was for comparison with the literature, where T2 values (such as T2
relaxation time and T2 relaxivity = r2) are predominantly reported
30,49.
2.2 Statistics
For most of the experiments in this thesis, a normal (or Gaussian) distribution was
assumed for the measured variables. This assumption was made in the context of a
highly controlled biomedical environment with the use of congenic mice, sterile
technique, the use of clonal cancer cell lines and the use of cellular vaccine aliquots from
a common pool. These controls were made to decrease the chance of unmeasured
variables influencing the measured variable in a non-random way. Each data set was
checked by examining its scatter plot for any evidence of a deviation from a normal
distribution. In all instances except one, there was no evidence of deviation from a
normal population distribution of the sampled variables. Therefore parametric
statistical tests were applied including student’s t-test for two group comparisons and
one-way analysis of variance (ANOVA) with a Bonferonni post-test for multiple group
comparisons.
The analysis of T2 weighted MR contrast in the lymph nodes (Figure 5-8) was prone to
volume averaging effects due to the presence of adjacent subcutaneous tissue along the
slice selection axis (which was three times as thick as the other two dimensions in order
to increase contrast to noise ratio). These effects were not seen when the lymph nodes
were imaged at 9.4T ex vivo in the context of better resolution (0.1 x 0.1mm with a 0.5
mm slice thickness and dissection of the peripheral tissue away from the lymph node.
This finding suggests that the variation seen in the T2 contrast in the lymph nodes in
vivo was not an intrinsic property of the lymph nodes themselves.
The subcutaneous tissue surrounding the lymph nodes had a different rate of T2
relaxation as the lymph nodes, so if it was averaged into the T2 weighted contrast it
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Figure 2.1: Non-parametric distribution of T2 contrast in lymph nodes. T2
contrast was measured in lymph nodes at 1.5T in vivo (Figure 5-8c) using a resolution
of 0.3 x 0.3mm with a slice thickness of 1.0mm. The red boxes indicate populations
that deviate from a normal distribution, with two boxes per group indicating a bimodal
population and one box indicating a skew population.
could change the measured T2 contrast of the lymph node. This resulted in a
non-normal distribution of T2 contrast in the lymph nodes. The sampled populations
possessed either a bimodal or a skewed distribution (Figure 2-1), presumably depending
on the amount of subcutaneous tissue sampling in the slice selection axis. This was
evident in most of the populations including control mice that received no injections of
dendritic cells or NP contrast. This did not affect the measurements of the lymph node
area in Chapter 6 because the distinction between the border of the lymph node and
the subcutaneous tissue was clearly discernible in the plane of the image where area was
measured (see Figure 6-1a). This could not be prevented with the use of fat saturation
techniques, which suppress the signal from protons in lipid molecules, indicating that
there were contributions to the volume averaging of the T2 signal from water protons in
the subcutaneous tissue.
It was therefore deemed appropriate to apply non-parametric statistics to the analysis
of T2 weighted MR contrast measurements in vivo. The Mann-Whitney rank sum test
was applied to all two group comparisons with the Kruskall-Wallis test with a Dunn’s
post-test applied to multiple group comparisons. Unless otherwise stated, all error bars
shown in graphs represent the standard error of the mean. All statistical calculations
were produced with Graphpad Prism Version 4 (Graphpad Software Inc).
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2.3 Methods from Chapter 3
2.3.1 Synthesis of Fe NPs
This method is the same as published by Cheong et al93. All reagents were used as
received without further purification. The iron precursor Fe(C5H5)(C6H7) was prepared
according to a previously described method94. For the synthesis of iron nanocrystals,
the iron precursor (0.4 g, ≈2 mmol), oleylamine (OLA) (2 mL, ≈6 mmol, Aldrich, 98%)
and mesitylene (8 mL, Aldrich, 98%) were added to a closed reaction vessel
(Fischer-Porter bottle), which was then flushed three times with hydrogen gas (H2)
before being filled with 100 kPa H2, and sealed. The bottle was placed into an oven
heated at 130◦C and remained for 2 days. The reaction was allowed to cool to room
temperature naturally before the reaction vessel was opened to air. Each synthesis
typically produced 60 mg Fe, which gave ≈50% yield.
2.3.2 Synthesis of FeOx NPs
The nanoparticles were synthesized following a commonly adopted method95. Briefly,
under vigorous stirring, two solutions, (i) FeCl3 (5.406 g, Aldrich, 99%) in 20 mL
deionized (DI) water, and (ii) FeCl2 (1.988 g, Aldrich, 98%) in 5 mL of HCl (2 M), were
added to 100 mL DI water, to which 120 mL of ammonia solution (2 M) was added, and
remained under stirring for 5 minutes. Black precipitate was purified by centrifugation
at 3500 rpm for 20 minutes, and redispersed in DI water. The same purification process
was repeated 4 additional times and the resulting precipitate was redispersed in 35 mL
DI water. DMSA coating was applied using the same ligand exchange procedure for the
core/shell nanoparticles.
2.3.3 Transmission electron microscopy
The transmission electron microscopy (TEM) images and electron diffraction patterns
were taken on a JEOL 2010, with a LaB6 filament operated at an acceleration voltage
of 200 keV. TEM samples were prepared by dipping a carbon-coated TEM grid into the
nanoparticle dispersion in toluene or water and allowing the solvent to evaporate under
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ambient conditions. The size distributions were determined by counting 100 NPs of
each type. The electron diffraction patterns were taken with a camera length of 30cm.
2.3.4 Ligand exchange with meso-2,3-dimercaptosuccinic acid
Ligand exchange to replace OLA with meso-2,3-dimercaptosuccinic acid (DMSA) was
carried out based on known methods96. The as-synthesized nanoparticle solution was
sonicated briefly and divided into four equal portions. For each aliquot, the solution
was dried in vacuum overnight to leave a powder, which was then dispersed in 20 mL of
deionized de-ionised (DI) water. Separately, DMSA (20 mg, Aldrich, 98%) was added to
20 ml of DI water. The pH of both solutions was adjusted to 3.0 with HCl, prior to
mixing the solutions. After adding the DMSA solution to the nanoparticle solution the
pH was again adjusted to 3.0 with HCl under vigorous stirring and constant nitrogen
bubbling, and remained for 30 minutes. The resulting mixture was centrifuged at 3500
rpm for 10 minutes, to give a black precipitate, which was redispersed in 20 ml DI
water. The supernatant, comprising aqueous and oil (OLA) layers, was discarded. The
pH of the product dispersion was adjusted with NaOH to 9.25-9.5 under constant
stirring and was maintained for 30 minutes before lowering the pH to 7.4 with HCl. The
resulting solution was centrifuged at 3500 rpm for 10 minutes. The supernatant was
discarded, and the nanoparticles were dispersed in water or sterile phosphate-buffered
saline (PBS), which was sterile filtered. The dispersion in PBS was used as stock
solution and was stored at 4◦C. The iron content of each stock solution was determined
by atomic absorption spectrometry.
2.3.5 Measurements of hydrodynamic size with dynamic light
scattering
DMSA coated Fe NPs or FeOx NPs were dispersed in water and filtered with a 0.2m
syringe filter to remove dust particles and large aggregates. Their hydrodynamic sizes
were measured by DLS at 20◦C with a Malvern Zetasizer Nano ZS.
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2.3.6 Determination of iron content by flame atomic
absorption spectroscopy
All samples for measurement of iron concentration by flame atomic absorption
spectroscopy (AAS) were first dissolved in 0.5ml of concentrated hydrochloric acid and
diluted up to 3mL with de-ionized water. Standard concentrations of 2, 4, 10 and 20µg
ml−1 of iron were prepared by dissolving iron wire in hydrochloric acid and serial
dilution in de-ionized water. The measurements were made with a GBC 906AA
spectrometer using an air-acetylene flame. A standard curve was made with the four
standard concentrations and further dilutions were made of any sample that was not
within the range of the standard curve. Measurements were made in triplicate and if
there was more than 5% variation between instances then the measurement was
discarded and performed again.
2.3.7 Measurements of T2 relaxivity and MRI at 9.4T
Preparation of nanoparticle dispersion in agar: 2% agar was made up from
dissolving agar powder (Aldrich) in de-ionized water and heating in a microwave until it
reached a boil. The stock solution of Fe NPs or FeOX NPs was diluted with PBS to give
concentrations of 1, 2, 3, 4, 10 and 20 µg ml−1 of Fe in PBS. To 100 µl of each of the
dilutions, 100 µl of 2% agar was added to give concentrations of 0.5, 1.0, 1.5, 2.0, 5.0
and 10.0 µg Fe ml−1 in 1% agar. The control was prepared by adding 100 µl of 2% agar
to 100 µl PBS. All samples were pipetted into plastic micro-PCR tubes (capacity 250µl).
MRI of nanoparticles: MRI was performed using a Bruker Instruments AVANCE400
nuclear magnetic resonance (NMR) spectrometer, equipped with a Bruker Micro 2.5
imaging module. MR images were acquired at 9.4 T using a 2D multi-slice spin-echo
sequence, at room temperature, with the following parameters: echo time (TE) = 8 ms,
repetition time (TR) = 2000 ms, pixel size = 100 µm x 100 µm, slice thickness = 0.5
mm, number of echoes = 64, 4 averages, total experiment time = 16 minutes.
Measurements were repeated on four separate samples for each iron concentration for
consistency.
Determination of transverse relaxivity (r2) and imaging at 9.4T: Paravision
software (Bruker) was used for MR image reconstruction and analysis. A region of
interest was manually selected within the axial image of each nanoparticle, cell or
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lymph node dispersion in agar. A plot of the signal intensity against the echo time was
fitted with an exponential function: S(t) = S0exp(
−t
T2
); where S(t) = signal intensity at
time t, S0 = signal intensity at 0ms, and the transverse time T2 was then calculated.




(control) against iron concentration ([Fe], in mM) was fitted




(control) = r2 x [Fe]; where the relaxivity r2 was
determined as the slope of the fit. This procedure was repeated four times for the Fe
NP and the FeOx NP dispersions to determine the average and the standard error of
the mean (SEM).
2.3.8 Culture of cancer cell lines
All cell culture was performed at 37◦C, with 5% CO2 and 95% humidity. The culture
medium used was Iscove’s Minimum Essential Medium (IMDM) supplemented with 5%
foetal calf serum (Aldrich), 2mM glutamax, 100U/ml penicillin, 100µg ml−1
streptomycin and 50µM 2-mercaptoethanol (all Invitrogen). This medium will be
referred to in this thesis as complete medium and incomplete medium indicates the
same medium without the foetal calf serum. All washing steps included centrifugation
at 472 x g for 4 minutes in a Megafuge 2.0R (Heraeus Instruments) with the
supernatant discarded and the cells re-suspended in the appropriate medium.
The tumour cell lines used were based on lines originally from the American Tissue
Culture Centre (ATCC). These cancer lines were not subject to genotypic confirmation
for this study. The cell lines GL261 glioblastoma cells (GL261), B16F10 melanoma cells
(B16), Henrietta Lacks cervical adenocarcinoma cells (HeLa) ,4T1 breast carcinoma
cells (4T1), EG7-OVA chicken ovalbumin-expressing thymoma cells (EG7ova) were
cultured in medium described above. Gentecin selective antibiotic (Gibco, Invitrogen)
was added to EG7ova culture at 0.5 mg/ml to maintain ovalbumin expression.
2.3.9 Labelling cancer cells with NPs
Fe NPs or FeOx NPs at 2µg Feml−1 were added to cancer cells. The total amount of
iron added was 50µg as the cells were cultured in 25mL media/flask. After incubation
for four h, the media was removed from the flask and the cells were washed with sterile
phosphate buffered saline (PBS). The adherent cells were detached with 0.25%
Trypsin/EDTA (Gibco, Invitrogen), counted with a haemacytometer and dispersed at
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500 cellsµl−1 in 100ml PBS. A modification to this procedure was necessary for EG7ova
cells as they are semi-adherent. After incubation with NPs, the cells were removed with
the media from their flask, washed twice in PBS before being dispersed in PBS. 100ml
of 2% agar was added to all of the cell dispersions followed by thoroughly mixing by
repetitive aspiration with a micropipette.
2.3.10 Perl’s stain
Two stock solutions of reagents were made with:
1) 20ml of concentrated HCl with 80ml of distilled water
2) 10g of potassium ferrocyanide trihydrate powder (Aldrich) with 100 ml of distilled
water.
Cells were fixed in 10% buffered formalin (4% formaldehyde, Aldrich) on polylysine
covered glass microscope slides. Perl staining was performed by first mixing equal
volumes of reagents 1 and 2 and placing the slides in a Coplin jar containing the reagent
mixture. The slides were removed after 10 minutes and placed in a dilute (0.1%)
solution of Safranin-O in distilled water as a counterstain for 5 minutes. The slides were
then successively dehydrated by 1 minute submersion in ascending gradients of ethyl
alcohol - 70%, 80%, 90%, 100%. The slides are then cleared in xylol (Aldrich) for 30
seconds. Mounting media (Vision Mount, Thermo Scientific) and cover slip were then
applied.
2.4 Methods from Chapter 4
2.4.1 Mice
All mice were handled in accordance with the Animal Ethics Policy 2008R7M, approved
by the Animal Ethics Committee of Victoria University of Wellington. All mice were
bred and maintained in the Biomedical Research Unit of the Malaghan Institute of
Medical Research. Mice were not used in experiments until they reached 6 weeks of age.
Breeding pairs of C57Bl/6 mice were originally sourced from the Jackson Laboratories,
Bar Harbour, ME, USA. Balb/c breeding pairs were originally sourced from the
Australian Research Council, Canberra, ACT, Australia.
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2.4.2 Administration of NPs for in-vivo MRI
Nanoparticles dispersed in PBS (200µl) were administered either intravenously through
the tail vein or subcutaneously into the hind limb of 6 week-old C57BL/6 mice. A
control mouse was injected with the same volume of PBS, without the presence of
nanoparticles. Doses of 3µmol Fekg−1 were employed for imaging the liver and 120µmol
Fe kg−1 for the spleen and lymph nodes.
2.4.3 In-vivo MRI
24 hours after injection of NPs, the mice were anaesthetized by intra-peritoneal (IP)
injection of a ketamine/xylazine mixture in PBS (100/10 mg kg−1, both from Phoenix
Pharm). Lacrilube (Allergan) was applied to the cornea to prevent dessication. MRI
was performed using a clinical 1.5 Tesla MR scanner (Philips Medical Systems),
equipped with a wrist solenoid coil. The mice were positioned in the centre of the wrist
coil and the same protocols were used for all images. T2-weighted multi-slice,
multi-echo, spin-echo images were acquired with the following parameters: TE = 54 ms,
TR = 2000 ms, pixel size = 300 µm x 300 µm, thickness = 1 mm, number of echoes =
8, averaged from a total of 3 scans, total experiment time = 4 minutes 24 seconds. Both
an axial and coronal series of images were perfomed. Images were analyzed with ImageJ
(National Institutes of Health) by manually selecting a region of interest (ROI)
corresponding to the liver, spleen, upper hind limb muscles or inguinal lymph nodes and
integrating the signal intensity of each ROI.
2.4.4 Histology
After MR imaging, the mice were euthanized by cervical dislocation and their tissues
(liver, spleen or tumours) were removed and placed in formalin. They were then sent to
the Wellington School of Medicine where they were embedded in paraffin and sectioned
at 5µm thickness using a cryotome. Haematoxylin and Eosin (H&E) and Perl stains
were performed on the sections as described in 2.3.10. Slides were examined under an
Olympus IX51 optical microscope, with digital images recorded.
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2.4.5 Administration of subcutaneous B16 tumours
B16 cells were cultured as in 2.2.8, and a dispersion of either 106 cells(Figure 4-4) or 105
cells (Figure 4-6) in 100µl of PBS was injected into the left flank of C57Bl/6 mice. Mice
were checked daily for the development of tumours. Tumours were measured by calipers
daily to ensure that no mouse had ulceration or a tumour measurement of more than
200mm2 by day 7.
2.4.6 Addition of Herceptin-conjugated to Fe NPs to HeLa
cells
Herceptin conjugation to Fe NPs: 10mg of EDC
(1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride, Thermo Scientific) was
added to 1ml of de-ionized water. Separately, 100µg of Fe NPs and 500µg of Herceptin
(transtuzumab, Genentech) were added to 1ml of de-ionized water. The solutions were
then combined, vortexed for 20 seconds and left at 4◦C for 40 minutes. The solution
was centrifuged at 1000 x g for 10 minutes. The supernatant was discarded and the Fe
NPs were resuspended in PBS. The iron concentration was determined by flame atomic
absorption spectroscopy (Section 2.3.6).
Addition of conjugated NPs: HeLa cells were added to a 96 well plate at 5000
cells/well in PBS. The Herceptin-conjugated Fe NPs were added to the cells in triplicate
at concentrations of 5, 12.5, 25 and 50µg ml−1 of Fe. As a control, unconjugated Fe NPs
were added in triplicate to HeLa cells at the same concentration. After 100 minutes of
incubation, the supernatant was removed from the plate. The cells were washed with
PBS three times before being harvested for analysis by MRI and AAS.
2.4.7 Administration of intrasplenic tumours
For the tumor studies, 6 week-old BALB/c mice were anaesthetized by IP injection as
described above. 10 and 5 mm incisions were made through the skin in the left
hypochondrium and the peritoneum, respectively. The spleen was exposed and injected
with 106 4T1 breast cancer cells. The peritoneum and skin were closed with 5.0 vicryl
sutures (Ethicon) and the mice were given buprenorphine (0.1 mg kg−1 single dose,
Phoenix Pharm) and carprofen (5 mg ml−1, 2 doses 12 hours apart, Phoenix Pharm)
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subcutaneously for analgesia. 72 hours after the cancer cell implantation the mice were
anaesthetized by IP injection of ketamine/xylazine and MRI was performed (Section
2.4.3).
2.4.8 Scoring tumours
Two consultant radiologists were recruited to the study, both of whom had extensive
experience reading MRI scans at a tertiary centre in New Zealand, and neither of whom
had interpreted images with FeOx based contrast agents previously. They were given an
example (Figure 4-8) of pre and post contrast images for mice with splenic tumours
given Fe NPs or FeOx NPs intravenously. Their instructions were to score the mice
with an integer from one to five (Table 4-1) according to the probability of an
intrasplenic tumour being present. The images were on a DVD and were identified with
only the scan number. They were advised to look through a dozen of the images at
random to get an idea of the range of appearances before commencing scoring. Their
scoring sheets were sent to an un-blinded investigator who analysed the results. No
feedback was given to the radiologists on their accuracy until they had performed their
second reading, which was at least one month from the first, and was performed
without reference to their previous scoring.
2.5 Methods from Chapter 5
2.5.1 Bone marrow-derived dendritic cell culture
Preparation of BMDC culture: The bone marrow derived dendritic cell (BMDC)
cell culture was prepared by first flushing the marrow cavity of the femur and tibia
bones removed from 6 week-old C57Bl/6 mice using a 25-gauge needle and a syringe
filled with complete medium, then passed through a 70µm cell strainer. Cells were
cultured in complete medium supplemented with IL-4 and GM-CSF in 6 well plates at
2x106 cells in 5ml per well, according to the method developed by Lutz97. IL-4 and
GM-CSF were derived from the culture supernatants of Chinese hamster ovary mIL-4
and X63/GM-CSF cells, respectively, with optimal concentrations determined by
titration. Non-adherent cells were harvested on Day 7 by gentle aspiration and
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expulsion (5 times for each well) with an auto-pipette. The following substances were
often added to BMDCs in culture, according to the specific experiment.
Addition of NPs: Fe NPs or FeOx NP labelling was performed by addition of 5g Fe
ml−1 on Day 5.
Addition of alpha-galactosylceraminde: α-gal (α-galactosylceramide) was
synthesized by Gavin Painter at Industrial Research Limited (Lower Hutt, New
Zealand) according to a published method98. α-gal was added to BMDCs as a vaccine
adjuvant at a concentration of 200ng ml−1.
Addition of LPS: To mature cells, a total of 500ng (=100ng ml−1) of bacterial
lipopolysaccharide (LPS, Sigma) was added to each well of the BMDC cultures on Day
6.
2.5.2 Cytotoxicity assays
Setting up BMDCS in a 96 well plate: BMDCs were cultured as in Section 2.5.1
but on Day 5 were transferred to a 96 well plate at 5000 cells/well in complete medium.
Fe NPs and FeOx NPs were added at concentrations ranging from 0-200µg Fe ml−1 in
triplicate wells. As a control, wells with media only (no cells) were set up for every
concentration of NPs.
Trypan blue exclusion for viability: On Day 7, 10µl aliquots were removed from
each well and counted using a haemacytometer. Live cells were distinguished by the
exclusion of trypan blue dye (Invitrogen).
MTT for metabolism: To test cellular metabolism, 20µl of 5mgml−1 MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Invitrogen) was added to
each well of the 96 well plate. The cells were incubated at 37◦C for a further 4 hours
then the medium was carefully removed. 150µl of DMSO (Aldrich) was added to each
well to dissolve the crystals completely. The absorbance of the each well at 570 nm was
then measured through a spectrophotometer (Versamax Plate Reader). Cell viability
was expressed as a percentage of the control - absorbance of NPs only.
2.5.3 Flow cytometry
Antibody staining: Cells were stained with antibodies in 96 well plates at 4C. The
medium used was PBS containing 1% foetal calf serum, 0.01% sodium azide and 2mM
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Table 2.1: Antibodies and fluorophores used in this thesis. The fluorophores
in the table include PerCP (peridinin-chlorophyll-protein), PacBlue (Pacific Blue), FITC
(fluorescein isothiocyante), PE (phycoerythrin), Cy7 (cyanine 7), PETR (phycoerythrin
texas red), APC (allophycocyanin), V450 and V500 (Horizon 450 and 500).
Antigen Fluorophore Source Clone number
CD4 PerCP BD RM4-5
CD8 PacBlue Biolegend SK-1
NK1.1 FITC BD PK136
CD3 PE-Cy7 BD 145-2C11
CD62L PE BD MEL-14
CD44 APC BD IM7
B220(CD45R) PETR BD RA3-6B
CD11b PE eBioscience M1/70
CD11c APC-Cy7 eBioscience N418
CD8 V500 BD 53-6.7
F480 PerCP RD Systems 521204
Ly6c PE-Cy7 Biolegend RB6-8C5
CD86 V450 BD GL1
EDTA. Non-specific Fc-receptor mediated antibody binding was blocked by incubation
with anti-CD16/32 antibody (2.4G2, in house production). After blocking, cells were
resuspended in medium with antibodies (Table 2-1) and incubated for 15 minutes. Cells
were washed twice in medium and to distinguish dead cells, 50ng ml−1 of propidium
iodide (PI, BD Pharmigen) or 0.1µg ml−1 DAPI (4,6-diamidino-2-phenylindole, BD
Pharmigen) was added to the cells before acquisition.
Analysis: Flow cytometry was performed using a BD FACScalibur or BD LSRII
SORP (Becton Dickinson) and analysed using FlowJo software (Treestar).
2.5.4 DC/peptide vaccine preparation
BMDCs were prepared as in Section 2.5.1 and were pulsed with SIINFEKL peptide
(Ovalbumin peptide257-264, Genscript Corp) in complete medium for two hours. The
cells were then washed twice in incomplete medium, then resuspended in PBS. Mice
were vaccinated by intravenous injection of 106 cells in 200µl of PBS through the tail
vein.
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2.5.5 VITAL assay
Peptide loading: The cytotoxic activity of CD8+ T cells induced by vaccinations was
measured by the VITAL assay as originally described by Hermans et al99. Syngeneic
splenocyte populations were loaded with 50nM, 5 nM, and 0.5 nM SIINFEKL peptide
in complete medium for two hours. Two washes in incomplete medium were performed
to remove excess peptide and once in PBS.
CFSE labelling of cells loaded with peptide: Splenocytes with increasing peptide
concentrations were then labelled with increasing concentrations (up to 2µM
determined by titration of each batch) of carboxy-fluoroscein succinimidyl ester (CFSE)
(Molecular Probes) for 8 mins at room temperature. After incubation, an equal volume
of foetal calf serum was added and cells were washed twice in complete medium and
once in IMDM before injection into mice.
CTO labelling of control cells: As a control, splenocytes unlabelled with peptide
were suspended in pre-warmed complete medium and CTO (Cell Tracker Orange,
Molecular Probes) was added at a final concentration of 10µM. After incubation for 15
minutes at 37◦C and centrifugation at 472 x g, cells were washed in complete medium
and washed twice in incomplete medium. Equal proportions of all four cell populations
were mixed together and 107 cells were injected intravenously into groups of immunized
and na¨ıve mice.
Lymph node harvesting: The assessment of specific lysis of the peptide-loaded
targets was assessed 24 hours later by euthanizing the mice by cervical dislocation and
removing the axillary, brachial and inguinal lymph nodes. The lymph nodes were
processed into a single cell suspension by passing through a fine (40µm) gauze mesh.
The cells were analysed by flow cytometry (Section 2.5.3).
2.5.6 DC migration by CFSE labelling
BMDCs were prepared into a vaccine (Section 2.5.4) and were labelled with CFSE
(Section 2.5.5) before subcutaneous injection at 106 cells in 50µl of PBS into the upper
hind limb of C57Bl/6 mice. The draining inguinal lymph nodes (on the same side as the
injection) were harvested (Section 2.5.5) at 48 hours and analysed by flow cytometry
(Section 2.5.3).
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2.5.7 Lymph nodes ex vivo at 9.4 T in agar
BMDCs labelled with NPs (Section 2.5.1) and loaded with peptide (Section 2.5.5) were
injected into the upper hind limb. The draining lymph nodes were harvested from mice
(Section 2.3.6) 48 hours later and placed in PBS without being passed through gauze.
The lymph nodes were dispersed intact into a 1% agar gel matrix and the T2 relaxation
time was determined at 9.4T (Section 2.3.7).
2.5.8 Tumour lysate preparation
Preparation of lysate: Tumour lysate from cancer cells was prepared by first
harvesting GL261 or EG7ova cells in culture (Section 2.3.8), washing twice in PBS then
placing 5 x 106 cells in 200µl of PBS in a plastic cryotube. The cells were snap frozen
by immersion of the cryo tube into liquid Nitrogen. After 1 minute they were removed
and placed in a hot water bath at 37◦C. This freeze-thaw was repeated four times.
After the final cycle, it was confirmed that no viable cells remained by trypan blue
exclusion (Section 2.5.2). The protein content was of the lysate was determined then
the lysate was added at appropriate concentrations to BMDCs at Day 5 of their in
culture (Section 2.5.1).
Determination of protein content: A Biorad Protein assay kit (BioRad) was used
to determine the protein concentration of the tumour lysate. 5 ml of lysate and protein
(bovine serum albumin, BioRad) standards were aliquoted to 96 well plate in triplicate.
25 ml of Biorad Protein Assay Reagent A, then 200 ml of Biorad Protein Assay Reagent
B was added into each well. ≈15 minutes was allowed for the reaction to proceed, with
some colour change occuring immediately after the addition of Reagent B. Absorbance
was analyzed at 750nm with a spectrophotometer (Versamax Plate Reader) and the
lysate concentrations were determined with reference to a standard curve of the protein
control.
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2.6 Methods from Chapter 6
2.6.1 In vivo lymph node measurement
MRI scans were performed as described (Section 2.4.3). Measurement of the inguinal
lymph nodes was performed using ImageJ. The area was measured by tracing around
the border of the lymph node and its surrounding fat on a coronal slice. The area of
each lymph node was taken from on the coronal slice in which it had the greatest area.
2.6.2 Cell gating strategies for flow cytometry of lymph nodes
Lymph nodes were harvested, processed (Section 2.5.5), counted and stained with
antibodies for examination by flow cytometry (Section 2.5.3). Compensation was
performed with anti-rat and anti-hamster compensation beads (BD). Cell types were
defined by the gating strategy defined by the flow plots in Figure 2-2. The gates were
set using flow data from the contralateral lymph nodes of the DC only group as these
were the closest to a true na¨ıve cell population. All cells went through two gates for
singlets (to remove clumped cells) based on forward scatter area versus height then side
scatter area versus height. All cells then went through a gate for forward and side
scatter area to remove debris, and a DAPI negative gate to remove dead cells. Different
cell types were then gated in the following way: CD4+ T cells (B220-/CD4+), CD8+ T
cells (B220-/CD4+) , B cells (B220+), NK cells (B220-/CD4-/CD3-/NK1.1+), NKT
cells (B220-/CD3+/NK1.1+), DCs (B220-/CD11c+), monocytes
(B220-/CD11c-/Ly6CHi) and macrophages (B220-/CD11c-/F480+). >95% of events
were recorded from each lymph node for analysis as determined by comparison with cell
counts using a haemacytometer.
2.6.3 Tumour protection studies
C57Bl/6 mice received a subcutaneous injection containing 106 EG7ova cells in 100µl of
PBS into the left flank, one week following vaccination. Mice were examined daily from
day 6 and deemed to be positive for tumours when they developed a mass measuring
greater than 4mm2 by external calliper measurements. Mice were euthanized by CO2
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Figure 2.2: Flow cytometry gating strategies for cells recovered from lymph
nodes. Gates are shown as polygons with purple boundaries, drawn on the flow plots
from samples from contralateral lymph nodes in the DC only group. The top line shows
the gates that all cells went through to exclude cell clumping, debris and dead cells. From
the second line, arrows indicate the passage through a gate. Cell types are labelled next
to the final gate they went through. The axes show the detector associated with the
fluorophore-labelled antibody (Table 2-1).
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asphyxiation or cervical dislocation when their tumour reached 200mm2 or at the end of
60 days.
Chapter 3
Characterisation of Fe NPs for
biomedical applications
3.1 Introduction
Magnetic nanoparticles (NPs) are effective in a range of biomedical applications
including magnetic resonance imaging (MRI) contrast enhancement. For more than 20
years, iron oxide nanoparticles (FeOx NPs) have been used to enhance T2 contrast in
clinical MRI28. A significantly larger magnetic moment and T2 contrast effect can
potentially be achieved with iron nanoparticles (Fe NPs), but development has been
limited by difficulty in preparing stable particles. In this chapter, stable Fe NP
prepared by a novel, simple, synthesis are characterised and compared with FeOx NPs
as T2 contrast agents in vitro.
3.1.1 Characterisation of magnetic NPs
There are multiple factors that determine the efficacy of MRI contrast produced by
magnetic NPs applied in vitro46,100 and in vivo101. In addition, synthesis of NPs is
complex because they are colloids102. Although the relationship between a NP’s
physicochemical characteristics and its efficacy as an MRI contrast agent are not yet
well understood103, the accurate characterization of size, crystal structure,
hydrodynamic size as well as the effects on MRI contrast in vitro can be helpful in
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assessing how a NP might perform as a contrast agent in vivo. This is particularly
important in determining the reproducibility of a novel synthetic method30.
The crystalline size of NPs can be measured by transmission electron microscopy
(TEM). TEM allows the imaging of individual particles and by sizing significant
numbers of NPs, the mean NP size can be estimated. The crystal size of NPs can be
also be determined by X-ray diffraction where it is calculated from the line broadening
on the diffraction pattern using the Scherrer formula104,105. The size of a NP affects
both its relaxivity and its biodistribution. Larger particles tend to have greater effects
on T2 relaxation within a certain range
106. Increasing a NP’s size also increases its
uptake into the liver and spleen106 (see Chapter 4 for mechanisms).
The crystal structure of a NP can be determined by the electron diffraction produced
using a TEM. The crystal structure has a large impact on the magnetic properties of a
NP, and thus its effectiveness in producing MRI contrast by enhancing transverse
relaxation. The different crystal structures of iron oxides have a wide range of magnetic
susceptibility values and effects on T2 relaxation, ranging from 0.3 emu g
−1 for
haematite, 7-20 emu g−1 for feroxyhyte to 92 emu g−1 for magnetite107. For the
purposes of this thesis FeOx NPs refers to NPs containing a core of maghemite or
magnetite. The crystal composition of the NP also affects its cytotoxicity, in particular
when the NP contains transition metals or lanthanides, such as Co108, Mn109 or Gd110,
with proven toxicity in humans.
The hydrodynamic size is commonly measured by photon correlation spectroscopy103,
otherwise known as dynamic light scattering (DLS). This gives the size of a NP
including its surface coating. The hydrodynamic radius distinguishes the two main
classes of commercial FeOx NPs, where NPs smaller than 50nm are referred to as
ultrasmall superparamagnetic iron oxide (USPIO) particles and those larger than 50nm
are referred to as merely superparamagnetic iron oxide nanoparticles (SPIO)111. SPIO
particles are used predominantly for liver imaging30, as they are rapidly taken up by
liver macrophages. USPIO, with their smaller size, have been used for blood pool and
lymph node imaging as they have a longer elimination half-life from blood allowing
them to reach deeper compartments112.
The magnetic susceptibility of NPs can be measured in a superconducting quantum
interfering (SQUID) magnetometer105. A NP’s magnetic susceptibility is related to its
ability to enhance T2 relaxation, in that NPs with a larger magnetic susceptibility can
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induce more efficient T2 relaxation of protons, resulting in greater T2 contrast
enhancement113,114.
3.1.2 Synthesis of Fe NPs
Fe has the highest saturation magnetization at room temperature among all elements115
and is biocompatible, making it an ideal candidate for MRI contrast enhancement.
Nevertheless, the development of Fe NPs for biomedical applications has been limited
due to the difficulty in preparing Fe NPs that are stable to oxidation using simple
synthetic methods and precursors115,116.
Under ambient conditions, Fe NPs of 8 nm or smaller oxidize completely upon exposure
to air117. For larger NPs, an oxide shell of 3-4 nm forms instantly on the surface,
forming Fe/FeOx core/shell NPs. The synthesis of Fe NPs larger than 8 nm has been
achieved by the decomposition of iron pentacarbonyl, [Fe(CO)5]
116. Additional reports
include the use of other precursors in forming iron nanocubes118. However, all of these
processes are limited in terms of ease of synthesis and scalability; [Fe(CO)5] is volatile
and highly toxic115, and other processes involve precursors that are expensive and
air-sensitive119, or require high decomposition temperatures118.
This thesis employs Fe NPs that have been prepared by a simple synthesis involving the
decomposition of the Fe precursor, Fe(C5H5)(C6H7), in the presence of oleylamine
(OLA) stabilizing molecules105. The sandwich compound was chosen for its simple
preparation and ease of decomposition compared to other more stable sandwich
compounds such as ferrocene120. The synthesis was carried out in a closed reaction
vessel under a mild hydrogen atmosphere, at 130◦C. The temperature required was
lower than the temperatures (150-300◦C) required for decomposition of other iron
precursors in previous studies. Once synthesized, the Fe NPs were exposed to air to
allow oxidation of the surface, forming Fe/FeOx core/shell NPs. The oxide layer can be
exploited as a passivation shell that prevents further oxidation117 and enables functional
adaptation for biomedical applications using protocols established for iron oxides45.
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3.1.3 Aims
The aim of this chapter is to test the hypothesis that Fe NPs can produce more effective
T2 contrast than FeOx NPs by:
1. Characterising Fe NPs and FeOx NPs produced by simple synthetic methods in
terms of their size, crystal structure and hydrodynamic radius
2. Developing a ligand exchange strategy and apply it to both Fe NPs and FeOx
NPs to make them water dispersible and biocompatible
3. Examining the T2 relaxivity of Fe NPs and FeOx NPs
4. Measuring the uptake of Fe NPs versus FeOx in multiple cell lines in vitro
5. Investigating the ability of Fe and FeOx NPs to improve T2 contrast of labelled
cancer cells in vitro
3.2 Results
3.2.1 TEM characterisation of Fe and FeOx NPs
The size and crystal composition of Fe-based NPs are important factors in determining
their induction of transverse relaxation of water protons49. This study was primarily
concerned with how the addition of a Fe core affects the T2 MRI contrast versus pure
iron oxide particles and whether this could improve the biomedical applications of MRI.
It was therefore important to compare the Fe NPs to FeOx NPs of similar size so that
any differences observed in T2 relaxation could be attributed to differences in their
crystal composition and not their size. The size and crystal composition of the
synthesized Fe NPs and FeOx NPs were examined by transmission electron microscopy
(TEM) to produce images (Figure 3-2) and electron diffraction patterns (Figure 3-3).
The transmission electron microscope (TEM) has similar optics to a light microscope
with several important differences (Figure 3-1). Firstly, the TEM uses a beam of
accelerated electrons travelling in a vacuum with a wavelength of 2.5pm instead of
visible light with wavelengths down to 400nm. This enables the TEM to resolve
distances as small as several angstroms (10−10m). Secondly, the lenses in the TEM are
electromagnetic instead of glass and are able to focus the electrons into a very narrow
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beam. When the electron beam hits the sample, electrons are transmitted through the
sample and can be made to form an image after enlargement by passing through
electromagnetic lenses.
As the distances between atoms in a crystal is of the same order as the wavelength of
the electrons, the lattice planes of the crystal can act as diffraction gratings so that
some electrons will be diffracted at the lattice planes producing an electron diffraction
pattern. Lattice planes can be labelled using Miller indices which consist of a three
integers h, k, and l, written (hkl), which describe how the plane intersects the main axes
of the crystal.
To determine the spacing of the lattice planes, the Bragg law describes the relationship
between interplanar distance d and diffraction angle θ: nλ = 2dsin2θ. Since the
wavelength (λ) of the electrons is known, the distances between the lattice planes can
be determined from the diffraction patterns (as seen in Figure 3-3). These distances are
related to the size and position of atoms in the crystal and can be used to determine the
crystal structure of the sample.
When imaged by TEM (Figure 3-2), the Fe NPs had a mean diameter of 16.1nm with a
central dark core of 9nm. The FeOx NPs had a mean diameter of 15.4nm and there was
a uniform density within each particle. The FeOx NPs were not as monodisperse as the
Fe NPs, however 90% of the FeOx NPs (versus 100% of the Fe NPs) were within 2 nm
of the mean of the Fe NPs.
3.2.2 Electron diffraction pattern confirms Fe NP and FeOx
NP crystal structure
The electron diffraction pattern of Fe NPs (Figure 3-3a) showed ring patterns consistent
with α-Fe assigned to the (110), (200), (211) and (310) lattice planes, and FeOx of
spinel structure: either magnetite (Fe3O4) or maghemite (γ-Fe2O3) assigned to the
(311) plane. Electron diffraction patterns produced using a TEM, called selective area
electron diffraction (SAED), can not differentiate between magnetite and maghemite122.
The spinel structure assigned to FeOx within the Fe NPs is consistent with the
structure of the passive FeOx film that forms on the surface of Fe123.
This is a key finding because it verifies the presence of α-Fe in the Fe NPs, which is
highly magnetic. Pure α-Fe NPs of a similar size have a reported magnetisation of 190
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Figure 3.1: Beam diagram of a transmission electron microscope. The TEM
electron beam is generated from an emission source such as a LaB6 filament and travels
in a vacuum through a series of condenser lenses (not shown) before reaching the sample.
Electrons transmitted through the sample are focused at the objective lens and are then
magnified by a projector lens (not shown) to form an image on a fluorescent screen at
the base of the TEM. Electrons diffracted by the sample form a diffraction pattern at
the back focal plane of the objective lens. This pattern can be viewed on the fluorescent
screen by adjusting the back focal plane of the objective lens to act as the objective plane
for the projector lens. Diagram adapted from source121.
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Figure 3.2: TEM images of Fe and FeOx NPs. Carbon coated TEM grids were
dipped into toluene dispersions of Fe and FeOx NPs and were dried at ambient conditions
before imaging at 200keV (a). The size distributions (b) were determined by counting 100
NPs of each type. (scale bar = 50nm, TEM image of Fe NPs taken by Soshan Cheong).
The TEM measurement of Fe NPs was performed on multiple (>10) specimens with a
representative result shown.
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Figure 3.3: Electron diffraction patterns of Fe and FeOx NPs. Electron diffrac-
tion was performed on Fe NPs and FeOx NPs using a 200keV TEM. The ring patterns for
Fe NPs (a) are assigned to planes of the crystal structures of α-Fe and spinel FeOx. The
ring patterns for FeOx (b) are assigned to planes of spinel FeOx. (Electron diffraction
pattern for Fe NPs taken by David Herman)
emu/g124. The Fe NPs with the FeOx shell synthesized here had a magnetisation of 140
emu/g when measured at 2T in a superconducting quantum interfering (SQUID)
magnetometer105. This is a much higher magnetisation than that of 40-70 emu/g
reported for pure FeOx125.
The FeOx NPs synthesized were also subject to analysis electron diffraction pattern
(Figure 3-3b). These NPs had a ring pattern consistent with the same spinel structure
as Fe NPs, indicating magnetite or maghemite. This important finding suggests that
the FeOx present in both types of NPs is of the same crystal structure. Sharing the
same surface has important implications, as it may mean that pharmacokinetics will be
similar, and that strategies for surface modification may be applicable to both types of
NP.
3.2.3 DMSA ligand exchange to produce water dispersible
NPs
After synthesis in an organic solvent (mesitylene) and coated with a hydrophobic
stabilising molecule (oleylamine), Fe NPs require surface modification before they will
readily disperse in aqueous solutions (Figure 3-4). This involves exchanging the
hydrophobic oleylamine molecules on their surface with a hydrophilic ligand. There are
a multitude of different molecules that have been chemically attached to the surface of
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Figure 3.4: Schematic of synthesis and DMSA coating of Fe NPs Fe NPs were
synthesized from a sandwich Fe precursor molecule in a closed container in the presence
of oleylamine (OLA) and a hydrogen atmosphere. After exposure to ambient conditions
an oxide shell forms. These NPs are dispersible in organic solvents such as hexane but
not dispersible in water. Following ligand exchange with DMSA, the Fe NPs disperse
readily in water. Schematic designed with Soshan Cheong.
Figure 3.5: Meso-2,3-
dimercaptosuccinic acid (DMSA).
DMSA is an organic acid containing two
carboxyl (COOH) and sulfhydryl (SH)
groups. It can bind to Fe atoms on the
FeOx surface of NPs through its carboxyl
groups.
FeOx NPs to improve their stability in aqueous dispersions and to alter their
pharmacokinetics50. A water soluble, sulfhydryl containing compound,
meso-2,3-dimercaptosuccinic acid (DMSA, Figure 3-5) was chosen as a coating molecule
as it has an excellent safety profile in humans126, having been used as a chelator for
heavy metal poisoning since the 1950s127. DMSA binds through its carboxyl group to
Fe atoms on the FeOx surface of the NP128, which assists in displacing oleylamine.
Furthermore, DMSA has two different functional groups (a thiol and a carboxyl group)
to which other molecules, such as antibodies can be readily attached for further
functional specialisation129,130.
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3.2.4 The importance of pH adjustments during DMSA
coating of NPs
One of the strategies used to assess the ligand coating of NPs is to determine their
hydrodynamic size when dispersed in water by dynamic light scattering (DLS).
Dynamic light scattering is performed by illuminating particles in a solvent with a laser
and recording the scattering produced. The intensity of the laser scattering fluctuates
at a rate that is dependent on particle diffusion in the solvent with smaller particles
producing more rapid fluctuations due to Brownian motion. If the viscosity of the
solvent is known then the hydrodynamic radius of the particles can be calculated from
analysis of the time dependence of the intensity fluctuation. Comparing the
hydrodynamic size of coated NPs to their TEM size before coating gives an indication
of the coating thickness and to a larger extent, particle aggregation131.
To coat Fe NPs with DMSA, a method from the recent literature for FeOx NPs was
adopted132. Fe NPs coated by DMSA using this method dispersed poorly in water with
a mean hydrodynamic diameter of > 1µm (Figure 3-6a), indicating significant
aggregation of NPs. An earlier paper by Fauconnier et al detailed the importance of
sequential pH changes to increase the stability of DMSA coated FeOx NPs in aqueous
dispersions96. The first pH adjustment (to pH 3) was shown to produce the maximum
amount of adsorbed DMSA to the surface of the FeOx NPs. The next step is to remove
the excess unbound DMSA by centrifugation and discarding the supernatant. The NPs
are redispersed in water and the second pH adjustment is made to 9.25. This assists in
the formation of disulfide linkages between adjacent molecules of DMSA to further
stabilise them on the surface of the NPs. At this pH, the carboxyl groups on the
unbound ends of DMSA are de-protonated and have a net negative charge which helps
prevent particle aggregation by electrostatic repulsion of like charges. By applying these
pH adjustments during the coating process, a superior aqueous dispersion was produced
with a mean hydrodynamic radius of 62nm (Figure 3-6b). The same DMSA ligand
exchange method was applied to FeOx NPs producing an aqueous dispersion with a
hydrodynamic radius of 76nm (Figure 3-6c).
The Fe NPs and FeOx NPs coated by the improved DMSA method here have a similar
hydrodynamic size to the 60nm commercial Resovist NPs which are FeOx with a
dextran coating133. These hydrodynamic sizes were much smaller than those reported
for DMSA coating methods without pH adjustment132 where 10nm FeOx NPs had a
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hydrodynamic diameter of 280nm after coating. The ratio of TEM pre coating to
hydrodynamic radius post-coating reported here was 1:4, which compares with results
reported with other coating molecules, such as dextran, where ratios of 1:3 up to 1:30
have been achieved30,125.
3.2.5 Stability of Fe NPs over time
After producing a stable dispersion of Fe NPs in water, it was important to check for
further oxidation of the Fe core, which would reduce its magnetisation and utility as an
MRI contrast agent. Under ambient conditions, Fe NPs of 8 nm or smaller have been
shown to oxidize completely upon exposure to air134. Fe NPs were imaged by TEM
before coating with DMSA (Figure 3-7a). After coating with DMSA the Fe NPs were
dispersed in water and stored at 4 ◦C for six months. There were no changes observed
in the overall size of the NPs or in the size of the FeOx shell (Figure 3-7b). This
suggests that oxide shell is acting as a passivation layer preventing further oxidation
which is a well described phenomenon in bulk Fe123. Note that the size of the DMSA
coated NPs measured by TEM (Figure 3-7) is significantly smaller than the
measurements obtained by DLS (Figure 3-6). This can be explained by the loss of the
hydration shell surrounding the NPs during the dehydration required for TEM, which is
performed in a vacuum.
3.2.6 T2 relaxation of Fe NP dispersions
The measurements performed up to this point had shown that the 16nm Fe NPs
possessed a highly magnetic α-Fe core, were covered in an FeOx shell preventing further
oxidation, and they dispersed in water after coating with DMSA. FeOx NPs had also
been synthesized with the same crystal structure as the outer shell of the Fe NPs; they
were of a similar size to the Fe NPs and they had been coated with the same molecule
(DMSA). The efficacy of Fe NPs as T2 contrast agents could now be directly compared
to the FeOx NPs, and any major differences between the two NPs could be ascribed to
the α-Fe core of the Fe NPs. The efficacy of T2 contrast agents is assessed by measuring
their effect on the transverse relaxation of the nuclear magnetic spins of water protons.
This effect is known as T2 relaxivity and it is defined as the amount of change in T2
relaxation produced per unit concentration of contrast agent (unit: mM−1s−1). T2
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Figure 3.6: Hydrodynamic size of NPs in aqueous solution. The hydrodynamic
size of NPs were analysed by dynamic light scattering (DLS) following coating with
DMSA. Fe NPs were sized before (a) or after (b) adjusting the pH during coating as
described in the text. FeOx NPs were sized after DMSA coating with pH adjustment (c).
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Figure 3.7: Stability of Fe NPs after DMSA coating. TEM images were taken of
Fe NPs dispersed in hexane before coating with DMSA (a). The NPs were then coated
in DMSA and dispersed in water for six months before being imaged (b). (scale bar =
10nm, images taken by Sujay Prakabar.)
relaxation can be measured by dispersing the NPs in an aqueous gel then analysing the
gel by nuclear magnetic resonance (NMR). For these measurements, the gradients used
in MRI to produce an image are not required because signal from the entire gel can be
taken with no slice selection being necessary.
Fe NPs and FeOx NPs were dispersed at 5µg Fe ml−1 in 1% agar and analysed at 9.4T
by a spin echo pulse sequence. This sequence corrects for magnetic field inhomogeneities
by the use of 180◦ pulses so that T2 relaxation and not T2* relaxation is being measured
(refer Chapter 1). The T2 times were calculated by using the monoexponential curve fit
S(t) = S0exp(−t/T2), where S(t) is the signal at time = t and S0 is the initial signal
intensity at time = 0. The T2 times for the Fe NP and FeOx NP groups can be seen on
the graph where their curves intercept the horizontal line at signal = 1
e
. At this point
the signal has decayed 1
e
= 63%, such that the S(t) = S0exp(−1) and t = T2. The
vertical line at time = 8 ms is shown as this was the echo time at which the images in
Figure 3-9a were taken. Fe NPs produced enhanced transverse relaxation relative to
FeOx NPs with T2 times of 5.4 ms versus 13.9 ms respectively (Figure 3-8). Both types
of NPs produced large changes in T2 relative to the control gel at 385 ms.
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Figure 3.8: T2 relaxation of Fe and FeOx NP dispersions at 9.4T. The transverse
relaxation of dispersions of Fe NPs and FeOx NPs in agar were analysed at 9.4T using a
spin-echo sequence. Each point represents the signal intensity at a given echo time relative
to the initial signal intensity (at t = 0). Curves were fitted by using a monoexponential
decay. The horizontal line drawn at signal = 1
e
represents the intercept where time = T2.
The vertical line drawn at t = 8 ms represents the echo time used for imaging in later
Figure 3-9a.
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3.2.7 T2 relaxivity of Fe NPs
To calculate the T2 relaxivity (r2) for each type of NP, multiple measurements of T2
relaxation were taken at varying concentrations of the NP dispersed in gel. Five
concentrations of NPs were used to determine their r2 (0, 0.5, 1.0, 2.0 and 5.0µg Fe
ml−1), as seen in Figure 3-9. A linear relationship between the change in T2 relaxation
of the gels versus the concentration of NPs was observed as reported elsewhere135.
The r2 of Fe NPs taken from the slope of Figure 3-9b were plotted versus FeOx NPs in
Figure 3-9c. The result was that Fe NPs had an r2 value of 324 mM
−1s−1 compared to
145 mM−1s−1 for FeOx NPs. Fe NPs therefore produce more than twice the amount of
contrast as FeOx NPs on T2 weighted images, which can be detected visually as darker
images at each concentration relative to FeOx NPs in Figure 3-9a.
These r2 measurements were taken after the Fe NPs had been in aqueous solution at
4◦C for up to six months. There was no trend towards a reduction in r2 over time (data
not shown) suggesting that the highly magnetic α-Fe core remained intact. This
observation, combined with the TEM data in Figure 3-7, is evidence that the Fe NPs
are stable against oxidation for months in solution.
3.2.8 In vitro MRI contrast in cells labelled with NPs
To improve cellular imaging with MRI, it was necessary to show that the greater T2
contrast effect of Fe NPs over FeOx NPs observed from dispersions of NPs was
applicable also to dispersions of cells labelled with NPs. To undertake this analysis,
cells from diverse tissue types were used, including cervix (HeLa adenocarcinoma cells),
brain (GL261 glioma cells), immune system (bone marrow derived dendritic cells,
BMDCs) and skin (B16 melanoma cells). These cells were cultured in the presence of Fe
NPs or FeOx NPs at 2µg Fe ml−1. The cells were then washed, harvested, dispersed at
500 cells µl−1 in 1% agar and imaged at 9.4T.
In all cell types tested, labelling with Fe NPs resulted in at least twice the T2 contrast
versus labelling with FeOx NPs (Figure 3-10). This difference in T2 contrast can be seen
in the image of B16 cell dispersions in Figure 3-10a. It is interesting to note that there
was no increase in T2 contrast in the BMDCs versus the other types of cells, which are
all cancer cells. BMDCs have phagocytic activity related to their function as antigen
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Figure 3.9: Relaxivity of Fe NPs and FeOx NPs at 9.4T. The T2 relaxation of
dispersions of Fe NPs and FeOx NPs in 1% agar were analysed at 9.4T using a spin-
echo sequence. The images in (a) were taken at an echo time of 8 ms. The T2 of each




control) versus the concentration of NPs in the observed gel (b). A linear fit was made
of the data in (b) and the slopes were plotted as r2 in (c). A different slope was fitted
for each batch of NPs to produce the standard error in (c). (***p<0.001 by two tailed t
test).
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Figure 3.10: T2 contrast in diverse cell types labelled with NPs in vitro. Cell
dispersions of 500 cellsµl−1 in 1% agar were imaged at 9.4T using a multi-slice spin echo
sequence with an echo time of 8ms. The T2 times of the cell dispersions were determined
by manually selecting a region of interest within the cell dispersion then plotting the T2
relaxation as in Figure 3-8. (a) Images of B16 cell dispersions labelled with Fe NPs, FeOx
NPs or PBS control. (b) The T2 times were compared to that of the control cell layer
and plotted as %∆T2 = (T2 control - T2 sample)/T2 control. (*p<0.05, **p< 0.01 by two
tailed t test).
presenting cells and it is known that phagocytic cells such as macrophages are
responsible for the majority of FeOx NP uptake in vivo. The in vivo uptake of Fe NPs
will be examined in Chapter 4 and BMDCs will be discussed in further detail in
Chapter 5.
In summary, the magnitude of cellular T2 contrast improvement of Fe NPs over FeOx
NPs is similar to the differences in their r2 values, supporting the hypothesis that the
improved r2 of Fe NPs can be translated into improving the biomedical applications of
FeOx NPs.
3.2.9 Fe uptake into cells
An alternative explanation could be proposed for the improved T2 contrast of cells
labelled with Fe NPs in Figure 3-8. Instead of Fe NPs producing more efficient
transverse relaxation of water protons than FeOx NPs at the same dose of Fe, as
indicated by a larger r2 value, the intracellular uptake of Fe NPs could be more efficient,
producing a greater concentration of Fe per cell. Therefore it was important to examine
the Fe content of cells after incubation in the same dose of Fe NPs or FeOx NPs. B16
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Figure 3.11: Fe content of cancer cells after labelling with Fe and FeOx NPs.
B16 cells incubated with 2µg Fe/ml of Fe NPs (a) or FeOx NPs (b) were washed, har-
vested, fixed and stained with Perl’s stain for Fe. A group incubated with PBS only was
used as a control (c). Atomic absorption spectroscopy was performed on the three groups
of cells to determine the quantitative Fe content per cell (d). (scale bar = 100µm)
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cells were incubated in NPs using the same method as for the cells imaged in Figure
3-10. After washing and harvesting, B16 cells were fixed and stained for Fe with Perl’s
stain. Images taken from light microscopy can be seen in Figure 3-11a-c. Fe uptake was
qualitatively the same in cells labelled with either Fe NPs (a) or FeOx NPs (b), whereas
no Fe was seen in the control cells that had not been exposed to NPs (c).
To produce a quantitative analysis of cellular Fe, flame atomic absorption spectrometry
was performed where samples were dissolved in concentrated hydrochloric acid and
atomised under an air/acetylene flame. Light of a specific wavelength, which is
absorbed only by the atom of interest, is radiated through the stream of atoms in the
flame. The amount of light absorbed at the specific wavelength is proportional to the
concentration of the atom. The result of this analysis again showed that there was no
significant difference in the amount of Fe acquired by cells incubated with either Fe
NPS or FeOx NPs (d).
The findings from microscopy and atomic absorption spectroscopy show that there is a
similar cellular uptake of Fe NPs and FeOx NPs in vitro. This finding is important
because it provides further evidence that there is a qualitative difference in T2 contrast
produced by Fe NPs. Although there are severe limitations in making comparisons
between in vitro and in vivo uptake, if a different rate of cellular Fe uptake was seen in
vitro it would have cast doubt on the hypothesis that these Fe NPs and FeOx NPs, with
the same outer shell and DMSA coating, would possess similar pharmacokinetics in vivo.
3.3 Discussion
3.3.1 Principle findings
Fe NPs were synthesized by a novel, simple technique and found to have a core of
highly magnetic α-Fe surrounded by a shell of FeOx. Water-dispersible Fe NPs and
FeOx NPs of a similar hydrodynamic size were prepared by ligand exchange with
DMSA, and compared as MRI contrast agents. Fe NPs were found to have more than
twice the T2 relaxivity as FeOx NPs. When added to cancer cells in vitro, Fe NPs
produced twice the T2 weighted signal change per cell than FeOx NPs, despite the same
amount of cellular NP uptake.
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3.3.2 Implications of the study
A significant contribution to the field of MRI contrast agents from this research is the
application of Fe NPs in biological systems. Fe NPs have been produced by other
synthetic methods, but have had minimal testing in cell culture or animal models. Most
studies of Fe NPs include magnetization data but no T2 relaxivity or bioapplication
data47,116,118,119,134,136–138.
A comparison was recently performed of Fe NPs with different FeOx shells and doping
with cobalt (Co) or manganese (Mn)139. In this study, Yoon and colleagues measured
the T2 relaxivity of various Fe NPs and applied them to a cell detection assay in blood.
They found that Fe NPs with the same overall size (16nm), oxide shell
(magnetite/maghemite) and surface coating (DMSA) as used in this study, proved more
sensitive when applied to the T2 contrast-based assay than FeOx NPs, including those
doped with manganese and cobalt. These findings were published in the same issue of
Angewandte Chemie as work from this thesis105 (see appendix). The strengths of the
paper by Yoon et al were the comparisons of multiple NPs and the detailed magnetic
studies with mathematical modelling. The paper from this thesis provided significant
additional information by confirming that T2 contrast differences were not due to
varying uptake of NPs and that Fe NPs could improve the MRI diagnosis of small
tumours in vivo (Chapter 4).
A criticism that could be raised against both of these papers is that they did not make
comparisons with commercial FeOx NPs. The primary concern of both papers was to
examine the effects of NPs with different metallic cores on T2 contrast. As the relaxivity
and cellular uptake of NPs is strongly affected by their size and coating
molecules100,125,138, it is important to compare NPs of the same size coated with the
same coating technique. Furthermore, the T2 relaxivity (r2) values of the FeOx NPs
used in these studies were similar or superior to all of the commercial FeOx NPs
contrast agents currently on the market49.
Although Fe NPs can induce more effective T2 relaxation than pure FeOx NPs, there
are FeOx NPs containing other metals and possess higher reported r2 values than the
Fe NPs in this study. Specifically, magnetic NPs have been synthesized with pure cobalt
metal140 and alloys such as FePt141, FeZn142, CoPt3
143. FeOx NPs have also been
doped with metals to improve their magnetic properties114,144, forming structures with
the general formula MFe2O4, where M is a +2 cation such as Mn, Co, nickel (Ni) or Fe.
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MnFe2O4 has reported r2 values of similar magnitude to the Fe NPs in this study
114,
358 versus 324mM−1s−1 at 1.5T, respectively. When directly compared at 0.47T, Fe
core/MnFe2O4 shell particles had a higher r2 than Fe NPs similar to those used in this
study139. While these metal doped magnetic NPs may make excellent in vitro MRI
contrast agents, cobalt108, nickel145, and manganese metals109 have proven toxicity,
making them unlikely candidates for clinical application. In contrast, Fe-based NPs
degrade to non-toxic Fe and oxygen components, which is evidenced by their excellent
safety profile in clinical studies146.
The improvement of T2 contrast with Fe NPs over FeOx NPs reported in this chapter
has implications not only for clinical applications but also pre-clinical applications, such
as stem cell tracking. There is increasing research involved with tracking stem cells in
vivo by MRI after in vitro labeling with FeOx NPs, and several different types of
applications have already been examined in clinical studies147. The injection of
mesenchymal stem cells (MSCs) represents a promising new therapy for regenerative
medicine106. There is a need to determine the fate of these cells after implantation, to
ensure that they migrate to their intended location and do not become oncogenic
following injection148. It has been shown that MSCs maintain their pluripotent
capabilities, including the ability to differentiate into functional cell lineages, after
labelling with FeOx NPs149,150. However, the sensitivity of detecting labeled cells by
MRI is low, making it only possible to identify large clusters of cells in some
studies151,152. As shown in this chapter, labeling cells with Fe NPs improves the
sensitivity of their detection by MRI, compared with cells labeled with FeOx NPs.
Substituting Fe NPs for FeOx NPs could enable fewer cells to be detected or enable
studies to be performed at MRI with lower field strength where sensitivity can be
reduced by a lower signal to noise ratio153.
3.3.3 Remaining questions
The aim of this thesis is to investigate whether Fe NPs can improve the biomedical
applications of MRI. For this reason, Fe NPs are compared with FeOx NPs with the
same surface coating across a range of applications. A question that remains
unanswered is whether the same differences in T2 relaxivity and the same similarities in
cellular uptake, between Fe NPs and FeOx NPs, would have been observed if a different
coating strategy was employed.
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The coating molecules of a magnetic NP can affect the motion of water molecules near
its surface by hindering water diffusion, immobilizing water molecules by forming
hydrogen bonds, or exclude water molecules by hydrophobic interactions, all of which
may affect the nuclear relaxation of water protons131. Although it is not well
understood, the coating molecules can affect the T2 relaxation and large differences in r2
have been observed between different coating schemes, even when the core magnetic
NPs are of the same crystalline structure and size154. Although it is hypothesized that
Fe NPs would still have a larger r2 value than FeOx NPs, it is uncertain whether the
difference in the r2 values would have the same magnitude if a different coating strategy
were employed.
A further question raised by the work performed in this chapter is whether Fe NPs and
FeOx NPs will have a similar biodistribution in vivo. Very few studies have compared
the uptake of Fe NPs and its effect on T2 relaxation in different organs versus FeOx NPs
in vivo. Differences in biodistribution compared to FeOx NPs could result in the failure
of Fe NPs to produce effective T2 contrast enhancement in various tissues. For example,
if Fe NPs were to be rapidly removed from the blood by uptake into the liver, they may
prove ineffective at imaging other tissues such as lymph nodes. This question will be
addressed in the next Chapter.
3.3.4 Conclusion
Fe NPs were found to be twice as effective than FeOx NPs at producing T2 contrast,
when administered at the same dose, with the same surface coating and with a similar
hydrodynamic size. Fe NPs have the potential to improve a range of MRI-based
biomedical applications including cell tracking and tumour detection. Further studies
with Fe NPs are required to investigate their cytotoxicity, pharmacokinetics and T2
contrast enhancement in vivo.
Chapter 4
Improving the diagnosis of small
tumours by MRI with Fe
nanoparticles
4.1 Introduction
The early and accurate detection of a wide range of cancers can improve the prognosis
and therapeutic options for the patient. Due to the characteristics of their cellular
uptake in the body, FeOx NPs have been used to improve the diagnosis of cancer in the
liver for more than 20 years. An active field of research is addressing whether FeOx NPs
can improve the diagnosis of cancer that has spread to involve lymph nodes. This would
have a large benefit to patients suffering from a range of cancers. Although there has
been modest success in this endeavour, there is a suggestion that MRI with FeOx NPs
is not able to effectively detect tumours in the lymph nodes at an early stage when they
are smaller than 5mm. Fe NPs produce more effective contrast than FeOx NPs in vitro
and therefore have the potential to improve the MRI diagnosis of smaller tumours in
vivo. In this chapter, a mouse model involving tumours with a diameter of 1-3mm is
employed to test whether Fe NPs can improve the diagnosis of small tumours58 above
that of Fe Ox NPs by two blinded, independent radiologists.
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4.1.1 Mechanisms of cellular uptake of magnetic NPs
Fe NPs and FeOx NPs can be readily taken up in vitro by a number of different cell
types without the use of transfection agents to improve uptake155,156, as seen in Chapter
3. This is one of the advantages of their use in MRI-based cell tracking studies.
However, following intravenous injection, the uptake of Fe NPs and FeOx NPs is
primarily into the macrophage-rich tissues of the liver, spleen and lymph nodes157,158.
The mechanisms of cellular uptake of FeOx NPs has been studied in a range of cell
types, and there are important implications for in vivo applications.
Labelling of cells with magnetic NPs is predominantly through surface attachment159 or
by endocytosis, a complex process with at least ten different pathways identified160.
Cellular uptake of magnetic NPs can occur via fluid phase endocytosis161,
receptor-mediated endocytosis106 or phagocytosis158. Phagocytosis is the predominant
pathway for uptake of large particles, such that FeOx NPs are more efficiently
phagocytosed with a size >50nm162. Phagocytosis is enhanced when NPs are coated
with antibodies or complement molecules, acting through the crystallizable fragment
(Fc) of an antibody molecule or the C3b complement molecule, respectively. This
process can be seen in vivo when the immune system reacts to a NP coating molecule,
such as dextran, by producing anti-dextran antibodies163.
Professional phagocytic cells, such as macrophages, are responsible for the majority of
cellular uptake of FeOx NPs after intravenous administration30. FeOx NPs accumulate
in tissues with a large macrophage population and abundant vascular access, such as
the liver and spleen164, although their uptake into macrophages in other tissues such as
transplanted organs can be identified165. Macrophages possess scavenger receptors that
are able to endocytose a wide array of NPs30. In vitro, FeOx NP endocytosis by mouse
peritoneal macrophages was dose-dependently inhibited by polyinosinic acid and
fucoidan, suggesting that a scavenger receptor SR-A-mediated endocytosis is involved
for this contrast agent166.
Using human activated monocyte THP-1 cells, Feridex (120-180nm dextran coated
FeOx NPs) was shown to undergo more intense macrophage uptake than Sinerem
(15-30 nm dextran coated FeOx NPs), probably due to its larger size166. Besides
particle size, phagocytic uptake is also dependent on the surface properties of the NPs,
as ionic carboxy-dextran coating of FeOx NPs of varying sizes leads to a higher uptake
than nonionic dextran coating167.
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NPs can also be taken up by target cells via receptor-mediated endocytosis. Ligands,
including monoclonal antibodies, can be conjugated to the surface of NPs to facilitate
receptor-mediated endocytosis of the particles. Other targeting molecules including
transferrin168, ceruloplasmin169, folic acid170 and epidermal growth factor171 have been
demonstrated to target cell surface receptors and improve endocytosis of FeOx NPs.
Uptake of NPs also occurs in vivo in cell types other than macrophages. Endothelial
cells can endocytose FeOx NPs conjugated to molecules that target cell surface
molecules172, T cells can be labelled in vitro with FeOx NPs without the use of
vectors100. Various cancer cells also uptake FeOx NPs without the use of vectors173, in
fact uptake has been shown to be more rapid in cells which proliferate quickly, which
may be due to an increased rate of endocytosis174. In Chapter 3 (Figure 3-11) and later
in Chapter 5 (Figure 5-2), it is shown that cancer cells and dendritic cells can efficiently
uptake both Fe NPs and FeOx NPs to a similar extent.
The cellular uptake properties of Fe NPs and FeOx NPs are important for their clinical
application. In particular, the tendency of NPs larger than 50nm to be rapidly
internalized by macrophages determines in which organs they can produce effective
contrast. In all the cell types tested in vitro in this thesis, Fe NPs and FeOx NPs had
similar uptake characteristics, which is likely due to their similar size and surface
coating.
4.1.2 Aims
The working hypothesis in this chapter is that Fe NPs can produce better T2 contrast in
vivo than FeOx NPs that not only enhances contrast in the liver, spleen and lymph
nodes but can improve diagnosis of tumours within these organs. This hypothesis will
be tested in C57Bl/6 and Balb/c mouse models, using melanoma (B16) and breast
cancer (4T1) cells, with MR imaging performed in a clinical scanner at 1.5T with
interpretation performed by two consultant radiologists in an independent, blinded
analysis. The following questions will be addressed:
1. Does Fe produce better in vivo contrast than FeOx in organs rich in macrophages?
2. How long does this contrast last for?
3. Can improved contrast be achieved by direct tumour uptake of Fe NPs?
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4. To what degree does antibody-conjugation affect the specific uptake of Fe NPs?
5. Can Fe enable greater detection of tumours (in a splenic tumour model) than
FeOx and/or no contrast control?
6. Can tumours smaller than 5mm be detected with Fe NP or FeOx NP contrast at
1.5T?
7. What is the inter-observer and intra-observer variability of NP-assisted MRI
tumour diagnosis, and does diagnostic accuracy improve with training?
4.2 Results
4.2.1 Fe NPs produce greater T2 contrast in the liver, spleen
and lymph nodes in vivo
FeOx NPs have been used for over a decade as T2 contrast agents for clinical imaging of
the liver175. Therefore the first evaluation of Fe NPs in vivo was to see how they
compared to FeOx NPs in producing T2 contrast in the liver after intravenous
administration. A working hypothesis from the in vitro studies was that Fe NPs could
produce around twice the change in T2 contrast as FeOx at the same dose. The
objectives for this series of experiments was to test this hypothesis in vivo to examine
whether Fe NPs could a) enable a dose reduction and/or b) improve efficacy at the
same dose.
Caution must be exercised in comparing doses of FeOx NPs in rodents versus humans
due to the different pharmacokinetics observed across species. Rodents have more active
uptake into the liver, with elimination half-life in rats is 2 hours versus 24-36 hours in
humans50. Therefore a larger dose is used to visualise other compartments in animal
experiments. Furthermore, younger rodents have been demonstrated to have up to a
50% decrease in half-life of circulating FeOx NPs indicating enhanced uptake by liver
macrophages176. With these findings in mind, experiments with six week-old mice were
performed with doses of Fe and FeOx NPs below the clinical dose used for liver
scanning and above the clinical dose used for scanning other compartments.
For imaging the liver, a dose of 3µmol Fe kg−1 was chosen as this was equivalent to less
than a third of the clinical dose of Feridex (a commercial agent used for liver imaging)
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at 10µmol Fe kg−1 177. Fe NPs produced a 45% reduction in the T2 weighted signal
intensity in the liver versus 21% for FeOx NPs (Figure4-1a,b). For imaging the spleen
and lymph nodes, the dose was increased above the clinical dose of Ferumoxtran-10 (a
commercial agent used for lymph node imaging) of 45µmol Fe kg−1 178. A dose of
160µmol kg−1 was used which is less than one fifth of the dose that can be used safely
in mice (935µmol kg−1)179. At this dose, the T2- weighted signal intensity in the liver in
both the Fe and FeOx groups was reduced by greater than 75% (see Figure 4-1c, 24
hours). However, in the spleen and lymph nodes, this higher dose of Fe NPs produced a
58 % and 25% reduction in the T2-weighted signal versus a corresponding reduction of
29% and 5% with FeOx NPs (Figure 4-2). These findings suggest that at higher doses,
the liver uptake of NPs becomes saturated and greater uptake into other organs occurs,
as demonstrated in other studies178. Further evidence of liver saturation was seen in
Figure 4-1c where the T2 weighted signal in the liver was still reduced at 12 weeks
compared to control. The important novel finding from these studies is that Fe NPs can
produce twice the change in T2 contrast in the liver, spleen and lymph nodes versus the
same dose of FeOx NPs.
4.2.2 Histology of NP uptake into the liver
The working hypothesis was that Fe NPs produced greater changes than FeOx NPs in
T2 contrast due to greater effects on the transverse relaxation of water protons per unit
of Fe (T2 relaxivity) in the tissue of the liver, spleen and lymph nodes. However, a
greater change in T2 contrast could also be explained by an increased quantity in the
uptake of Fe NPs over FeOx NPs in the tissues of interest. To test this hypothesis, mice
were given a dose of 3µmol Fekg−1 of either Fe NPs or FeOx NPs and imaged, as shown
in Figure 4-1a. The mice were culled after scanning and their liver tissue was removed,
sectioned and examined for the presence of Fe under light microscopy. As seen in Figure
4-3, there is increased Fe (blue stain) seen in the livers of mice that received Fe NPs or
FeOx NPs over control mice that received PBS only. There was no qualitative difference
in the amount of Fe in mice that received either Fe NPs or FeOx NPs. Quantitative
analysis by atomic absorption spectroscopy was not useful in determining the amount of
Fe uptake from Fe NPs or FeOx NPs due to the high background content of Fe in the
liver (data not shown). The results from light microscopy here suggest that there is no
substantial difference in the uptake of either NP in the liver, which supports the
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Figure 4.1: Contrast in the liver following intravenous Fe and FeOx NPs. For
imaging of liver contrast, mice were given 3µmol Fe kg−1 (a, b) or 160µmol Fe kg−1 (c) of
Fe NPs or FeOx NPs intravenously and imaged 24 hours later at 1.5T. A control group was
imaged which received injections of PBS only. The mice receiving 160µmol Fekg−1 NPs
were imaged again at 6 weeks and 12 weeks without receiving further contrast agents (c).
For all images the signal intensity was measured by first calibrating the signal intensity
in the organ of interest with a reference of skeletal muscle in the same image. The values
for each organ of each mouse in the Fe NP and FeOx NP groups were then compared
with the corresponding mean of the control group and plotted as %∆T2 contrast as
follows: (signal intensity mean of all control organs)-(signal intensity in organ of mouse
of interest)/ (signal intensity mean of all control organs). (p<0.05 by Mann-Whitney
rank-sum test).
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Figure 4.2: Contrast in the spleen and inguinal lymph nodes following intra-
venous Fe NPs and FeOx NPs. For imaging of contrast in the inguinal lymph nodes
(a,b) and spleens (c (arrow),d), a dose of 160µmol Fekg−1 Fekg−1 was administered intra-
venously and the mice were imaged 24 hours later at 1.5T. A control group was imaged
which received injections of PBS only. The images were analysed and results plotted
using the same method as described in the previous figure. (p<0.05 by Mann-Whitney
rank-sum test).
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hypothesis that the difference in T2 contrast is produced by the greater T2 relaxivity of
Fe NPs.
4.2.3 Direct tumour imaging in vivo with a subcutaneous
melanoma model
The majority of clinical and biomedical studies which employ FeOx NPs as MRI
contrast agents to improve tumour detection do not target the tumour directly. Instead,
the NPs are taken up by macrophages in the surrounding normal tissue (parenchyma)
of the liver or lymph nodes where cancers often metastasize. This limits the use of
FeOx NPs to detecting cancers that have spread to (or in some cases, have originated
from) these organs. Some studies in the literature report selective tumour targeting in
vivo with FeOx NPs that have specialised surface coatings, including the conjugation of
antibodies that recognise specific molecules on the surface of a tumour180. This
approach was investigated here to examine whether the uptake of NPs into tumours
could be improved by surface conjugation with antibodies and to determine whether Fe
NPs could provide enhanced tumour detection. The first step was to examine the
uptake of NPs without any antibody conjugation into tumours in vivo. The previous
chapter showed that there was effective uptake of Fe NPs and FeOx NPs into a range of
cancer cell lines in vitro (Figure 3-10). This was not assured to be the case in vivo due
to both the competing uptake of NPs by macrophages in other tissue and the
limitations in accessing the tumour microenvironment - parts of which have poor
vascular supply, raised interstitial pressure and can be difficult to penetrate by
molecules smaller than NPs, such as antibodies181.
To test the non-specific uptake of NPs by tumours in vivo, a subcutaneous melanoma
model using B16 cells was employed. Fe NPs were administered at 160µmol Fe kg−1
intravenously to mice after they had developed significant subcutaneous tumours. As
discussed above, this dose of NPs produces a saturation of the liver and enhances
uptake into other compartments. Mice were imaged 24 hours later and the T2 weighted
signal in skeletal muscle of each mouse was compared to the signal in its liver, inguinal
lymph nodes and tumor. Similar measurements were made for control mice with
tumours that received no NPs. These measurements were made to assess the effect of
Fe NPs on the T2 contrast in the tumour compared to other tissues where FeOx NPs
have been shown to accumulate and produce effective contrast (liver, lymph nodes) or
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Figure 4.3: The Fe content in liver tissue following administration of Fe NPs
and FeOx NPs Mice were given an intravenous dose of 3µmol Fe kg−1 of Fe NPs or
FeOx NPs then culled 14 hours later. The livers were removed, fixed in paraformaldehyde,
sectioned and stained with Perl stain. The livers of control mice that received injections
of PBS only were used for comparison. (scale bar = 100µm).
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tissues into which they have minimal uptake such as skeletal muscle164.
The results showed that there was no difference in the muscle:tumour ratio of T2
contrast between mice that received Fe NPs versus controls (Figure 4-4). In the liver
and lymph nodes, the ratio of tissue:muscle T2 contrast was actually greater in the Fe
NP group versus control. These findings suggest that there is no change in tumour T2
contrast produced by non-specific uptake of Fe NPs in the model studied. Furthermore
the presence of a large tumour does not inhibit the contrast enhancement of the liver
and the lymph nodes by competitive uptake of Fe NPs. This presents a significant
barrier for direct tumour imaging in liver and lymph nodes because for a tumour to be
readily visible by direct targeting, it must have less T2 weighted signal (i.e. appear
darker) than surrounding tissue. In this model, the tumours had no change in T2
contrast whilst there was decreased T2 contrast intensity observed in both liver and
lymph nodes. Therefore, for direct tumour targeting to be effective, a substantial
increase in the relative uptake of Fe NPs in the tumour must be achieved.
4.2.4 Investigating the central, hypointense regions of
tumours observed in a subset of mice following Fe NP
administration
Although the average T2 weighted signal of tumours were not found to differ in mice
that received Fe NPs versus controls, in 2 of the 5 mice that received Fe NPs there was
a central, hypointense region of the tumour observed on T2 weighted MRI (Figure 4-5a).
These observations could potentially be explained by uptake of NPs into this region of
the tumour due to leakage from abnormal blood vessels or by the presence of
macrophages that have taken up NPs and have infiltrated the tumour. Both leaky
microvasculature and infiltrating macrophages have been well documented in
tumours182,183. If either of these processes were indeed resulting in increased delivery of
Fe NPs to the tumour, they could be worth further investigation as a means of
increasing the sensitivity and or specificity of direct tumour imaging. To examine this
further, the mice from this series were culled after imaging and their tumours were
removed for examination for Fe by light microscopy.
The central regions of both tumours with hypointense regions on T2 weighted images
showed extensive necrosis and haemorrhage on Haemotoxylin and Eosin staining
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Figure 4.4: T2 contrast in large tumours versus other tissues following intra-
venous Fe NPs. C57BL/6 mice were injected with 106 B16 cells in the left flank and
imaged by MR one week later. Mice in the Fe NPs group received an intravenous dose of
160µmol Fe kg−1 of Fe NPs 24 hours prior to MRI, whereas control mice received PBS
only. The signal intensity in the tumours (T) were compared within the same mouse to
that of the liver (L), contralateral inguinal lymph node (N) and skeletal muscle (M) and
plotted as %∆T2 contrast versus tumour as follows: (signal intensity of tumour)-(signal
intensity in organ)/ (signal intensity of muscle). (p<0.05 by Mann-Whitney rank-sum
test, NS= not statistically significant defined as p>0.05).
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Figure 4.5: Histology of hypointense regions of tumours on T2 imaging. Mice
imaged in Figure 4-4 that had hypointense regions of their tumours on MRI (dashed circle)
were euthanized and their tumours were fixed, sectioned and stained with haemotoxylin
and eosin (a) for general histology and Perl stain (b) for Fe. (scale bars = 200µm).
(Figure 4-5a). This is a common process in rapidly growing tumours where the tumour
outgrows its own blood supply resulting in the death of poorly perfused tumour cells184.
The Perl stains of this region showed no significant presence of Fe, indicating that the
hypointensity on MRI was not likely to be due to the presence of Fe NPs. Central
hypointensity on unenhanced T2 scans has been previously described in several different
tumour types, and has also shown to be correlated with necrosis on histology185,186.
Here it was not associated with increased uptake of NPs and was therefore independent
of T2 contrast agent administration.
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4.2.5 T2 contrast in smaller tumours after intravenous
administration of Fe NPs
An argument could be made that the subcutaneous tumours in Figure 4-4 were so large
in comparison with the organism that it is possible that they did uptake the Fe NPs to
a significant amount but in a concentration too diffuse to detect by MRI impact T2
weighted MRI or Perl-stained histological sections. In section 4.2.3, B16 tumours were
injected at 106 and can double every 12-16 hours in vitro187. By taking an estimate of
doubling time at the shorter end of this range and assuming the B16 could keep up the
same rate of growth in vivo, this would present approximately 8x109 tumour cells
imaged on day 7. Assuming the entire dose of Fe NPs (200µg) was taken up by tumour
cells there would be approximately 40pg Fe/cell at the time of imaging. This is more
than double the cellular concentration of Fe NPs that produced a 70% reduction in T2
contrast at 9.4 T in vitro (Figure 3-9). A conservative conclusion could therefore be
argued from this series of estimations that the Fe dose administered to image the
tumours in Figure 4-4 was of an adequate order of magnitude to produce a detectable
change in T2 contrast if tumour uptake was as low as 50% of the total Fe dose.
However, the percentage of the Fe NPs uptaken by tumours is likely to be much less
than 50% because a significant amount of Fe was reaching the liver and the lymph
nodes to produce a T2 contrast change over controls (Figure 4-4) and no significant Fe
was seen in the tumours on Perl stain (Figure 4-5). So if the amounts of circulating Fe
NPs available to the tumours were reduced due to uptake by macrophage-rich tissues,
then an alternative would be to image smaller tumours. Therefore, 1 x 105 B16 cells
were injected to produce tumours that were approximately 1/10 to 1/20 of the area on
coronal section (6-8mm3 versus 80-100mm3) of the tumours in the previous experiment.
Mice were given an intravenous dose of Fe NPs or PBS only (control) and imaged 24
hours later at 1.5T (Figure 4-6a). No difference was seen in the tumour:muscle T2
contrast ratios between the control and Fe groups. There was a significant change in the
tumour:liver and tumour:lymph contrast ratios in the Fe versus control groups. This
suggests that there is uptake of Fe NPs into liver and lymph nodes with minimal uptake
into the tumour, despite a reduction in tumour size.
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Figure 4.6: T2 contrast in small tumours versus other tissues following intra-
venous Fe NPs. C57Bl/6 mice were injected with 105 B16 cells in the left flank and
imaged by MR one week later. Mice in the Fe NPs group received an intravenous dose of
160µmol Fe kg−1 of Fe NPs 24 hours prior to MRI, whereas control mice received PBS
only. The signal intensity in the tumours (T), liver (L), contralateral inguinal lymph
node (L) and skeletal muscle (M) were analysed and plotted as in Figure 4-4. (p<0.05
by Mann-Whitney rank-sum test, NS= not statistically significant defined as p>0.05).
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4.2.6 Antibody conjugation of Fe NPs to improve tumour
specific uptake
To improve the selective uptake of Fe NPs into tumour cells, tumour selective
antibodies can be conjugated to their surface30. The HeLa cervical cancer line is known
to overexpress the HER2 receptor on its surface and bind the anti-HER2 antibody,
Herceptin188. Herceptin was conjugated to the outer DMSA shell of the Fe NPs to
produce improved uptake into HeLa cells. This reaction involves a linker molecule,
1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) that binds a
carboxyl group from the DMSA and an amine group on the Herceptin antibody to form
an amide linkage. Herceptin-conjugated Fe NPs (Fe-Herceptin) were added to HeLa cell
culture at varying concentrations of Fe. For comparison, Fe NPs and unbound
Herceptin were added to HeLa cells at the same concentrations. Fe-Herceptin
conjugates produced a 39% increase in uptake of the Fe NPs into HeLa cells (Figure
4-7) with a 37% greater change in T2 weighted contrast. This is of a similar magnitude
to other studies where antibody conjugation to FeOx NPs produced a decrease in T2
contrast of between 30-50% in other tumour models in vitro189. However, even if it were
maintained in vitro, this was not an adequate improvement in Fe uptake to produce
effective in vivo contrast, particularly for tumours in organs such as the liver and lymph
nodes. As seen in Figure 4-4; liver, lymph nodes and skeletal muscle have a 96, 26 and
71% reduction in T2 contrast versus tumours following Fe NP administration. Even
assuming that the improvement in T2 contrast of 37% seen in vitro translated fully in
vivo, the difference in T2 contrast between the tumour and these organs would actually
reduce in all three cases. In the case of the liver, with untargeted Fe NPs the tumour
appears 96% brighter than the liver on T2 images. If tumour targeting was as effective
as in the in vitro HeLa/Herceptin model, the tumour would still be brighter but only by
approximately 59%.
The improvement in tumour specific uptake required for effective in vivo contrast is
therefore likely to be of a much larger magnitude than the improvement in T2 contrast
of Fe NPs over FeOx NPs. Furthermore, in most clinical tumours there is not consistent
expression of tumour specific antigens presenting a further challenge for antibody
mediated targeting190. At this point it was decided not to pursue targeted tumour
delivery and to take advantage of the abundant uptake of Fe NPs in the liver, spleen
and lymph nodes to improve the detection of tumours in these organs.
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Figure 4.7: Uptake of Herceptin conjugated Fe NPs into HeLa cells Fe NPs
conjugated to Herceptin antibodies were added to HeLa cells in culture for 1 hour at
varying concentrations (a). The cells were harvested and washed twice before analysis
of Fe content by flame atomic absorption spectroscopy (a) or dispersed at 500cells/µL in
agar and imaged at 9.4 T (b). For comparison Fe NPs with free Herceptin were added at
the same concentrations. The HeLa cells imaged in (b) were incubated in 50µg Fe ml−1.
(p<0.05 with two tailed t test).
4.2.7 Detection of intrasplenic tumours following intravenous
Fe NPs
A recent meta-analysis highlights the potential of using FeOx to image lymph node
metastases191. Increases in sensitivity and specificity were seen over unenhanced MR
scans or computed tomography (CT) across a wide range of cancers191 but this
decreases substantially if the size of the lymph node metastasis is less than 5 mm38.
The hypothesis that Fe NPs could improve this threshold of detection due to their
improved relaxivity was tested in a mouse model. The model involved direct injection of
tumour cells into the spleen as a surrogate model of human lymph node metastasis.
The spleen in 6 week old C57 mice has a diameter of 2-10mm depending on the axis
and orientation, which is of similar size range to the diameter of human lymph nodes,
3-15 mm (if not enlarged)192. The spleen and lymph nodes are both rich in
macrophages and an improvement in both splenic and lymph node contrast can be seen
with FeNPs over FeOx (Figure 4-2). Four different cancer cell lines were trialled for
experiments to assess tumour detection. Each was injected into the spleen of mice
under anaesthesia, and then ex vivo macroscopic examination of the spleen was
conducted between 2 and 9 days later (data not shown). The mouse breast cancer line,
4T1 was chosen as it consistently produced tumours (100%) three days after injection
into the spleen within a narrow size range (1-3mm).
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A series of experiments was set up to determine whether Fe NPs could improve the
detection of the intrasplenic tumours when compared to FeOx NPs. Mice were injected
with 4T1 cells into the spleen and imaged by MR 2 days later (Figure 4-8 pre-contrast).
They then received an intravenous dose of 200µg of Fe NPs or FeOx NPs 8 hours before
a second scan on day 1 (Figure 4-8 post contrast). As in previous experiments, the mice
that received Fe NPs had a greater reduction in T2-weighted signal intensity in their
splenic tissue which provided clear contrast with the high level of signal intensity
maintained in the intrasplenic tumours (Figure 4-8b,d). The tissue to tumour contrast
in the spleen was greater in mice that received Fe NPs (60%) versus FeOx NPs (25%,
Figure 4-8i). This was a very encouraging result because it demonstrated that the same
dose of Fe NPs could produce significantly better tissue:tumour contrast enabling clear
discernment of small tumours in vivo.
4.2.8 Histology of spleens and tumours
The hypothesis at this point was that the differences in T2 signal intensity seen in the
contrast-enhanced scans was due to increased uptake of Fe NPs or FeOx NPs in the
normal splenic tissue (parenchyma) versus the tumours. This would produce a
hypointense (dark) area in the normal splenic tissue on T2-weighted MRI scenes due to
a higher relative concentration of magnetic NPs. In contrast, tumour tissue has a lower
uptake of magnetic NPs and produces a corresponding hyperintense (white) region on
MRI. Other processes, such as tumour necrosis (as seen in Figure 4-5), could also cause
heterogenous signal intensity within the spleen.
To ensure that the reduction in T2-weighted signal intensity seen on the contrast
enhanced scans was associated with uptake of NPs, the spleens of mice were removed ex
vivo then fixed and sectioned for light microscopy. There was a clear difference between
the large, confluent tumour cells and the splenic parenchyma (Figure 4-9). On Perl
stain, there was positive staining for Fe throughout the parenchyma and at the
parenchyma/tumour boundary in both the Fe NPs and FeOx NPs groups. No Fe was
seen in any of the tumours. In the control group there was no Fe seen in either the
tumour or the parenchyma. These findings are further evidence of a correlation between
Fe NP uptake and increased T2 contrast with the surrounding tissue on MRI.
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Figure 4.8: Imaging intrasplenic tumours after enhancement with Fe and
FeOx NPs. 6 week old Balb/c mice were injected with 106 4T1 breast cancer cells into
their spleens under anaesthesia and were imaged by MR 48 and 72 hours later, with
coronal (a,b,e,f) and axial (c,d,g,h) scans. An intravenous dose of 160µmol Fekg−1 of
Fe NPs (b,d) or FeOx NPs (f,h) was administered 8 hours before the second scan. The
signal intensity in the tumours was compared within the same mouse to that of the spleen
and plotted as %∆T2 contrast as follows: (signal intensity of tumour)-(signal intensity in
spleen)/ (signal intensity of tumour)(*p<0.01 Mann-Whitney rank sum test).
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Figure 4.9: Histology of intrasplenic tumours with intravenous Fe NPs or
FeOx NPs. Mice from Figure 4-8 were euthanized after the second MR scan, then the
spleens were removed, fixed and sectioned for light microscopy. A Perl stain was applied
to detect the presence of Fe. (scale bar = 100µm).
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4.2.9 Effect of Fe NPs on tumour detection by blinded
radiologists
To provide robust evidence that Fe NPs could improve the detection of small tumours
in vivo, a study with analysis by two independent, blinded radiologists was performed.
A large series of mice (30 per group) received an intrasplenic injection of either 4T1
tumour cells or PBS only. Three days later, these mice were then randomly assigned to
one of three groups corresponding to the contrast agent they were to receive: Fe NPs,
FeOx NPs or PBS only (control). The mice were imaged by MR 8 hours after receiving
intravenous contrast. The spleens were removed ex vivo to confirm the development of
intrasplenic tumours measuring 1-3mm (in the tumour group). The images of all 60
mice were sent to two radiologists who had no knowledge of whether the mice had
tumours or what type of contrast agent they had received. They were instructed to
independently score the spleens on a simple numerical scale as shown in Table 4-2.
Table 4.1: Scoring system for intrasplenic tumours.
Score Description
1 Confident that no tumour is present
2 Probably no tumour present
3 Equivocal
4 Probably a tumour present
5 Confident that a tumour is present
The scores were sent to an un-blinded investigator and a receiver operator curve was
generated (Figure 4-10). Receiver operator curves (ROC) are commonly used to
determine a cut-off point for a diagnostic test. The principle behind ROCs is that as a
test becomes more sensitive, it usually becomes less specific and ROCs provide
visualisation of this relationship so that an appropriate cut-off point can be chosen.
ROCs are generated by plotting the sensitivity versus the false positive rate
(1-specificity) for each output value of the test. A cut-off point can then be chosen
above which all the output values of the test are deemed to be positive for the disease
and below which are deemed to be negative. The cut-off point is often made where the
slope of the curve begins to level off, indicating that further gains in sensitivity of the
test are made only at the expense of increasing losses in specificity. The null hypothesis
can be depicted as a line of slope 1 which indicates a test that is 50% specific and 50%
sensitive; an improvement in one of these parameters can only be achieved with an
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equivalent loss in the other. This represents a test that has only a chance relationship
to the disease status of the patient; an example of which could be flipping a coin to
determine whether a patient had cancer.
Diagnosis of tumours in the control mice was no more accurate than the null hypothesis
for radiologist 1 and only slightly more accurate for radiologist 2 (Figure 4-10c-d,
dashed line). This indicates that without contrast enhancement, the tumours were not
able to be distinguished easily from the splenic parenchyma. FeOx NPs improved the
diagnostic accuracy with a sensitivity and specificity superior to controls at two
different cut points for radiologist 1 and three points for radiologist 2. Fe NPs produced
a further improvement in both specificity and sensitivity beyond FeOx NPs at four
different cut-off points for radiologist 1 and one point for radiologist 2. The specificity
of the scans in the Fe NPs group could be increased to 100% whilst maintaining a
sensitivity of 70% or 90% (radiologist 1 and 2 respectively). Alternatively, 90%
sensitivity was achieved at a cut-point with 80% or 100% specificity (radiologist 1 and 2
respectively). Interestingly, radiologist 2, who scored with overall higher accuracy,
achieved a cut-off point where 100% of tumours were detected in the FeOx group, albeit
at a low specificity of 40%. This highlights the fact that there was a greater
improvement in specificity than sensitivity when comparing Fe to FeOx NPs.
In general, the closer the area under the receiver operator curve (ROC) is to 1, the more
accurate the diagnostic test, with 1 representing a perfect test and 0.5 the lowest value
possible (i.e. the null hypothesis). In this study, the average area under the curve was
0.92, 0.82 and 0.59 for Fe NPs, FeOx NPs and control groups, respectively. This data
set is strong evidence that Fe NPs can produce contrast enhancement that is more
effective than FeOx NPs in detecting small tumours in vivo at 1.5T.
4.2.10 Intra-observer accuracy and variability
As FeOx NPs are not marketed in Australia or New Zealand, many radiologists in New
Zealand have no experience with using T2 contrast agents, such as the two in this study.
This raises the question of whether a difference in diagnostic consistency and accuracy
would be seen between images enhanced with Fe NPs and FeOx NPs. To answer this
question, each radiologist’s scoring of each mouse was compared and plotted as
inter-observer variability (Figure 4-11a). To address intra-observer variability,
radiologist 1 was given training with a member of the research team using a random
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Figure 4.10: Receiver operator curve of in vivo tumour detection with Fe
NPs versus FeOx NPs. 60 mice received an intrasplenic injection of either 4T1 cells or
PBS. The mice were then randomly assigned to receive one of three intravenous contrast
agents; Fe NPs, FeOx NPs, or PBS only (control). MRI scanning was performed 72 hours
following tumour inoculation, with contrast administered 8 hours before the scan. The
scans were scored by blinded radiologists (a,c - radiologist 1, b,d -radiologist 2) according
to Table 4-1, then analysed and plotted as scatter plots (a,b) and receiver operator curves
(c,d) by an un-blinded investigator. In a and b, the splenic tumour scores given to the
mice that received Fe NPs (red) and FeOx NPs (blue) are shown where PBS and tumour
represent mice that received intrasplenic injections of PBS or tumour cells respectively.
(NS = p>0.05, *p<0.01, **p<0.001 by Mann-Whitney rank sum test.)
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Figure 4.11: Changes in tumour scoring with observer training. The scoring
of each mouse was compared between the radiologists (a). After training, radiologist
1 rescored all the mice (b). The variation between the scorings was plotted for each
contrast agent group (a,b), with the two scores for each mouse defined as variant if they
differed by more than one point. The change in accuracy was determined between the
first and second scoring of the data by radiologist 1 (c), with a value of 1-2 considered
correct if no tumour was present and 4-5 correct if a tumour was present.
selection of images from the same image set over two thirty minute sessions. One week
following training, radiologist 1 was asked to go through and score the image set
independently for a second time. The intra-observer variability (Figure 4-11b) of his
scoring was plotted for each type of contrast agent. To determine whether accuracy
improved with training, the difference in accuracy between the two scorings by
radiologist 1 was plotted (Figure 4-11c). When it came to variation both between
radiologists (inter-observer) and between different analysis sessions by radiologist 1
(intra-observer), mice in the Fe NP group were scored with the most consistency and
those in the FeOx NPs group were scored with the least consistency. The intra-observer
variability was not associated with a commensurate change in accuracy meaning that
there was no substantial improvement in performance in scoring the FeOx NPs after
training. Interestingly, the only change in accuracy of note between scorings was an
increase in correct scoring of the control group. This could be due to an improved
appreciation for the appearance of non-enhanced images of normal spleen in mice. As
analysis of mice in the Fe NP group had the lowest intra-observer and inter-observer
variation, this suggested that the images enhanced with Fe NPs were distinct enough to
produce consistent scoring and that there was no benefit from radiologist training.
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4.3 Discussion
4.3.1 Principle findings
Fe NPs enhanced the in vivo T2 contrast in the liver, spleen and lymph nodes above
that of FeOx NPs. Although specific uptake of Fe NPs into tumour cells was
demonstrated in vitro through antibody-conjugated NPs, the in vivo uptake of Fe NPs
was predominantly seen in macrophage-rich organs. The preferential in vivo uptake of
Fe NPs and FeOx NPs into the spleen over intrasplenic tumours was demonstrated and
exploited to improve tumour detection. Fe NPs improved the MRI-based diagnosis of
small intrasplenic tumours over FeOx NPs by increasing both the sensitivity and
specificity of tumour detection and by decreasing the inter-observer and intra-observer
variability.
4.3.2 Mechanism of improved tumour diagnosis
Fe NPs demonstrated a superior T2 relaxivity over FeOx NPs, which translated into
improved specificity and sensitivity of small tumour diagnosis. There is sufficient
evidence from this study to consider a mechanism for this observation. It is proposed
that there was similar uptake of Fe NPs and FeOx NPs into splenic macrophages in
normal spleen parenchyma, with limited uptake into tumours. The larger magnetic
moment of Fe NPs produced more efficient transverse relaxation of water protons in the
splenic parenchyma versus tumour tissue, resulting in increased tissue:tumour contrast.
The improved contrast with Fe NPs produced MR images that were scored with greater
accuracy and consistency than those enhanced with FeOx NPs or control.
Fe NPs produce more efficient transverse relaxation than FeOx NPs, as demonstrated in
Chapter 3 (324 mM s−1 versus 145 mM s−1, Figure 3-9). When cells were labelled with
Fe NPs in vitro, there was at least twice the contrast produced per cell versus those
labelled than FeOx NPs (Figure 3-10), with no quantitative difference in the uptake of
NPs seen in the cell types tested (Figure 3-11 and 5-2). The in vivo T2 contrast seen in
the liver and spleen after administration of Fe NPs was more than twice that of FeOx
NPs with no qualitative differences seen in amount of NP uptake in these organs
(Figure 4-3 and 4-9). These findings all suggest that there are no major differences in
the cellular uptake in vitro or in vivo between the Fe NPs and FeOx NPs, and that the
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improved T2 contrast seen with Fe NPs is a result of differences in relaxivity relating to
the greater magnetic moment of a-Fe versus FeOx.
The same principle could be applied to the imaging of intrasplenic tumours where both
types of NP were predominantly taken up by cells in the splenic parenchyma over the
introduced tumours, and Fe NPs produced more than twice the tissue to tumour
contrast as FeOx NPs (Figure 4-8). The improved contrast with Fe NPs over FeOx NPs
produced a clearer distinction between normal and tumour tissue, translating into
better overall diagnosis (area of ROC 0.92 versus 0.82 respectively, Figure 4-10) and
higher accuracy (mean of 85% versus 55%, Figure 4-10).
It was interesting to note that if a very low specificity (40%) were acceptable, then a
higher sensitivity of tumour detection could be achieved with FeOx NPs over Fe NPs by
radiologist 2. This was examined further and it was found the difference in sensitivity
was due to the misdiagnosis of a single tumour by radiologist 2 (Figure 4-10b).
Interestingly, radiologist 1 misdiagnosed this tumour as well (Figure 4-10a). This
tumour measured approximately 1.3mm on gross histology, making it one of the smaller
tumours in the study (range 1-3mm). Although this is a single example, tumours of
similar size were diagnosed correctly in other groups (1.0mm in FeOx group and 1.2mm
in control). This raises the possibility that there may be a size limit at which the gains
in accuracy produced by improving relaxivity of a contrast agent is negated by
dephasing and partial volume imaging effects caused by the contrast agent around the
borders of small tumours.
In this study, a relaxivity ratio between Fe and FeOx NPs of 2.2 translated into an
accuracy ratio of 1.5 in diagnosing small intrasplenic tumours. It would be easy to
over-interpret this result as there are many factors involved in the diagnostic accuracy
of tumours in this study that may vary in other tumour models including tumour size,
location and T2 characteristics. However, this finding does suggest that a large
difference in T2 relaxivity between contrast agents with the same coating and similar
uptake characteristics translates to a smaller difference in diagnostic accuracy.
4.3.3 Implications of this study
This study was designed to answer the question of whether Fe NPs can improve the
clinical diagnosis of lymph node metastases. The relevance of a mouse model using Fe
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NPs to detect intrasplenic tumours needs to be defended with reference to studies with
FeOx NPs in rodents and humans.
The spleen was chosen in this study because lymph nodes in mice are too small and the
size of a mouse spleen is of similar size to human lymph nodes. Murine lymph nodes,
which measure up 1-2mm in diameter193,194 are small enough that tumours between 1-3
mm would produce lymph node enlargement, which has many other causes and is not
specific for metastasis. Furthermore, there would not be a significant contrast effect
produced with Fe-based NPs as the normal lymph node tissue, which takes up the NPs
to produce contrast, would be replaced almost entirely by tumour. The mice used in
this study had spleens that were 8-12mm long by 4-5mm wide. This is of a similar
magnitude to human lymph nodes with a mean size of 5-13mm167,195, and is of adequate
size that tumours can grow up to 3mm without replacing a significant amount of
normal tissue, as seen in Figure 4-8.
As shown in many studies, including this one, the spleen and lymph nodes have
different amounts of contrast produced after intravenous injection of Fe-based NPs,
owing to different uptake between the organs158. Nanoparticles with a hydrodynamic
radius greater than 50nm tend to be taken up by the liver and spleen within minutes,
with limited access to lymph nodes31. The particles used here had a radius of around
60-80nm, which would favour hepatosplenic uptake and improved T2 contrast in these
organs relative to the lymph nodes as seen in Figures 4-1 and 4-2. This was appropriate
in this study as the tumours were in the spleen but to translate these findings into
human lymph nodes a different coating strategy could be applied, such as
carboxy-dextran, to produce particles with a smaller hydrodynamic radius103 which
have been shown to be effective in lymph node imaging38. Another coating may affect
the relaxivity of the Fe NPs196, but it is hypothesized that the Fe NPs will still
maintain a higher relaxivity than FeOx NPs with the same coating.
To achieve the maximum improvement in small tumour diagnosis, the dose of Fe NPs
and FeOx NPs used in this study was chosen to correspond with the clinical dose in
humans. A dose of 8 mg/kg was used which is below doses used safely in mice of
30mgkg−1 197 and rats of 10-12 mgkg−1 44,198. Rodents have more active uptake into the
liver, with elimination half-life in rats is 2 hours versus 24-36 hours in humans.
Therefore a larger dose is used to visualise other compartments in animal
experiments50,178. Furthermore, younger rodents have been demonstrated to have up to
a 50% decrease in half-life indicating enhanced uptake by liver macrophages176. Feridex
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is a commercial Fe Ox NP contrast agent with a similar relaxivity to the Fe Ox NPs
used in this study199. The recommended clinical dose of Feridex is 0.5mg Fekg−1, which
reduces T2 contrast in the liver by 68%
175 compared to a 72% reduction with FeOx NPs
at a dose of 8mg Fekg−1 in this study. This suggests that the dose of Fe Ox NPs used in
this study for tumour diagnosis was not significantly below the equivalent clinical dose
that produces a similar change in T2 liver contrast in humans. If the dose of Fe Ox NPs
used in this study were significantly less than the equivalent clinical dose, it would
imply that the increased efficacy in tumour diagnosis seen with Fe NPs could
potentially be matched by increasing the dose of Fe Ox NPs to match the clinical dose.
To answer the question of how this study compares with the results of human studies,
comparison can be made with a meta-analysis that combined 34 studies using FeOx
NPs to diagnose lymph node tumours57. The pooled sensitivity of all the studies in this
analysis was 0.91 with FeOx NPs compared to 0.39 in unenhanced scans. This
compares with results in this chapter of 0.90, 0.70 and 0.30 for Fe NPs, FeOx NPs and
unenhanced control, respectively. This implies that the diagnostic task was more
challenging in the study performed in mice, which was anticipated as the tumours were
smaller. This could also be explained by the fact that the studies compared in the
meta-analysis were not all blinded and many of the investigators scoring the tumours
had prior research experience with FeOx NPs. The fact that the improvement between
FeOx NPs over unenhanced scans was of a similar magnitude to that in the human
studies suggests that the mouse model had similar contrast characteristics to that of
cancer in human lymph nodes.
4.3.4 Conclusion
The MRI diagnosis of small tumours by radiologists was significantly improved with Fe
NPs over FeOx NPs in a blinded study. Although the detection of cancer in human
lymph nodes was modeled with an splenic tumours in mice, comparison with other
studies suggests that Fe NPs have real potential to deliver more effective diagnosis of
early lymph node involvement with cancer.
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Chapter 5
MRI tracking of DC/peptide
vaccines labelled with Fe NPs to
determine antigen-specific responses
5.1 Introduction
Cancer immunotherapy with dendritic cell (DC)-based vaccines has shown promising
outcomes in a small subset of patients. One of the difficulties in optimising this therapy
has been in assessing the generation of immune responses following vaccination. Most
assays of immune responses are performed ex vivo and are beset with difficulties in
standardisation. This chapter describes a novel in vivo strategy using Fe nanoparticles
and MRI to detect an induced antigen-specific immune response to a DC-based vaccine
combined with a peptide antigen (DC/peptide) in mice.
5.1.1 Mechanisms of tumor suppression and escape from the
immune system
In order to design therapies which specifically target cancer cells for removal, it is
important to consider what distinguishes cancer cells from the large variety of
non-neoplastic tissue present in the body. Weinberg and Hanahan produced a review of
the hallmarks of cancer200 which include resisting cell death, sustaining proliferative
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signaling, evading growth suppressors, activating invasion and metastasis, enabling
replicative immortality and inducing angiogenesis. These were recently updated to
include deregulation of cellular energetics and avoiding immune destruction201. Whilst
all of these processes are important in distinguishing malignant cells, it is the escape
from immune control that is of particular interest when designing therapeutic cancer
vaccines, for this is the aspect that cancer immunotherapy seeks to remedy in the first
instance.
There are multiple lines of evidence from studies of immunosuppressed hosts to suggest
that a functioning immune system plays an important role in the prevention of tumor
development. Firstly, there is a markedly increased rate of cancers in patients with
immunodeficiencies which are uncommon in non-compromised individuals202. Secondly,
in mouse knock-out models where selective cells from the innate and adaptive immune
system (NK cells and CTLs respectively) are absent, an increased incidence of
malignancy was observed203,204. Thirdly, when tumours that have arisen in
immune-deficient mice are transplanted to immunocompetent hosts they are rejected,
whereas cancer cells that are taken from immunocompetent mice can produce invasive
disease in both immunodeficient and immunocompetent recipients203–205. These findings
suggest that there is active surveillance by the immune system which can prevent
certain instances of malignancy and that tumours that have already developed in an
environment of impaired immunity can be eliminated in the presence of a competent
immune system.
The list of proposed mechanisms by which tumors evade the immune system has
expanded significantly in the last decade206. Three important mechanisms from this list
include regulatory T cells, myeloid-derived suppressor cells and T cell exhaustion. The
processes by which these entities suppress anti-cancer immunity will be discussed with a
view to how they could be overcome by cancer immunotherapy.
Regulatory T cells are T lymphocytes that suppress the activity of other immune cells.
They possess a T cell receptor which, like other T cells, can recognize specific antigen
presented on an MHC molecule. When regulatory T cells encounter their cognate
antigen they secrete immunosuppressive substances such as TGF-β 207. There is
evidence that regulatory T cells inhibit anti-tumour responses208 and that blocking
regulatory T cells improves the efficacy of cancer immunotherapy209.
Multiple types of cancer have demonstrated the accumulation of myeloid derived
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suppressor cells (MDSC) within the tumour210–212. MDSC originate in the bone marrow
and are recruited to the tumour by substances such as transforming growth factor
(TGF)-?, and IL-10[19]. Note that these substances can be produced by the cancer cells
themselves or by other cells such as regulatory T cells. MDSC can suppress anti-tumour
immunity by preventing DC maturation213 thus inhibiting their ability to co-stimulate
T cells. MDSC also release reactive oxygen species (such as nitric oxide synthetase)
which can inhibit and cause programmed cell death (apoptosis) of T cells212. There are
a number of substances which have proven potential to disrupt the immunosuppressive
actions of MDSC including inhibition of nitric oxide synthetase214 as well as cytotoxic
therapy with 5-Flurouracil215. The preventention of DC maturation can be
circumvented by vaccination with DC that are exposed to tumor antigen and activating
substances ex-vivo before administration in vivo.
As discussed in chapter 1, cytotoxic T lymphocytes (CTL) have proven effectiveness in
eliminating cancer cells. Like other T cells, CTL require the expression of
co-stimulatory molecules along with the presentation of cognate antigen to become fully
activated. If there is prolonged exposure to antigen, particularly in the absence of
co-stimulatory molecules, CTL can become ”exhausted” and unable to mount a
cytotoxic response against tumor cells216. This is often the situation in cancers where
there is a low level of tumor associated antigens expression combined with the absence
of the necessary co-stimulatory molecules of professional antigen presenting cells (like
CD86 on DCs). This problem can be addressed with vaccination using autologous DCs
which have been manipulated ex-vivo to express both high levels of tumour antigen and
co-stimulatory molecules.
5.1.2 DC elimination assay
Dendritic cell (DC)-based vaccines can produce striking remissions of advanced disease,
but the clinical response rate in most studies is less than 10%90. To improve the
response rate to DC-based vaccination, there are numerous parameters yet to optimise
such as ex-vivo handling, antigen loading, and finding the ideal subtype and activation
of DCs. To investigate the interplay of these factors, it is necessary to monitor the
immune responses generated by vaccination. Although several types of assays exist,
they have not been applied in a standardised manner and have not been consistently
correlated with clinical responses217.
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The most common clinical assays of immune responses to DC-based vaccination assess
the generation and or function of antigen-specific CTLs. These in vitro assays are most
often performed on peripheral blood taken following vaccination89. However, it has been
shown that detecting CTLs in peripheral blood, after in vitro culture, can introduce
artefacts218,219 such as detection of na¨ıve, tumour-specific T cells220. It has been shown
that more antigen-specific CTLs can be detected in the draining lymph node than
peripheral blood following DC-based vaccination221, which suggests that the draining
lymph node may be a more relevant site to measure immune responses. Hermans et al
developed an assay222 which detects the vaccine induced activity of CTLs by measuring
the elimination of antigen-loaded DCs in the draining lymph node. This DC elimination
assay is performed by ex vivo analysis of the draining lymph node by flow cytometry.
The basic principle behind the DC elimination assay is the somewhat paradoxical
finding that the antigen-loaded DCs used in a vaccine can ultimately become targets of
the cytotoxic immune responses they induce. To elaborate further, a peptide antigen is
chosen that binds to MHC I molecules on DCs, and is then presented to CD8+ T cells
that possess a T cell receptor that recognizes the antigen-MHC class I complex. The
DCs have been matured, so they present co-stimulatory signals to CD8+ T cells that
promote their proliferation and differentiation into CTL, which takes several days. If a
sufficiently large population of CTL is generated, the next time the same peptide-loaded
DC are administered, the activated CTLs will recognize the peptides the DC present,
and rapidly induce cell death. Depending on the strength of the induced response, it is
likely that significant numbers of DCs will be eliminated before they can migrate to the
draining lymph node. DCs presenting no antigen or a different antigen will not be
affected and will migrate to the draining lymph node. Therefore, the degree of DC
elimination is much greater in mice that have been vaccinated with the same antigen
versus unvaccinated (na¨ıve) mice. If the injected DCs are fluorescently labelled, they
can be detected by flow cytometry ex vivo, and the degree of DC elimination from the
draining lymph node can be quantified.
If this assay could be adapted from an ex vivo assay to a non-invasive assay performed
in vivo, it could provide useful information in clinical studies of DC/peptide vaccines.
The work presented in this chapter is concerned with adapting the DC elimination
assay to an in vivo technique by labelling the DCs with magnetic nanoparticles, as
opposed to fluorescent dyes, and by tracking them with MRI. Fe and FeOx NPs are
compared with the hypothesis that the improved T2 contrast seen with Fe NPs in
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previous chapters will optimise the MRI sensitivity to labelled DCs.
5.1.3 Aims
The aim of this chapter is to test the hypothesis that the DC elimination assay of
antigen-specific CTL function can be adapted to an in vivo assay by labelling DCs with
magnetic NPs and imaging the draining lymph node in vivo with MRI. An adjunct to
this hypothesis is that Fe NPs will improve the sensitivity of MRI to detect labelled
DCs, which will result in improved sensitivity of the assay. The following questions will
be addressed in the context of a C57BL/6 mouse model using bone marrow generated
DCs labelled with Fe NPs or FeOx NPs, imaged in a clinical MRI scanner in vivo at
1.5T and ex vivo at 9.4T.
1. What is the sensitivity of MRI to detect DCs labelled with Fe or FeOx NPs?
2. Does labelling with Fe NPs affect DC function?
3. Can NP-labelled DCs be tracked in their migration to the draining lymph node at
1.5T?
4. Is there a difference in the contrast of the draining lymph node in na¨ıve versus
primed mice?
5. Is there a correlation between the original and the adapted DC elimination assays?
6. Can the assay be applied to DC/tumour lysate vaccines?
5.2 Results
5.2.1 Fe nanoparticles improve sensitivity of dendritic cell
detection
The first step in developing an in vivo cell-tracking assay was to determine the
sensitivity of MRI to detect DCs labelled with magnetic nanoparticles. Of particular
interest was whether this sensitivity could be improved with Fe NPs over that of FeOx
NPs.
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When 5µg Fe ml−1 of either contrast agent was added to dendritic cell culture for 48 h,
DCs cultured with Fe NPs produced significantly greater change in T2 relaxation in
vitro (Figure 5-1) across a range of cell concentrations. The amount of T2 reduction/cell
was calculated by linear regression of the data shown in Figure 5-1b and found to be 0.1
% per cell for Fe labelled DCs and 0.05% per cell for those labelled with FeOx (95% C.I.
0.08-0.11 and 0.04-0.06 respectively).
To determine the sensitivity of DC detection, a threshold of a certain % change in T2
relaxation can be applied. If a threshold of 20% change in T2 relaxation is applied, DCs
labelled with Fe NPs were detectable at 200 cells µl−1 whereas FeOx were not detected
below 500 cells µl−1. A threshold of 50% change in T2 relaxation could only be reached
by DCs cultured in Fe NPs at a concentration of 500 cells µl−1. The visual distinction
between these thresholds can be appreciated from Figure 5-1a where the FeOx labelled
DCs (middle circle) have produced a greater than 20% reduction in T2 weighted signal
versus the unlabelled control DCs (left circle) and the Fe labelled DCs (right circle)
have reduced the T2 weighted signal by more than 50%. Adjusting the threshold will
trade off specificity against sensitivity but it is clear that any threshold set between
20%-50% change in T2 relaxation would result in a greater sensitivity for detecting DCs
labelled with Fe NP versus FeOx NPs.
It was next investigated whether the improved MRI sensitivity to detect DCs labelled
with Fe NPs was due to their improved uptake by DCs relative to FeOx NPs. After
incubation with the same concentration of Fe NPs or FeOx NPs (5µg Fe ml−1) used for
MRI detection, DCs were stained with Perl stain to detect the amount of Fe retained in
the cells (Figure 5.2a). There was no qualitative difference in the amount of positive Fe
stain seen on light microscopy as both Fe and FeOx NPs produced appreciable Fe
uptake into DCs. There was no Fe detected in unlabelled controls. Flame atomic
absorption spectrometry showed that the quantitative amount of Fe uptake in Fe NP
and FeOx NP labelled DCs was similar (Figure 5.2b) at around 10pgFecell−1. These
findings combined with the relaxivity data strongly suggest that there remains a
qualitative rather than quantitative difference in the iron present within DCs labelled
with the two different NPs, most likely due to the retained α-Fe core of the Fe NPs with
its superior magnetic properties.
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Figure 5.1: Detection of DCs labelled with Fe NPs and FeOx NPs at 9.4T.
DCs were cultured in 5µg Fe ml−1 of Fe NPs or FeOx NPs and dispersed in 1% agar at
concentrations ranging from 100-500 cells µl−1. Unlabelled DCs were used as a control.
The DC dispersions were imaged at 9.4T using a multi-slice spin echo sequence with an
echo time of 8ms. The T2 times of the cell dispersions were determined by manually
selecting a region of interest within the cell dispersion then plotting the T2 relaxation as
in Figure 3-6. (a) MR images of DC cell dispersions at 500 cellsµl−1 labelled with Fe NPs,
FeOx NPs or PBS control. (b) The T2 times of the DC dispersions were compared to
that of the control cell layer and plotted as %δT2 = (T2 control - T2 interest)/T2 control.
(**p<0.01 by two tailed t test)
Figure 5.2: Fe NP and FeOx NP uptake into DCs. DCs incubated with 5µg Fe
ml−1 of Fe NPs or FeOx NPs were washed, harvested, fixed and stained with Perl’s stain
for Fe. A group incubated with PBS only was used as a control (a). Atomic absorption
spectroscopy was performed on the three groups of cells to determine the quantitative Fe
content per cell (b).
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5.2.2 Fe NPs and FeOx NPs do not effect DC viability,
metabolism or activation at the dose used for MRI
labelling
After establishing the sensitivity and Fe uptake characteristics of labelled DCs, it was
important to determine whether labelling the different NPs produced measurable
differences in cell viability, metabolism or activation. The viability and metabolism of
Fe NPs was examined in DCs in vitro and compared to that of FeOx NPs (Figure 5-3).
The viability assay (Figure 5.3a) distinguishes live cells with intact membranes by their
ability to exclude the dye trypan blue. There was no significant difference in viability of
DCs cultured with either type of NP. No significant effects on viability were evident
compared to unlabelled controls until the concentration of NPs exceeded 20 times that
used for MRI detection.
Cell metabolism was measured by the
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, a
colorimetric assay where metabolically active cells reduce MTT to formazan dye,
producing a purple colour that can be measured by spectrophotometry. There was no
significant difference seen in the metabolism of DCs cultured in Fe NPs versus FeOx
NPs but there was a sharp decline in both groups versus unlabelled controls once the Fe
concentration exceeded 160µg/mL. This assay is a more sensitive measure of viability
than trypan blue exclusion and indicates that the dose at which the DC viability
declines below 50% (LC50), is between 160-180µg Fe ml
−1 for both Fe and FeOx
labelled cells.
For DCs to efficiently migrate to the draining lymph node after subcutaneous injection,
they have to be activated by stimulatory molecules such as bacterial
lipopolysaccharide223 (LPS). If Fe NPs interfered with this activation it would render
them inappropriate as labels for tracking DC migration. DC activation is associated
with the increased expression of surface molecules involved in T cell stimulation,
including the co-stimulatory molecule CD86. This is particularly important in the
context of DC vaccines as immature DCs are not good at stimulating T cell responses
and can induce tolerance224.
The expression of CD86 can be determined by the addition of CD86 specific antibodies
conjugated to fluorescent dyes, and then examining the cells by flow cytometry. Flow
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Figure 5.3: Cytotoxicity of Fe NPs versus FeOx NPs in DCs. DCs were trans-
ferred to a 96 well plate at 5000 cells/well in complete medium on Day 5 of culture.
Fe NPs and FeOx NPs were added at concentrations ranging from 0-200µg Fe ml−1 in
triplicate wells. As a control, wells with media only (no cells) were set up for every con-
centration of NPs. On Day 7, live cells were distinguished by the exclusion of trypan blue
dye (a) and an MTT assay was performed to assess cellular metabolism (b). The dashed
line represents a decline of 50% relative to control. These experiments were repeated five
times with representative examples shown.
cytometry works by directing a beam of laser light onto a stream of fluid containing a
column of cells in single file. Each cell scatters the laser beam according to its size and
granularity and fluorescent molecules attached to the cell can be detected by their
excitation and emission of light of a lower wavelength than the laser beam.
The DCs were incubated with Fe or FeOx NPs for 48 hours, stimulated with LPS for
the final 24 hours, and then analysed by flow cytometry for the expression of CD86
(Figure 5-4). At the doses used for MR detection (5µg Fe ml−1), there was no
appreciable change in LPS-mediated up-regulation of CD86 expression in DCs cultured
with either type of NP versus unlabelled control (Figure 5-4a-c). However, when DCs
were labelled with a higher concentration of NPs (50µg Fe ml−1) there was an increased
proportion of CD86+ cells when no LPS added and conversely a decrease in the
proportion of CD86+ when LPS was added (Figure 5-4d,e). These results suggest that
Fe and FeOx NPs may interfere with DC activation at a dose that is significantly lower
(50µg Fe ml−1) than the lowest dose at which cytotoxic effects are seen (160µg Fe ml−1).
The expression of CD86 was also examined on DCs that had been exposed to 5µg/ml of
the different NPs in vitro, and then labelled with CFSE before injection into na¨ıve
mice. All injected DCs recovered from the draining lymph node 48 hours later had
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become further activated in vivo, expressing similarly high levels of CD86 regardless of
the type of NP they had been labelled with (Figure 5-4c).
5.2.3 VITAL assay demonstrates antigen-specific cell
elimination in vaccinated mice
Before applying Fe NP labelling to DC-based vaccines, it was important to first check
that the DC/peptide vaccine was producing antigen specific killing by CTLs by
performing an in vivo cytotoxicity assay. The key concept of this assay is that in a
vaccinated mouse there will be preferential removal of cells that are expressing a greater
concentration of the vaccine antigen. This is measured by assessing the elimination of
fluorescent ”target” cells (typically syngeneic splenocytes) that have been loaded with
specific antigen before injection225,226 . The VITAL assay99 is a variation on this assay
in which three groups of target cells with three different concentrations of antigen are
injected. The fluorescent dye CFSE is used at a different concentration on each group
to allow discrimination by flow cytometry. As a control, a fourth group of cells that has
not been loaded with antigen is labelled with a different dye, cell tracker orange (CTO).
The four populations of cells are administered together intravenously in equal number.
In mice that have received an effective vaccination with DCs loaded with the same
antigen, selective elimination of target cells will result in an increasing ratio between the
cells without antigen (CTO labelled ”control cells”) and those that were labelled at
increasing concentrations (CFSE labelled ”target cells”).
The results of the VITAL assay are shown in Figure 5-5. The peptide antigen used in
the vaccine was SIINFEKL, a well-studied derivative of the chicken ovalbumin protein
which is known to be presented by the MHC molecule H-2Kb227, and can therefore
induce strong immunity in the C57BL/6 strain of mice. As expected, in the na¨ıve mice
there was no significant difference in the ratio of control cells to any of the target cell
populations. In primed mice there was an increase in the ratio of control to target cells,
which increased with increasing SIINFEKL concentration of the target cells. The
difference between the control to target cell ratios was significantly different between
na¨ıve and primed mice at all three concentrations of SIINFEKL (Figure 5-5b). This
indicates that the DC/peptide vaccine assayed in this study did induce a CTL response
that resulted in measurable antigen-specific cell lysis, providing a useful model for
analysing vaccine-induced responses by MRI.
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Figure 5.4: DC maturation after incubation with Fe NPs and FeOx NPs. DCs
were cultured with 5µg Fe ml−1 (a,b,c) or 50µg Fe ml−1 (d,e) of Fe NPs, FeOx NPs
or PBS only (control) from Day 5. LPS was added to DCs (b,e) 24 hours later. Cells
were harvested from culture (a,b,d,e) or from the draining lymph nodes after injection
into mice (c) and analysed by flow cytometry for the expression of CD86 after passing
through gates to exclude debris and dead cells (Figure 2-2).
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Figure 5.5: VITAL assay demonstrates antigen-specific cell lysis in vaccinated
mice. Splenocytes were loaded with 50nM, 5 nM, and 0.5 nM of SIINFEKL peptide and
labelled with increasing amounts of CFSE, respectively. Splenocytes not loaded with
peptide were labelled with CTO as a control. Equal proportions of all cell populations
were injected intravenously into groups of immunized (”primed”) and na¨ıve mice. Na¨ıve
mice that received injections of PBS only were used as a further control (c). Lymph nodes
were removed from mice 24 hours later and analysed by flow cytometry. Representative
flow plots of na¨ıve (a), primed (b) and control mice are shown. The ratio of CTO
labelled control cells to CFSE labelled target cells is shown for na¨ıve and primed mice
(d). (*p<0.05 by unpaired t-test)
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5.2.4 Fe NPs and FeOx NPs do not affect DC migration or
antigen presentation to cytotoxic T cells
After demonstrating that the DC/peptide vaccine induced antigen-specific killing, it
was important to ensure that loading DCs with NPs did not affect their ability to
migrate to the draining lymph node or to present the SIINFEKL antigen to T-cells,
both of which could interfere with the proposed MRI-based assay of CTL induction.
Three groups of DC/peptide vaccines were set up on the basis of the contrast agent
they were cultured with: Fe NPs, or FeOx NPs or PBS control. All groups were
activated with LPS, loaded with SIINFEKL and labelled with CFSE before
subcutaneous injection. A similar number of CFSE positive cells were recovered at 48
hours from the draining lymph nodes of na¨ıve mice from all three groups (Figure 5.6 a),
indicating that the NPs did not affect in vivo migration of the DCs.
When the same DC/peptide vaccines were given to mice primed one week earlier with
DCs loaded with SIINFEKL, almost no labelled cells were recovered from the draining
lymph nodes of any of the three vaccine groups (Figure 5-5b). The abrogation of DC
migration to the lymph node in primed mice is consistent with the induction of a
cytotoxic T cell response against the SIINFEKL peptide causing elimination of the cells
before from the nodes228. This indicates that loading DCs with Fe NPs or FeOx NPs
does not interfere with either their migration to the draining lymph nodes or their
presentation of antigen to cytotoxic T cells.
5.2.5 DC migration can be detected ex vivo by MRI at 9.4 T
Before performing experiments to track migration of NP-loaded DC in a clinical scanner
at 1.5 T, an ex vivo trial of tracking labelled DCs was performed at 9.4 T. Na¨ıve mice
and mice primed with a DC/peptide (SIINFEKL) vaccine received a subcutaneous
injection of DCs labelled with Fe NPs and loaded with SIINFEKL into the upper
hindlimb. After 48 hours the draining inguinal lymph nodes were removed and
examined at 9.4 T (Figure 5.7). There was a significant decrease in the T2 relaxation
time of the nodes removed from na¨ıve versus either primed mice or controls (no
vaccination). This indicated that in the na¨ıve mice there was a significant amount of Fe
NPs in the draining lymph node resulting from migration of peptide-loaded DCs,
whereas in primed mice the induced CTL effectively eliminated the peptide-loaded cells
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Figure 5.6: Migration of DC/peptide vaccines labelled with Fe NPs or FeOx
NPs to the draining lymph node by ex vivo flow cytometry. DCs were incubated
with Fe NPs, FeOx NPs or PBS only (control), loaded with peptide, matured with LPS,
labelled with CFSE and injected subcutaneously into na¨ıve and vaccinated (”primed”)
mice. Lymph nodes were removed from mice 48 hours later and analysed by flow cy-
tometry. (a) Representative flow plots of control (left column), DCs labelled with FeOx
NPs (middle column) or Fe NPs (right column). (b) Histogram plots of the number of
CFSE+ cells recovered from the lymph nodes are shown beneath their respective groups
from left: control, FeOx NPs and Fe NPs. (**p<0.01 by unpaired t-test)
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Figure 5.7: MRI of draining lymph nodes ex vivo at 9.4T. DCs labelled with Fe
NPs, loaded with peptide and matured with LPS were injected into the upper hind limb
of na¨ıve and vaccinated (”primed”) mice. Mice injected with DCs unlabelled with NPs
were injected as a control. The draining lymph nodes were harvested 48 hours later and
dispersed intact into a 1% agar gel matrix and the T2 relaxation time was determined at
9.4T (b). MR images were acquired (a) using a 2D multi-slice spin-echo sequence, with
the following parameters: echo time (TE) = 8 ms, repetition time (TR) = 2000ms, pixel
size = 100µm x 100µm, slice thickness = 0.5mm. (*p<0.05 by ANOVA with Bonferroni
post test)
and few NPs reached the node.
5.2.6 Only Fe NPs are effective for tracking DC migration in
na¨ıve versus primed mice
The proof of principle had been demonstrated: Fe NP labelling could enable the
different degree of DC migration in na¨ıve versus primed mice to be distinguished by
MRI. The task remained to test the system in vivo at 1.5 T and compare the
performance of Fe NPs with FeOx NPs.
Three groups of DC vaccines were set up on the basis of the contrast agent applied: Fe
NPs, or FeOx NPs or control (PBS). The three different vaccines were each injected into
the upper hindlimb of both na¨ıve and primed mice. The MRI appearance of the
draining lymph nodes 30 hours after injection are shown in Figure 5-8. The
contralateral (non-draining) lymph nodes are also shown and were used as an internal
control (Figure 5-8b, right column). Na¨ıve mice that were injected with DCs labelled
with either contrast agent tended to show a reduction in T2 weighted signal in the
draining lymph node versus the contralateral lymph node (Figure 5-8c) indicating
migration to the draining node. In primed mice, there was no difference detected
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Figure 5.8: MRI of draining lymph nodes in vivo at 1.5T following DC/pep-
tide vaccine labelled with Fe NPs or FeOX NPs. DCs were labelled with Fe NPs,
FeOx NPs or PBS only (control), loaded with peptide, matured with LPS and injected
into the upper hind limb of na¨ıve and vaccinated (”primed”) mice. MRI was performed
48 hours later in vivo at 1.5T, with a representative image from the Fe NP group shown
(a). For all images the signal intensity was measured by comparing the signal intensity
in the draining inguinal lymph node (a-arrow, b) with a reference of skeletal muscle in
the same image. The values for each draining lymph node of each mouse in the Fe NP
and FeOx NP groups were then compared with the contralateral node (a-arrowhead) and
plotted (c) as %∆T2 contrast as follows: (signal intensity of contralateral node)-(signal
intensity in draining lymph node)/ (signal intensity of contralateral node). (*p<0.05 by
Mann-Whitney rank-sum test)
between draining and contralateral lymph nodes in any of the groups, indicating
CTL-mediated elimination of migrating cells. However, only the mice injected with Fe
NP labelled DC did the difference between na¨ıve and primed mice show statistical
significance. This indicates that although cells labelled with either NP migrated to the
draining lymph node in a similar numbers (as seen in Figure 5-6), Fe NPs produced
more effective contrast. This was an important distinction as if this test were applied as
a marker of an antigen-specific CTL mediated immune response, only Fe NPs would
have enabled enough MRI sensitivity to distinguish when DCs migrate or are eliminated
before reaching the lymph nodes.
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5.2.7 Dose of Fe NPs injected without cells detectable at
inguinal lymph node
Despite the different MRI contrast in na¨ıve and primed mice displayed in Figure 5-8, it
remained important to investigate whether the Fe NPs were transported to the draining
lymph node by DCs and thus a true measure of DC migration. Another explanation
could be that the Fe was released from the vast majority of DCs that accumulate at the
injection site, and do not migrate to the draining lymph node.
To examine this, the total amount of Fe NPs or FeOx NPs that would normally be
added to 106 DCs before injection (106 cells x 10 pg Fe/cell =10µg) was injected
without DCs subcutaneously in the upper hind limb and the draining lymph nodes were
imaged. As shown in Figure 5-9b, there was no significant change in contrast with
either Fe NPs or FeOx NPs at this dose. When a 200µg dose of Fe was injected in the
same manner, there was a difference in T2 contrast seen in both groups with Fe NPs
producing significantly better contrast than FeOx NPs (Figure 5-9a,b). However, there
was no significant difference in the contrast between a 200µg dose given subcutaneously
and a 10µg dose loaded onto DCs within either NP group (see Figure 5-8). This
suggests that the transport of Fe to the draining lymph node is much more efficient by
loading in DCs, and that changes in the T2 contrast in the draining lymph node are
related to migration of NP-labelled DCs and not Fe NPs released at the injection site.
5.2.8 DC/lysate vaccines fail to induce DC elimination
The next series of experiments addressed the question of whether this cell tracking
assay could be applied to a tumour lysate-based vaccine where the vaccination consists
of multiple unknown tumour antigens. These vaccines are thought to generate immune
responses to multiple antigens, but because the density of each antigen on the injected
DCs is low, the cytolytic responses to each individual antigen may be low. When DCs
were loaded with lysate from tumour cells killed by freeze-thawing, they failed to
generate a cytotoxic lymphocyte response powerful enough to abrogate DC migration.
Even with the addition of a powerful adjuvant98 (the iNKT cell ligand α-GalCer) to
enhance the response, or when increasing doses of tumour lysate were employed, there
was no reduction in the number of DCs recovered in the draining lymph nodes in
primed mice (Figure 5-10). In this context, mice vaccinated with DCs loaded with Fe
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Figure 5.9: Inguinal nodes after s.c. injection of 10µg and 200µg of Fe. Mice
were injected subcutaneously in the upper hind limb with a dose of 10 or 200µg Fe
ml−1 of either Fe NPs or FeOx NPs, or PBS only (control). MRI was performed 48
hours later in vivo at 1.5T, with a representative draining lymph node from each group
shown at a dose of 200µg Fe (a-circles). For all images the T2 contrast was measured by
comparing the signal intensity in the draining lymph node with a reference of skeletal
muscle in the same image. The values for each draining lymph node of each mouse in
the Fe NP and FeOx NP groups were then compared with the contralateral node and
plotted (b) as %∆T2 contrast as follows: (signal intensity of contralateral node)-(signal
intensity in draining lymph node)/ (signal intensity of contralateral node). (*p<0.05 by
Mann-Whitney rank-sum test)
NPs produced significant contrast changes in the draining lymph node in both na¨ıve
and primed mice (Figure 5-11). Did the DC/lysate vaccine fail to induce an
antigen-specific immune response? This was shown not to be the case in Chapter 6,
where experiments showed that DC/lysate vaccines were able to protect mice against
tumours from the same cell tumour line as the lysate (Figure 6-6). The results here
showed the assay to be ineffective for assessing the broad, but potentially weaker
cytotoxic immune responses induced to this DC/lysate vaccine.
5.3 Discussion
5.3.1 Principle findings
Labelling DCs with Fe NPs was shown to improve the MR sensitivity to twice the level
of DCs labelled with FeOx NPs, without altering the maturation, migration or viability
of the DCs. The increased sensitivity of DCs labelled with Fe NPs enabled the
translation of the ex-vivo DC elimination assay to be performed in vivo with MRI. The
adapted version of the DC elimination assay was able to detect an antigen-specific CTL
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Figure 5.10: Migration of DC/lysate vaccines to the draining lymph node
by ex vivo flow cytometry. DCs were loaded with varying concentrations of GL-261
tumour lysate, matured with LPS, labelled with CFSE and injected subcutaneously into
na¨ıve and vaccinated (”primed”) mice. Lymph nodes were removed from mice 48 hours
later and analysed by flow cytometry. (a) Representative flow plots are shown of na¨ıve
(a-left plot) and primed (a-right plot) mice injected with DCs cultured with 35µg of
tumour lysate/106 cells. (b) Histogram plots of the number of CFSE+ cells recovered
from the lymph nodes are shown for different groups based on the amount of tumour
lysate added to DC culture.
Figure 5.11: MRI of draining lymph nodes in vivo at 1.5T following DC/lysate
vaccine labelled with Fe NPs or FeOX NPs. DCs were labelled with Fe NPs, loaded
with 35µg of tumour lysate, matured with LPS and injected into the upper hind limb
of na¨ıve and vaccinated (”primed”) mice. MRI was performed 48 hours later in vivo
at 1.5T. For all images the contrast was measured by comparing the signal intensity in
the draining inguinal lymph node (a) with a reference of skeletal muscle in the same
image. The values for each draining lymph node of each mouse in the Fe NP and FeOx
NP groups were then compared with the contralateral node and plotted (a) as %∆T2
contrast as follows: (signal intensity of contralateral node)-(signal intensity in draining
lymph node)/ (signal intensity of contralateral node)
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driven immune response to DC/peptide but not DC/lysate vaccination, with the MRI
measurement of DC migration correlating in all instances with the ex vivo flow
cytometry measurements.
5.3.2 Mechanism of DC elimination
The phenomenon of antigen-specific elimination of DCs from the draining lymph node
was first described in 2000 by Hermans et al229, who demonstrated that DCs loaded
with a peptide antigen are eliminated in a CD8+ T cell dependent manner from the
draining lymph nodes in mice vaccinated with the same DC/peptide preparation. The
same phenomenon was observed when mice were infected with influenza virus, with
DCs loaded with an influenza peptide antigen eliminated from the draining lymph
node222. Furthermore, it was suggested that measuring the elimination of CFSE
labelled DCs by ex vivo flow cytometry could be used as the basis of an assay of in vivo
CTL responses222. These findings were followed up by a series of studies examining the
mechanism and the importance of this phenomenon.
The mechanism of antigen specific elimination of DCs was shown to be dependent on
CTLs229,230. These cells recognise antigen presented on MHC class I molecules through
direct contact with their T-cell receptor. CTLs possess the ability to rapidly induce
apoptosis mediated cell death of the antigen presenting ”target” cells through two main
mechanisms. CTLs can release cytoplasmic granule toxins including perforin, a
membrane disrupting protein231 and granzyme B, a serine protease that activates
apoptosis pathways directly (Bcl-2 pathways)232 and indirectly(caspase
pathways)233,234. CTLs can also promote apoptosis of target cells by the ligation of
their Fas ligand, FasL, with Fas receptors on the target cell235.
The relative importance of perforin, granzyme B and FasL ligand pathways in CTL
mediated elimination of target cells has been investigated. The FasL has been shown to
be inessential for target cell killing as demonstrated through models of genetic
knockdown of FasL230 and FasL antagonism236. This is combined with some evidence
that DCs are resistant to FasL mediated killing237. In contrast, both perforin228,236 and
granzyme B236 have been shown to play critical roles such that if either pathway is
inhibited, reduced or absent killing of target cells result.
The physiological role of CTL mediated elimination of DCs is considered to be
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important in immune regulation and the prevention of autoimmunity, with evidence for
this is seen in both humans and mice. CTL mediated DC elimination has been shown
to reduce CD8+ T cell proliferation228, and in mice the inability of perforin-deficient T
cells to eliminate DCs and control T cell proliferation leads to autoimmune damage in
mice infected with lymphocytic choriomeningitis virus238. This was also seen in
infections with Listeria monocytogenes. In humans, uncontrolled lymphoproliferation is
seen in viral infections in patients with perforin mutations239 or increased resistance of
DCs to apoptosis240. These findings suggest that mechanisms such as CTL-mediated
DC elimination are important in preventing autoimmune damage and pathogenic
lymphoproliferation by regulating CD8+ T cell proliferation.
The process of CTL mediated killing of target cells is itself regulated by at least two
mechanisms that can protect the antigen-presenting target cells from elimination.
Meuller et al demonstrated that antigen-specific CD4+ T cells can protect DCs from
CTL elimination through binding to CD40 on DCs241. Watchmaker et al showed that
CD8+ memory cells can provide similar protection through secretion of TNF-alpha236.
Interestingly, both mechanisms were shown to involve upregulation of a granzyme B
inhibitor in DCs236. However, studies by Ronchese and colleagues suggest that the
upregulation of granzyme B inhibition is not enough to protect DCs from CTL
elimination242, which suggests that CD4+ T cells and CD8+ memory T cells may
bestow protection to DCs by other undiscovered mechanisms as well.
From these findings, which elucidate some of the mechanisms involved in CTL mediated
elimination of target cells, can the failure of CTL-mediated elimination of DCs loaded
with tumour lysate be explained? The hypothesis generated was that the DCs in
DC/lysate vaccines are protected from CTL-mediated lysis by increased numbers of
antigen-specific CD4+ T cells and CD8+ memory T cells. DC/lysate vaccines present
antigens to both CD4+ and CD8+ T cells and can produce proliferation in both cell
types243. This is in contrast to DC/peptide vaccines made with MHC I restricted
peptides (such as SIINFEKL in C57Bl/6 mice) that are presented only to CD8+ T
cells244 (although MHC II peptides could be also present in DC/lysate cultures - from
proteins in foetal calf serum). CD4+ T cells are important (but not essential) in the
generation of CD8+ memory T cells245. In Chapter 6 (Figure 6-5), it is shown that
DC/lysate vaccines cause a marked increase in memory CD8+ T cells in the draining
lymph node. It is hypothesized that DC/lysate vaccination induced proliferation of
CD4+ T cells and CD8+ memory T cells, which were of a quality and/or quantity that
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differed from those generated by the DC/peptide vaccine, such that they were able to
protect the injected DCs loaded with tumour lysate from CTL mediated killing.
This hypothesis would take further studies to test but what can be argued with the
available data is that the DC/lysate vaccine could have generated an antigen-specific
immune response that did not result in CTL mediated elimination of DCs loaded with
tumour lysate. Further evidence of this is seen in Figure 6-6 where DC/lysate vaccines
provide antigen-specific tumour protection. In summary, mechanistic studies suggest
that a vaccine could induce an antigen-specific immune response that does not
necessarily result in CTL mediated elimination of DCs arriving in the draining lymph
node. An assay based on DC elimination would therefore detect a subtype of
antigen-specific immune responses, producing a loss in sensitivity and a gain in
specificity.
5.3.3 Implications of the study
DCs play an important role in regulating adaptive immune responses246, highlighted by
their use in cancer immunotherapy87. Crucial to this role is the transport of antigen by
DCs to secondary lymphoid tissue where it is recognised by T cells. Accordingly, there
has been a wide range of imaging modalities applied to tracking DCs after their
administration in vivo. These include gamma scintigraphy247, positron emission
tomography248, two-photon intravital microscopy249, bioluminescence250 and MRI251.
MRI has the advantage of producing the best spatial resolution of all the non-invasive
imaging modalities39 and does not involve exposure to ionising radiation.
In order to distinguish DCs from surrounding tissue by MRI, they need to be labelled
with a contrast agent. FeOx NPs have been employed for this task in both humans252
and mice251. Ahrens et al. were the first to load DCs with FeOx NPs and track their
migration in vivo at 11.7T253. No DCs were detected by MRI in the draining lymph
nodes over four days, which was attributed to the source of the DCs, which were from
an immortalized cell line as opposed to bone marrow derived DCs used in this thesis.
De Vries et al. demonstrated that MRI of DCs labelled with FeOx NPs can be used for
tracking DC-based vaccines in humans at 4.7T252. Baumjohann and colleagues found
that there was correlation of FeOx NP labelled DC migration by histology, flow
cytometry and MRI at 4.7T251. All three studies found that labelling with FeOx NPs
did not result in changes in DC surface marker expression, induction of apoptosis,
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migration or T cell priming in vivo.
The findings reported in this chapter present several advances to the application of MRI
to DC cell tracking. Whilst this study was not the first to show that DC migration to
the draining lymph node can be effectively tracked at 1.5T254, it adds further support
to the concept and remains one of the few studies carried out at 1.5T. Clinical MRI
scanners with a field strength greater than 1.5T are not widely available in New
Zealand, so being able to track DC migration at 1.5T greatly improves the feasibility of
including such technology in a clinical trial.
This study was the first to apply MRI tracking of DCs to measure DC elimination in
vivo, measuring the CTL mediated DC elimination assay described by Hermans et al222
with in vivo MRI correlated with ex vivo flow cytometry. The use of Fe NPs to label
DCs was essential for this advance as performing the elimination assay with MRI was
not effective with the use of FeOx NPs at 1.5T. This was assisted by the use of Fe NPs
that increased the sensitivity of MRI to detect loaded DCs to twice the level of FeOx
NPs in this study and reported elsewhere255, whilst loading a similar amount of
Fe/cell252,255. The adaptation of this assay to a non-invasive technique performed in
vivo means that it could be applied to clinical immunotherapy trials.
The DC elimination assay has potential advantages over other assays used to assess the
generation of an antigen-specific immune response. Although the DC elimination assay
is not sensitive enough to assess DC/lysate vaccines, it has been shown to be more
sensitive than the detection of CTL cytotoxicity in vitro following DC/peptide
vaccination222. It can provide information about in vivo function of CTL activity that
is not available with other assays used in clinical trials256. Furthermore, the DC
elimination assay may prove to have a greater sensitivity than blood based assays in
clinical trails based on the clinical findings that antigen-specific CD8+ T cells can be
detected in the biopsies of the draining lymph node221 or the vaccine injection site252,
whereas at the same time, these T cells were largely undetectable in blood. These
factors, combined with the non-invasive nature of the assay, warrant consideration of
the DC elimination assay with Fe NP enhanced MRI, to be applied to DC/peptide
clinical vaccine trials.
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5.3.4 Remaining questions
One of the most vital questions that this study raises is whether the DC/elimination
assay, performed in vivo with Fe NP labelled DC/peptide vaccines, would detect
antigen-specific immune responses in a human clinical vaccine trial, and whether such
immune responses would be associated with improved clinical outcomes.
It has been shown that MRI tracking of DCs labelled with FeOx NPs can be applied
safely and effectively to a clinical vaccine trial, and is more accurate than scintigraphy
for detecting DC positive lymph nodes252. This clinical study by de Vries et al. was
performed at 4.7T where there is approximately three times the signal to noise ratio
compared with imaging at a field strength of 1.5T. There are some advantages in
moving from the imaging lymph nodes in mice to humans. The volume of lymph nodes
in humans is approximately 100-200 times that of the murine lymph nodes imaged in
this study221. This would enable multiple slices of 1mm thickness (used in this study)
to be imaged through the node, thereby reducing the partial volume imaging seen in
this study. Since clinical studies typically involve injection of around 5 -10 x 106
DCs256, which is more than the number used in this study (1 x 106), the DC/lymph
node volume ratio would be reduced by a factor of 10-40 in depending upon the volume
of the draining lymph node in the patient. This may not prove to be a severe limitation
as the identification of regions of DC migration within the lymph node may be visible in
larger lymph nodes252.
The biggest factor in whether the in vivo DC elimination assay will be of ultimate
benefit is whether it correlates with positive clinical outcomes. An argument could be
made that by elimination of DCs loaded with peptide, administered in successive
booster vaccinations, that T cell proliferation is being limited and this may negatively
impact on the anti-tumour activity. There is evidence that DC elimination does reduce
T cell proliferation228,230, but the effect of this on anti-tumour immune activity has not
been determined. Conversely, it could be argued that if DC elimination is shown to
have a negative association with clinical outcome then it could be just as useful an
assay to perform. As the timing of booster vaccinations has been shown to influence
T-cell proliferation through varying the amount of DC elimination236, the DC
elimination assay could provide valuable information about the optimum timing of
specific DC/peptide vaccines.
In summary, the most important outstanding question is: what is the relationship
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between DC elimination and clinical outcomes in response to a DC/peptide vaccine?
Future studies addressing this relationship could have more than one potential outcome
in which the DC elimination assay could provide information of benefit.
5.3.5 Conclusion
The use of Fe NPs has distinct advantages over FeOx NPs for tracking DCs in vivo with
MRI. The successful adaptation of the DC elimination assay to a non-invasive
procedure, using the MRI detection of DCs labelled with Fe NPs, makes it a strong
candidate for inclusion in future clinical studies of DC/peptide vaccines.
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to vaccination by monitoring
enlargement of draining lymph
nodes by MRI
6.1 Introduction
DC vaccines prepared with exogenously administered peptide tumour antigens have
traditionally been the most common method of DC-based cancer immunotherapy244.
However, DC vaccines prepared with tumour cell lysate have several advantages over
DC/peptide vaccines and have produced better results in clinical studies257–259. One of
the disadvantages of DC/lysate vaccines is the difficulty in assessing antigen-specific
responses to the ill-defined tumour antigens in the tumour lysate. DC/lysate vaccines
were observed to produce enlargement of the draining lymph node on MRI during
experimental work performed in the last chapter. Based on this response, this chapter
introduces a novel assay to determine the presence of an antigen-specific response




Assessing antigen-specific responses to vaccination by monitoring enlargement of
draining lymph nodes by MRI
6.1.1 The advantages of lysate-based vaccines
DC/lysate vaccines have been shown to be more effective than DC/peptide vaccines for
producing clinical responses in cancer immunotherapy, with a review of clinical trials
finding more than twice the objective response rate with DC/lysate based vaccines258.
The relative limitations of DC/peptide vaccines have been well documented and recent
years have seen the increasing use of alternative vaccine strategies88. The three main
restrictions to peptide vaccination include restricted patient selection on the basis of
HLA alleles expressed, limited activation of CD4+ T cells due to the size constraints of
the peptide (MHC class II molecules requiring longer peptides), and a limited repertoire
of known tumour antigens that can be targeted by the vaccine-induced response. These
restrictions limit the clinical application and effectiveness of peptide vaccines and are
explored in further detail below.
One of the main deficiencies of peptide vaccination is that patients with different human
leukocyte antigen (HLA) subtypes have different MHC molecules that bind different
peptide antigens. Therefore the peptides used in vaccines have to be especially chosen so
that they bind MHC class I and/or II molecules in a given patient’s HLA-subtype. This
restricts the number of candidate peptides, the number of patients in which they can be
effectively deployed and potentially the type of immune cells that they can activate. For
example, if a peptide is used that contains an epitope that binds MHC class I but not
class II, it may successfully produce large numbers of CTLs, but it will be ineffective at
CD4+ T cell stimulation. Lack of CD4+ T cell-stimulation by peptide vaccines could
explain lack of long-lived immunity as it has now been well established that
antigen-specific CD4+ T cells are crucial for the priming of long lived memory CD8+ T
cells245,260. Furthermore, vaccinating with a single peptide antigen generates only a
restricted repertoire of tumour antigen-specific T cells224. Tumours possess antigenic
variation261 and could escape the immune response induced by DC/peptide vaccination
through reduced levels of expression262 or a mutation in a single targeted antigen263.
An alternative to DC/peptide vaccines is DC/tumour lysate vaccines where cells from a
patient’s tumour are lysed and loaded onto the patient’s DCs ex vivo. This has several
advantages over DC/peptide vaccines in that it provides patient and tumour specific
therapy with a relevant array of tumour antigens loaded onto a patients MHC
molecules, regardless of their HLA type. DCs loaded with killed tumour cells ex vivo
have been shown to present antigen to both CD4+ and CD8+ T cells264,265 and produce
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long lived memory86 and protection against tumours266. However, the development of
DC/lysate vaccines has been limited by difficulty in assessing their generation of
tumour antigen-specific immunity, the induction of which has been correlated with
positive clinical outcome in two thirds of DC/peptide clinical trials256.
6.1.2 The need for an assay to detect an immune response to
multiple (unknown) antigens
The main goal of monitoring antigen-specific T cell responses in immunotherapy trials
is to determine whether a treated patient has developed an immune response following
vaccination and if the detected response is associated with a clinical outcome. This
assists in future vaccine development by determining whether the current vaccine is
potent enough to produce a detectable immune response and, if an immune response is
generated, whether it is capable of improving clinical outcomes.
The previous chapter discussed a novel in vivo strategy for detecting an antigen-specific
immune response generated by DC/peptide vaccines. It was not sensitive enough to
detect the immune response generated by DC/lysate vaccines. This a common problem
with the variety of in vitro assays that can detect the generation of antigen-specific
CD8+ T cells by DC/peptide vaccines. Antigen-specific immune responses generated by
DC/lysate vaccines are more difficult to detect with these assays due to the multiple,
poorly defined antigens in the tumour lysate.
As an example to illustrate this point, consider the tetramer assay used to quantify
antigen-specific CD8+ T cells267. In this assay, T cells from the patient are taken from
peripheral blood and exposed to fluorescent multimeric MHC I molecules loaded with
peptide antigen for analysis of binding by flow cytometry. Any CD8+ T cells with
antigen receptors that recognise the peptide presented on the MHC tetramer will stain
positive. If this number increases after DC/peptide vaccination it indicates expansion of
antigen-specific T cells and is considered a positive response. This assay is not able to
quantify antigen-specific T cells induced by a DC/lysate vaccine unless all of the
antigens in the tumour lysate were known and were able to be loaded onto MHC Class I
and Class II tetramers, which is not feasible. A compromise is to load tetramers with
generic tumour antigens that the tumour type has been shown to express268. This
approach is severely limited in the information it provides as patients may develop
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effective immune responses against other undefined tumour antigens and therefore be
regarded as tetramer negative. Another commonly used assay to measure
antigen-specific immune responses, Elispot, may also fail to identify responses to
relevant antigens with tumour lysate vaccines269. Therefore, a more effective assay of
immune responses to DC/lysate vaccination is required.
6.1.3 Enlargement of the draining lymph node following
DC/lysate vaccination
During the DC tracking experiments in the previous chapter, it was noted that the
draining lymph nodes were enlarged in mice that received both priming and secondary
vaccination with the same DC/lysate vaccine. This was observed on MRI 30 hours
following subcutaneous secondary vaccination and was not observed in mice that did
not receive a priming vaccine. The phenomenon of sequestration of antigen-specific
lymphocytes from the peripheral blood into lymphoid tissues, peaking at 24-48 hours
after antigen exposure, was first described over 30 years ago270. Draining lymph node
enlargement has been shown to be due to an antigen-specific reaction where challenged
nodes can weigh up to three times the contralateral node at 48 h271.
The work in this chapter investigates whether the observations of early draining lymph
node enlargement by MRI is related to the described phenomenon by the
antigen-specific recruitment of lymphocytes. The selective enlargement in the mice that
received priming vaccinations could be explained by the generation of increased
numbers of tumour lysate antigen-specific lymphocytes, which were then recruited to
the draining lymph on secondary vaccination. More importantly, could MRI of the
draining lymph nodes be used as the basis for a non-invasive in vivo assay to assess the
generation of an antigen-specific immune response following DC/lysate vaccination?
6.1.4 Aims
The aim of this chapter is to test the hypothesis that the MRI measurement of early
draining lymph node enlargement can be used as a marker of an antigen-specific
immune response generated by DC-based vaccination. The following questions will be
addressed in the context of a C57BL/6 mouse model using bone marrow generated DCs,
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established mouse tumour cell lines and MRI in a clinical scanner at 1.5T.
1. Is early lymph node enlargement an antigen-specific response to vaccination?
2. Is early lymph node enlargement seen following challenge with DC/lysate and
DC/peptide vaccines?
3. What is the time course of the enlargement?
4. Does re-enlargement occur after a third vaccination?
5. What are the cell types involved in the enlargement?
6. Does early lymph node enlargement correlate with tumour protection?
6.2 Results
6.2.1 Lymph node enlargement is an antigen-specific response
to vaccination
Based on the knowledge that induction of immune responses is associated with trapping
of lymphocytes in lymphoid tissue, it was speculated that an MRI-based assay of lymph
node size could be used to assess vaccine-induced responses. It was hypothesized that
measurable increases in lymph node size would be observed shortly after a second round
of vaccination, as the response induced by the primary vaccination would orchestrate
rapid lymphocyte trapping upon re-exposure to vaccine-associated antigens. In
contrast, where primary vaccination has failed to elicit an immune response, no such
increase would be observed. The first step in developing such an assay was to show that
MRI could detect post-vaccination changes in lymph size in vaccinated animals relative
to na¨ıve controls. Vaccines comprising DCs loaded with tumour lysate were used for
this analysis. These were prepared by first harvesting 106 glioma cancer cells in culture
and lysing them by rapid freezing in liquid nitrogen and thawing to 37◦C three times.
The glioma cell lysate was then added to 106 DCs on day 5 of their culture in vitro.
The adjuvant, a-GalCer, was added on day 6 to enhance vaccine potency. On day 7,
DCs were harvested and 106 were injected intravenously into each mouse in the
”primed” group only. The secondary (or ”challenge”) vaccine, injected 7 days later, was
prepared in same way except that LPS was added on day 6, instead of a-GalCer, to
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improve DC migration to the draining lymph node223.The DCs were injected
subcutaneously, 106 cells/mouse in the upper hind-limb of mice, in the primed animals,
and also a group of na¨ıve controls. The draining and contralateral inguinal lymph nodes
were imaged by MR 30 hours later with the results shown in Figure 6-1.
In primed mice, there was a significant increase in the mean area of the draining lymph
nodes compared with the contralateral lymph nodes; no such difference was observed in
na¨ıve mice. This response was reproducible, with all of the draining lymph nodes in the
primed group being larger than the opposite nodes in the same mouse (Figure 6-1c).
The areas of the lymph nodes can be expressed by plotting the area of each lymph node
(as in Figure 6-1b and c) or by taking the difference (area of draining lymph node) -
(area of contralateral lymph node) and expressing this as a percentage of the area of the
contralateral lymph node for each mouse (Figure 6.1d). The latter method is employed
for the rest of this chapter as it removes some of the background statistical noise
produced by comparing mice of different sizes (up to a 10% difference in mass was
observed in 6 week old syngeneic littermates) and obviates the need to use paired
statistical tests when comparing groups of mice.
These initial results were promising but not altogether convincing as the primed mice
had received a powerful adjuvant, (a-GalCer), that the na¨ıve mice had not.
Furthermore, it remained to be proven that the enlargement was related to any
mechanism specific to the tumour antigen in the DC/lysate vaccine. It could perhaps be
a marker of an induced immune response to a non-tumour constituent of the vaccine,
such as to foetal calf serum in which the DCs are cultured. Therefore, a further series of
experiments was performed to tease out whether the enlargement of the draining lymph
node was indeed a marker of a tumour antigen-specific response following DC/lysate
challenge. For these experiments, all mice were primed with DCs loaded with glioma
cell lysate, then challenged with a DC/lysate vaccine made from either glioma cells
(”G:G” group) or from an unrelated thymoma cancer cell line (”G:T” group). Analysis
30 hours after vaccine challenge showed that the G:G group had more than three times
the increase in the size of their draining lymph nodes versus the G:T group (Figure
6-2b, mean 95% versus 31% respectively). This finding indicates that the major
contribution to enlargement of the draining lymph nodes was a specific immune
response to the glioma cell lysate constituent of the DC/lysate vaccine.
As the glioma cell line originates from neuroglial cells that express antigens that are
immunoprivileged272 (not normally accessed by the immune system), the results in
Results 145
Figure 6-1e may be unique to the glioma cell line and not applicable to other types of
cancer. To test this, a similar experiment was performed with a crucial difference: all
mice were primed with the thymoma cell line and then challenged with a DC/lysate
vaccine containing either glioma (”T:G” group) or thymoma (”T:T” group) cell lysates.
Enlargement of the draining lymph nodes was observed only in mice that received the
same priming and challenging DC/lysate vaccine (Figure 6-1f,T:T group). Therefore, it
can be concluded from these experiments that significant lymph node enlargement is
attributable to antigen-specific responses to the lysate constituents of the vaccine; hence
the same antigens must be present in priming and challenging vaccines.
Was the observed phenomenon of antigen-specific enlargement of the draining lymph
node particular to DC-based vaccines with the incorporation of tumour lysate? To
answer this question the same DC/peptide vaccine described in Chapter 5 was
employed. Lymph node enlargement was seen following DC/peptide vaccination in
primed mice but not in na¨ıve mice (Figure 6-2). This implies that enlargement of the
draining lymph node can be induced with single or multiple antigens incorporated into
a DC-based vaccine.
6.2.2 Time course of the draining lymph node enlargement
For the examined phenomenon of draining lymph node enlargement to become the basis
of an assay to measure antigen-specific responses to DC-based vaccines, it was
important to determine the time course of the enlargement. Of particular importance
was to determine the window of time in which significant antigen-specific enlargement
of the draining lymph node was observed.
An important factor in the size of a lymph node is the network of blood vessels within
the lymph node, which are lined by endothelial cells. Mature DCs can induce
proliferation of endothelial cells, which in turn increase the cellularity and size of a
lymph node by expanding the network of blood vessels and increasing the supply of
cells entering the node273. DCs in all of the DC-based vaccines examined here could
induce this process after migrating to the DLN following subcutaneous injection. This
process is not antigen-specific and will therefore produce lymph node enlargement in
the DLN in na¨ıve mice as well as primed mice - potentially interfering with the
proposed antigen-specific assay. Endothelial cell proliferation peaks at 7 days but can
be seen as early as 48 hours post injection of DCs273. Therefore the time course of
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Figure 6.1: Area of draining and contralateral lymph nodes following
DC/lysate vaccination. Mice were scanned at 1.5T with a T2-weighted spin echo se-
quence 30 hours after receiving subcutaneous vaccination into the upper hindlimb. The
area of the draining (a, solid arrow and b, DLN) and contralateral (a, arrowhead and b,
CLN) inguinal lymph nodes were measured with the areas plotted in (b). The pairing
of the draining and contralateral lymph nodes in the same mice are shown in (c). The
percentage difference in the area of the draining versus the contralateral lymph nodes
was calculated for each mouse and plotted d as follows: (area of draining lymph node) -
(area of contralateral lymph node)/ (area of contralateral lymph node). In (e), all mice
were primed with the same glioma cell-based DC/lysate vaccine, then challenged with a
DC/lysate vaccine made from either glioma cells (G:G) or from thymoma cells (G:T). In
(f), both groups were primed with thymoma based DC/lysate vaccines and challenged
with either glioma (T:G) or thymoma based (T:T). (*p<0.05 by two-tailed t test)
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Figure 6.2: Difference in the area between draining and contralateral lymph
nodes following DC/peptide vaccination. Mice primed with a DC/peptide vaccine
(primed) and na¨ıve mice were imaged 30 hours after DC/peptide vaccination. The results
are plotted as the difference in the area between the draining and contralateral lymph
nodes for each mouse as in Figure 6-1. (*p<0.05 by two-tailed t test)
Figure 6.3: Time course of draining lymph node enlargement following
DC/lysate vaccination. All mice were primed with the same thymoma cell-based
DC/lysate vaccine, then challenged with a DC/lysate vaccine made from either glioma
cells (Thymoma:Glioma) or from thymoma cells (Thymoma:Thymoma). The mice were
scanned in groups at 12, 30, 48 or 72 hours following vaccination. (*p<0.05,**p<0.01 by
two-tailed t test)
lymph node enlargement was examined around this point at 12, 30, 48 and 72 hours
post administration of DC/lysate vaccine (Figure 6-3).
Only at the time points prior to 48 hours was there a difference in DLN enlargement
between the two vaccine groups that reached statistical significance. For this reason,
measuring DLN enlargement is no longer a marker of an antigen-specific response from
48 hours post-vaccination and the assay must be applied before this time point.
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6.2.3 Re-challenge vaccination produces re-enlargement
Cancer immunotherapy with DC-based vaccines usually involves multiple vaccinations
separated by one to four weeks87 to improve the memory response274. Therefore it was
investigated whether DLN enlargement was seen after multiple vaccinations.
Experiments were set up to distinguish the difference in the size of the DLN between
mice that received two versus three of the same DC-lysate vaccines. All mice received
two vaccines, 1 week apart. Two weeks later, only mice in the ”re-challenge” group
received a third vaccine; all mice were then imaged 30 hours later.
The results showed that all mice had a similar degree of DLN enlargement 30 hours
following the second vaccination (Figure 6-4). However, the mice in the re-challenge
group developed further DLN enlargement after a third vaccine. In contrast, over the
same timeframe, the DLN of the mice that did not receive this last boost were reduced
in size to the point that they were no longer significantly larger than the contralateral
nodes. These findings are evidence that it would be appropriate to use MR imaging of
the DLN, as a marker of an antigen-specific response, when vaccines are as close as 2
weeks apart. This would not have been the case if either the DLN had remained
enlarged 2 weeks following the second vaccine, or if there had not been a repeat in DLN
enlargement following the third vaccine.
6.2.4 Cell types involved in lymph node infiltration
After investigating the antigen-specificity and timing of DLN enlargement, it was
important to look at the nature of the enlargement. Could the enlargement of the DLN
be explained by cellular infiltration and if so what were the types of cells involved in the
response?
To answer this question, the DLN and contralateral lymph nodes were removed and
processed into single cell suspensions for analysis by flow cytometry (Figure 6-5). All
mice were vaccinated with a thymoma cell based DC/lysate vaccine then a week later
were challenged with either DCs only (T:DC), a glioma based DC/lysate vaccine (T:G)
or the original thymoma based DC/lysate vaccine (T:T).
The total cells recovered from the DLN versus the contralateral lymph nodes was
increased by almost 400% in the T:T group. The increase in cell numbers alone was of
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Figure 6.4: Area of draining lymph nodes following re-challenge with
DC/lysate vaccine. A schematic shows the vaccine administration and MRI sched-
ule in the two groups (a). All mice received two doses of the same thymoma cell based
DC/lysate vaccine one week apart. MRI of all mice was performed 30 hours following
the second vaccination (b, week 1). Two weeks later, only the mice in the ”re-challenge”
group received a third vaccine. MRI of all mice was performed 30 hours later (b, week
3). (*p<0.05)
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sufficient magnitude to explain the DLN enlargement observed on MRI without
involving other mechanisms such as oedema or an increase in vascularity of the lymph
node, although these other mechanisms could not be ruled out.
The increase in cell numbers was made up of a broad variety of cell types including all
lymphocytes: CD4+ (B220-/CD4+) and CD8+ (B220-/CD4+) T cells, B cells (B220+),
NK (B220-/CD4-/CD3-/NK1.1+) and NKT cells (B220-/CD3+/NK1.1+) as well as
myeloid cell types such as DCs (B220-/CD11c+), monocytes (B220-/CD11c-/Ly6CHi)
and macrophages(B220-/CD11c-/F480+). In all cell types examined there was an
increase in the mean cell number in the DLN of the repeated thymoma-based DC/lysate
vaccination (T:T group) relative to other challenge groups, although this trend did not
reach statistical significance for myeloid cells. Challenge with DC only, or the
glioma-based DC/lysate vaccine (T:G) showed a trend to increased myeloid cell numbers
in the DLN (Figure 6-5c) although these increases did not reach statistical significance.
The T cells were further separated into na¨ıve, central memory and effector memory
cells. na¨ıve cells are those that have not been activated through their T-cell receptor
coming into contact with antigen presented on an antigen presenting cell. Central and
effector memory T cells are both important for anti-tumour activity and prevention of
relapse88, and they possess distinct phenotypes and functions275.
Central memory T cells (Tcm) circulate through secondary lymphoid tissues and have
little effector function276. They can respond to antigen rapidly and dividing and
differentiating into effector T cells. In contrast, effector memory T cells (Tem) can
migrate to peripheral tissues and mount an immediate cytolytic response with Tcm
cells277. Effector memory cells undergo modest proliferation upon antigenic stimulation,
at lower levels than central memory cells278.
Tcm were defined in this study as CD62L+CD44+ cells and effector memory cells as
CD62L−CD44+ cells279,280. The number of CD4+ and CD8+ na¨ıve and Tem cells were
increased in the DLN of the T:T group but not to a greater extent than the overall
CD4+ or CD8+ T cells. However, both CD4+ and CD8+ Tcm were markedly increased
in the T:T group over the other two vaccine groups. This increase was approximately
twice the magnitude of the total cell increase, suggesting a selective recruitment. This
indicates that all subsets of T cells were being recruited, with a specific excess in one of
the subtypes associated with tumour protection. Caution must be taken not to over
interpret the relationship between the number of different cells recruited and the
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effectiveness of the vaccine as the number of T cells specific for tumour antigens can not
be determined or even estimated from this method of analysis. In summary, the results
show that there is a broad-spectrum recruitment of lymphocytes, dominated by central
memory cells, to the DLN of mice primed and boosted with the same DC/lysate vaccine
and that this process is antigen-specific.
6.2.5 Lymph node enlargement correlates with tumour
protection
The final step in testing the DLN enlargement phenomenon was to examine whether a
DC/lysate vaccine, which had been shown to produce antigen-specific DLN
enlargement, could also provide antigen-specific protection against tumour challenge.
The same glioma- and thymoma-based DC/lysate vaccines that were examined earlier
in this chapter, were administered to mice for tumour challenge experiments. Two
control groups were also set up, one which received a DC-only vaccine (DC only) and a
group which received no vaccination at all (no vaccine). One week later all mice
received a subcutaneous challenge with thymoma cells. It was shown that the mice that
received the thymoma vaccine had significantly better protection from developing
tumours within 60 days (Figure 6-6). All of the mice within the other three groups
developed tumours within 20 days, whereas in the thymoma vaccine group fewer than
50% developed tumours within 60 days. The experiment was repeated three times with
a representative experiment (Figure 6-6a) and the pooled data shown (Figure 6-6b).




The enlargement of draining lymph nodes as measured by MRI was found to be an
antigen-specific response to DC/lysate and DC/peptide vaccines occurring within 48
hours of secondary vaccination. When the draining lymph nodes were imaged 2 weeks
after secondary vaccination, they were no longer enlarged, unless a third vaccine was
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Figure 6.5: Cell types involved in lymph node infiltration. The draining and
inguinal lymph nodes were removed 30 hours post-vaccination in mice that were primed
with a thymoma based DC/lysate vaccine and boosted with either DCs only (T:DC), a
glioma based DC/lysate vaccine (T:G) or the original thymoma based DC/lysate vaccine
(T:T). The gating strategies of different cell types were as follows: CD4+ (B220-/CD4+)
and CD8+ (B220-/CD4+) T cells, B cells (B220+), NK (B220-/CD4-/CD3-/NK1.1+),
NKT cells (B220-/CD3+/NK1.1+), DCs (B220-/CD11c+), monocytes (B220-/CD11c-
/Ly6CHi) and macrophages (B220-/CD11c-/F480+). The antibodies, fluorophores and
flow cytometry plots are detailed in Chapter 2-6. The increase in the number of cells was
plotted as percentage difference as follows: (number of cells in DLN) - (number of cells
in the contralateral lymph node) / (number of cells in the contralateral lymph node).
(*p<0.05,**p<0.01 by ANOVA with Bonferonni multiple comparison test)
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Figure 6.6: Subcutaneous thymoma tumour challenge in mice following vac-
cination. Mice were vaccinated with a DC/lysate vaccine based on either glioma or
thymoma cell lysate. A DC-only and a no vaccine group were used as controls. A sub-
cutaneous injection containing 106 thymoma cells was administered to all mice one week
following vaccination. Mice were examined daily from day 6 and deemed to be positive for
tumours when they developed a mass measuring greater than 4mm2 by external calliper
measurements. The survival curve of a representative experiment with 5 mice per group
is shown (a) along with a pooled sample of three individual experiments (b). (*p<0.05,
**p<0.001 by log rank test)
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administered, in which case there was further enlargement. The lymph node
enlargement was associated with an increase in all lymphocyte populations with the
largest increase seen in CD4+ and CD8+ central memory T cells. Mice that received
DC/lysate vaccines were protected from tumour challenge with the same tumour used
in the lysate. This protection was not seen with DC/lysate vaccines made from another
tumour cell type. Therefore, a correlation was observed between the induction of an
antigen-specific immune response by DC/lysate vaccination, as measured by early
draining lymph node enlargement, and tumour protection.
6.3.2 Mechanism of the draining lymph node enlargement
Although the mechanism of cell recruitment into the draining lymph node following
DC/lysate vaccination was not investigated in this study, a hypothesis can be generated
by comparison with similar studies in the literature. Since lymphocyte migration into a
lymph node was shown to markedly increase in the presence of antigen over 45 years
ago281, there have been many studies investigating the importance and the mechanisms
of lymphocyte trafficking into lymph nodes in response to antigen-specific interactions.
This process of early lymphocyte recruitment to the draining lymph node is conserved
across multiple species282–284 indicating a fundamental role in adaptive immunity. What
is the functional significance of lymphocyte accumulation in antigen-challenged lymph
nodes? The increased lymphocyte traffic through an antigen challenged lymph node can
improve the probability that lymphocytes will come into contact with their cognate
antigen281. Furthermore, the specific migration of clonally expanded memory T cells to
sites of antigen deposition enables a rapid functional response if they encounter their
cognate antigen285 which could be applied to antigen-challenged lymph nodes286.
Strong evidence of the importance of this phenomenon is seen when the cells are
removed from an antigen challenged lymph node resulting in the failure to develop
systemic immune memory to that antigen287.
Hall and Morris performed one of the earliest studies looking at the mechanism of
lymph node recruitment to antigen challenged lymph nodes. They showed that the
increase in lymphocytes within an antigen stimulated lymph node is not caused by
lymphocyte proliferation within the node, or by increased migration into the node
through the afferent lymphatics, but is due to traffic of cells from the blood281.
Lymphocyte entry into the lymph node from the blood is further supported by the
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finding that there is a four fold increase in blood supply to the lymph node following
antigen challenge288. Mackay et al showed that, in addition to the general increase in
cell traffic through an antigen challenged lymph node, there are also specific increases in
the ratio of central memory to other T cell subsets286.
Cahill et al. showed that a ”cell shutdown” occurs in lymph nodes when challenged
with antigen282. This cell shutdown causes reduced efferent outflow and accumulation of
all lymphocytes within the lymph node, including B cells, within 12 hours. This
response was markedly increased in animals that had been primed to the antigen.
These early studies describe a similar phenomenon to what was observed in this study,
namely the accumulation of lymphocytes into the antigen challenged nodes of primed
mice within 48 hours and the preferential recruitment of central memory cells.
Furthermore, these studies show that the increase in cell numbers into the antigen
challenged lymph node is due to lymphocyte influx from the blood and not cell
proliferation within the node. They do not answer the question of how the response is
antigen-specific or its molecular mechanism.
McConnell and Hopkins examined the mechanism by which cell shutdown occurs in
lymph nodes only on secondary challenge with antigen. They showed that complement
activation can cause cell shutdown with similar kinetics to antigen mediated cell
shutdown289. Complement can be activated by antibody bound to antigen and could
therefore be a result of an antigen-specific response by B cells (a subtype of which,
plasma cells, secrete antibody). Complement activation causes release of PGE2 and by
inhibiting PGE2 cell shutdown was abrogated
290.
There is evidence that T cells also play a key role in shutdown of cell egress from
antigen challenged lymph nodes. Lymphocyte retention can be induced by the
intra-lymphatic infusion of primed T cell supernatant289. Cytokine production is rapid
after antigen re-exposure in memory T cells (2 hours) versus na¨ıve T cells (6-20
hours)291. If the DC/lysate vaccine produced an increased memory T cell population,
specific for tumour antigens in the lysate, this could explain why the cell accumulation
was seen within 12 hours. It is not unlikely that an expanded pool of memory T cells
specific for tumour antigens would soon come into contact with antigen in the draining
lymph node as ≈2% of the recirculating lymphocyte pool transits through a single
inguinal lymph node in a mouse per day292. Central memory cells are known to
recirculate through lymph nodes until they come into contact with antigen, at which
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point they mount strong recall responses whenever the antigen returns277,293.
These findings suggest antigen-specific mechanisms of lymphocyte accumulation in
lymph nodes that could well be at play in the DC vaccine model described in this
chapter. They are somewhat lacking in molecular detail, as the mechanisms of
antigen-specific inhibition of egress are still yet to be determined294,295. Promising
candidates, such as the secretion of T-cell chemokines by DCs, including CCL22,
CXCL10 and CXCL13, were shown not to mediate the early sequestration of T cells
into the lymph node within 48 hours of vaccination296.
There exists a powerful molecular mechanism of inhibiting lymphocyte egress from
lymph nodes that has been actively researched in the last decade. FTY-720 is a
sphingosine 1-phosphate (S1P1) receptor agonist that inhibits the egress of lymphocytes
from thymus, lymph node and Peyer’s patches (but not from the spleen), thereby
depleting lymphocytes from the circulation, resulting in an immunosuppressive effect297.
S1P1 receptors are present on T and B lymphocytes and when S1P is present at low
levels it promotes chemotaxis298. There is debate in the literature about how S1P acts
within a lymph node to inhibit lymphocyte egress249. One hypothesis proposes that a
concentration gradient of S1P exists in lymph nodes, with a low concentration within
the node except near exit sites. S1P is secreted by cells near the exit site to the lymph
nodes and by acting on S1P1 receptors on lymphocytes, it drives their egress and
re-circulation. When S1P is present in high concentrations (i.e. with exogenous
administration of FTY720) it binds to S1P1 receptors on lymphocytes, promoting
receptor down-regulation and preventing chemotaxis toward the exit sites299. A second
hypothesis proposes instead that S1P1 agonists act on endothelial cells to block
lymphocyte egress300 through the sinus endothelium of the lymph node. Although the
connection between S1P1 and early antigen-specific lymph node accumulation of
lymphocytes has not been determined294, it is a credible candidate pathway that
restricts lymphocyte egress from lymph nodes.
The mechanism of early lymphocyte accumulation in antigen challenged lymph nodes
remains to be clearly elucidated. It is hypothesized from the studies above that it is
both an important process in producing memory responses, and that it is likely to
involve several different cell types and pathways. When antigen-specific memory T cells
which come into contact with antigen presented on DCs in the lymph node, cytokines
are released that can induce cell accumulation. Complement activation, presumably
from antibody-antigen complexes, can produce PGE2 mediated shutdown of cell egress
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from lymph nodes and this is reversible by inhibition of PGE2. No involvement in this
process has been proven for the S1P pathway as yet, but it is likely that future studies
will reveal how its potent ability to prevent lymphocyte egress from lymph nodes could
be related to early antigen-specific accumulation in antigen challenged lymph nodes.
6.3.3 Implications of the study
The assay introduced in this chapter was sensitive enough to detect an antigen-specific
immune response generated by DC/lysate vaccines, whereas the assay discussed in the
last chapter, based on elimination of migrating antigen-loaded DCs, was not. It is worth
examining why the lymph node enlargement assay is more sensitive than the DC
migration assay. The DC migration assay depends on the CTL dependent elimination
of DCs before they reach the draining lymph node. As hypothesized in Chapter 5, this
could be prevented by the production of a CD4+ T cell and CD8+ memory cells that
protect the DCs from CTL mediated killing. Whatever the mechanism, it was shown
(in Figure 5-10,11) that the DC/lysate vaccine did not prevent DCs migrating to the
draining lymph node.
In contrast, the draining lymph node enlargement assay potentially depends on three
different steps: i) the stimulation of an antigen-specific immune response that is not
necessarily CTL predominant, ii) the recognition of the tumour antigens presented on
DCs by specific lymphocytes that then release cytokines but do not need to induce
apoptosis in the antigen presenting DC, iii) recruitment of cells to the draining lymph
node on an order that can produce enlargement detectable by MRI. Step ii) requires
further dissection (see section 6.3.2) but assuming that these general principles are
correct, it can be seen why the draining lymph node assay was able to detect
antigen-specific responses from both DC/lysate and DC/peptide vaccines, whereas the
DC migration assay from Chapter 5 was sensitive enough only for responses to
DC/peptide vaccines.
Another advantage of the draining lymph node enlargement assay was that it is very
simple to measure the size of lymph nodes with MRI. Measuring contrast in murine
lymph nodes was prone to volume averaging effects due to the presence of adjacent fat
along the slice selection axis (which was three times as thick as the other two
dimensions in order to increase signal to noise ratio). This did not affect the
measurement of the lymph node area because the distinction between the border of the
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lymph node and the fat was very clear in plane of the image (see Figure 6-1a).
Comparing the area of the draining with the contralateral lymph node was a very
straightforward method to standardise the degree of enlargement, which minimised the
error of group comparisons. Furthermore, the assay does not require the use of high
field (>1.5T) MRI nor does it require the use of contrast agents. The measurements of
lymph node area can be made within minutes without requiring specialist radiologist
interpretation. This is in contrast to two of the major assays used in clinical vaccine
trials tetramer and ELISPOT, which remain labour intensive and are difficult to
standardize88. A standardisation study of the tetramer assay performed across 27
laboratories showed a wide variation in the frequencies of antigen-specific T cells
reported267. Similar discrepancies have been reported for ELISPOT301. Although the
lymph node enlargement assay does not quantify the production of antigen-specific T
cells, nor does it assess their function such as cytokine release on re-exposure to antigen,
the tetramer and ELISPOT assays have limited utility to detect these immune
responses in the context of DC/lysate vaccines (refer Section 6.1.2).
The requirement for an MRI scan could be seen as a limitation of the lymph node
enlargement assay, but arguably not a major one. All tertiary hospitals in New Zealand
now have access to at least one 1.5T MRI scanner and it is unlikely a clinical vaccine
trial, with its stringent requirements for good medical practice standards (GMP), would
be performed outside a tertiary centre. In fact, maintaining a licensed GMP laboratory
to prepare the vaccines in a clinical trial is a far more limiting factor than the
availability of MRI, with only 2 such laboratories registered in Auckland and Wellington
in 2008302.
The requirement for an MRI scan to be timed within 48 hours of vaccination is perhaps
more of a constraint. If the human kinetics of early draining lymph node enlargement
resemble that of the mouse (Figure 6-3), then enlargement will be associated with an
antigen-specific response from 12-30 hours following vaccination. This is window is large
enough to allow a clinic visit to perform vaccination with an MRI the following day,
with either procedure able to be performed in the morning or afternoon.
The use of MRI highlights some of the clear advantages of the lymph node enlargement
assay over peripheral blood based assays in that it is performed non-invasively, in vivo
and at a site that it is immunologically relevant. Most other assays sample the
circulating lymphocyte pool to monitor specific T-cell responses, although it may not be
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the most relevant in terms of establishing correlations with clinical tumour response217.
Antigen-specific T cells were readily detected in the biopsies of the draining lymph
node221 or the vaccine injection site303, whereas at the same time, these T cells were
largely undetectable in blood. Responses in the draining lymph node are known to be
specifically relevant. When T cells harvested from the draining lymph node are
adoptively transferred, they can protect against tumours, which is not seen if T cells
from non draining nodes, or peripheral blood are used304. This could explain why the
lymph node enlargement assay has increased sensitivity to detect antigen-specific
immune responses generated by DC/lysate vaccines.
The identification of the draining lymph node(s) from the site of vaccination is an issue
that will need to be addressed in humans. The draining lymph node(s) can be identified
using transcutaneous evaluation of gamma counts using a standard handheld gamma
probe following technetium-99 administration around the site of vaccination221. This
has the undesirable requirement of further hardware and the administration of
radioactive substances. An alternative method would be to take measurements of a
cluster of lymph nodes associated with drainage of the vaccination site and compare
them to the contralateral side. The larger the cluster of lymph nodes analysed the
larger the noise in the measurement. The upper extremity, which is the most common
site of vaccine administration89, has one of the most consistent lymphatic drainage
patterns in the body305. Therefore it may be possible to identify a typical pattern of
drainage to a restricted number of lymph nodes using a consistent vaccination site. This
will require further research to address, the burden of which is lessened by the
simplicity and non-invasive nature of the early draining lymph node assay.
There is a general limitation in translating studies performed by measuring tumour
protection by prophylactic vaccination in healthy mice. Restraint is required in the
degree of comparison that can be made to clinical vaccine trials conducted in patients
with compromised immune systems306. The tumour studies were performed here to test
the proof of principle that early draining lymph node enlargement could be associated
with some measure of tumour protection.
6.3.4 Remaining questions
This study raises some questions pertaining to its potential application in clinical
cancer vaccine trials. The unresolved issues surround the mechanism of early lymph
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node enlargement, whether the same result can be achieved in humans and whether the
magnitude of the enlargement would be associated with clinical benefit.
In the absence of an identified mechanism of early lymph node enlargement, no
correlations can be drawn between the magnitude of the lymph node enlargement and
the number and function of antigen-specific cells. The mechanism of early lymph node
enlargement could be further elucidated by measuring the cytokines in the supernatant
of draining versus contralateral lymph nodes in primed and na¨ıve mice at various time
points following vaccination. If a difference were found in the secretion of certain
cytokines, these cytokines could then be inhibited by blocking antibodies in a further
experiment, and observing whether this abrogated lymph node enlargement and/or
tumour protection. In addition, the implicated cytokines could be added to lymph
nodes in na¨ıve mice to see if they produce lymphocyte accumulation. If the cytokine
milieu were found to be more typical of an immunoregulatory (suppressive) process,
with increased levels of IL-10, TGF-α or interferon-γ 307–309, then the association
between early draining lymph node enlargement and tumour protection in this study
may not be closely related or reproducible in other studies.
One of the main reasons for establishing the mechanism of early lymph node
enlargement is associated with the type of immune response that is associated with
tumour protection. A more direct approach would be to address this in a clinical trial.
The question remains as to whether lymph node enlargement following DC/lysate
vaccine will be seen in humans and whether it will be associated with an
antigen-specific immune response. Sequestration of lymphocytes in antigen-challenged
lymph nodes is known to occur in humans195. It would also be interesting to determine
if the magnitude of the draining lymph node enlargement was associated with positive
clinical outcomes. Due to the simplicity and non-invasiveness of the lymph node
enlargement assay, the next step could be to examine these questions in a clinical trial
before investing further resources into solving its mechanism in mice. This would assess
the utility of the lymph node enlargement assay in the most relevant context: the
patient with cancer undergoing immunotherapy.
A final question is whether the assessment of early lymph node enlargement could be
performed with ultrasound. Ultrasound is effective at assessment of peripheral lymph
nodes310 and is cheaper and generally more available than MRI. The downsides of
ultrasound are that it has poor spatial resolution and its signal is attenuated in obese
individuals311. Furthermore, reproducibility of ultrasound in repeat measurements of
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the same lymph node can be difficult due to the lack of external landmarks. Despite
these shortcomings it could well prove adequate for this assay, which only requires a
simple series of measurements to be performed in peripheral lymph nodes.
6.3.5 Conclusion
This chapter introduces a novel assay to assess the generation of an antigen-specific
response to DC-based vaccination by measuring the area of the draining and
contralateral lymph nodes with MRI. Enlargement of the draining lymph node within
48 hours of vaccination was found to be associated with an antigen-specific immune
response and tumour protection in the mouse model studied. This novel assay, based on
a well-described phenomenon, is easy to perform and standardise, is applicable to both
DC/peptide and DC/lysate vaccines and it could be readily applied in clinical vaccine
trials to examine the generation of an antigen-specific immune response following
vaccination.
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Chapter 7
General discussion
This thesis argues that Fe NPs produce more effective MRI contrast on T2 weighted
sequences than FeOx NPs. It has been shown that the enhanced contrast with Fe NPs
translated into improved MRI-based applications, including increased sensitivity of
cellular detection (Chapter 3), improved diagnosis of small tumours (Chapter 4) and
increased accuracy of cell tracking enabling assessment of antigen-specific immune
responses following DC/peptide vaccines (Chapter 5). Observations from this research
led to the development of an MRI-based assay that can detect antigen-specific immune
responses induced by DC/lysate based vaccination (Chapter 6). In this chapter, the
limitations and broader implications of these findings are explored with reference to
replacing FeOx NPs and gadolinium-based contrast agents with Fe NPs.
Limitations of this study
This study has several limitations worth noting. Such limitations are related to the
methods by which the central hypothesis was tested. They concern the FeOx NPs
which were used for comparison with the Fe NPs, the type of MRI techniques employed
and the use of animal models.
Instead of purchasing clinically approved FeOx NPs, the decision was made to
synthesize FeOx NPs following a well known synthetic method (see Chapter 2). A
direct comparison between commercial FeOx NPs (such as Sinerem) and Fe NPs would
have the advantage of establishing whether Fe NPs outperform a type of FeOx NP with
proven clinical efficacy. This course was not taken because there are no commercially
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available FeOx NPs which have a DMSA coating. As discussed in Chapter 3, the
coating of a NP has a significant effect on its magnetic properties and
pharmacokinetics. The central question of this thesis was whether the presence of a
highly magnetic iron core could improve the biomedical applications of FeOx NPs, and
this was best addressed by comparing NPs with the same coating molecules.
Determining the optimal coating strategy to improve the performance of magnetic NPs
is important but has been extensively investigated by others168–171.
The MR imaging in this thesis relied exclusively upon T2 weighted spin echo imaging.
This is not the most sensitive method to detect the magnetic field distortions produced
by magnetic NPs. Gradient echo techniques which can detect changes in T2* are known
to be more sensitive to detect the presence of FeOx NPs52. However, the image
distortion produced by Fe NPs was found to compromise image quality significantly
using gradient echo techniques in our in vivo mouse imaging experiments, such that any
gains in sensitivity were not appreciable. A further potential limitation with this study
was that T2 mapping of images was not performed in any of the in-vivo imaging at 1.5
T. This technique has the advantage of potentially greater sensitivity and specificity
compared to single T2 weighted images. For example, T2 mapping can better distinguish
areas of signal void due to low proton content, such as in lung tissue, versus rapid T2
decay, such as in an area of high Fe NP concentration. T2 mapping was not available for
experiments in this thesis due to software restrictions in operating the clinical MRI
scanner. There was certainly an advantage in not using T2 mapping in that it is not
used in routine clinical practice and would have presented a potential hurdle in
translating this research into the clinic.
This study used models which were used cells (surgically administered immortalized
cancer cells), organs (spleen) and organisms (mouse) different to those of which it is
ultimately concerned with (native metastatic tumours, lymph nodes and humans
respectively). This was a necessary step because the use of non-human organisms are
currently necessary to establish proof of principle and general toxicity before phase 1
human trials can be commenced. As discussed in Chapter 4, the use of a mouse model
involving implanted intrasplenic tumors as a surrogate for lymph node metastases was
necessary due to the difference in size between the lymph nodes of mice and men. All
three of these factors will require future verification in clinical studies before conclusions
about the clinical effectiveness of Fe NPs can be ultimately determined.
165
Could Fe NPs supplant GBCA?
Gadolinium-based contrast agents (GBCA) were first approved by the United States
Food and Drug Administration (FDA) in 1988, as MRI scanners were becoming more
widely available312. Since then, the number of FDA-approved GBCAs313 has grown to
seven and these have been administered with over 100 million MRI scans worldwide22.
GBCAs are the only MRI contrast agent available in Australia and New Zealand.
The longstanding use and popularity of GBCAs presents a barrier to their substitution
with another type of MRI contrast agent. There are many well described pathological
lesions that can be diagnosed with GBCA-enhanced MRI (as discussed in Chapter 1)
and familiarity with the interpretation of GBCA-enhanced scans is part of not only
specialist radiology training but also the standard medical curriculum in Australasia
and elsewhere. It could be argued that a new contrast agent with similar effectiveness
to GBCAs would face a significant hurdle to gain market share. The best strategy
might be to target the areas where GBCAs are contraindicated or where they do not
perform particularly well.
Until recently, MRI with GBCAs had few contraindications and was used preferentially
in patients with renal impairment over CT using iodine based contrast agents314. A
concern was first raised in 2006 that GBCAs may be associated with a fibrosing skin
disorder with multiorgan involvement called nephrogenic systemic fibrosis (NSF)315. A
meta-analysis performed in 2009 reported a significant association between all GBCAs
and the development of NSF, with an odds ratio of 26.7 (95% confidence interval
10.3-69.4). This means that patients who were administered GBCAs were 27 times
more likely to develop NSF than those who had no exposure. NSF was seen almost
exclusively in patients with advanced renal disease316 where the combination of
metabolic acidosis317, high concentrations of competing metal ions318 and inadequate
clearance of GBCA317 leads to gadolinium ion dissociation. The gadolinium ion can
form salts with phosphate317 and other anions that are elevated in renal failure, with the
salts then being potentially deposited in many organs including muscle, bone, liver and
skin. A study examining the skin biopsies of patients with NSF found gadolinium in six
out of seven samples examined319. Although there is a suggestion that some GBCAs
carry a greater risk than others in inducing NSF320, all GBCAs may best be avoided in
renal failure, as the gadolinium is toxic to the kidneys in renal impairment, even at the
recommended reduced doses321 and there is no effective treatment of NSF322.
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The total number of reported cases of NSF, since the original description in 2006, is 350
as of June 2011323. Despite the incidence of NSF being estimated at a very modest 4 for
1000 patient-years with end-stage renal failure324, the relationship between GBCAs and
NSF has generated a lot of publicity. It is important to emphasize that NSF has only
been reported in patients with end-stage renal failure321. Nevertheless, an internet
search for ”gadolinium MRI” performed in June 2011 with the Google search engine
returned 13 of the first 20 hits involving NSF (including advertisements from American
legal firms specialising in malpractice). Combine this with the observation that FeOx
NPs have been administered clinically with an excellent safety profile for over 50 years
(initially for the treatment of anemia)325 and patients with hepatic and renal failure
were included in a large FeOx NP trial51, and it seems that a solid opportunity exists to
develop Fe NPs to be marketed in patients with renal failure.
The main limitation to this hypothesis is that FeOx NPs (and by extension Fe NPs)
provide different information to GBCAs. For example, in stroke imaging, GBCAs and
FeOx NPs can provide different results since breakdown of the bloodbrain barrier (as
detected by GBCAs) and cellular infiltration of the brain by macrophages (as detected
by FeOx NPs) are not closely linked326. Interpretation of FeOx NP enhanced scans
requires radiologist training because the resulting hypo intense (dark) areas on T2 -
weighted images can be confused with the signals from bleeding, calcification, or metal
deposits327. The interpretation of MRI with FeOx NPs has proven difficult in cancer
trials with untrained radiologists328. A path of least resistance for radiologists wanting
to image patients with renal failure may be the development of GBCAs with more
stable chelating agents that are able to retain the gadolinium ions and prevent NSF.
Promising biomedical applications of Fe NPs
Although FeOx NPs may not be the panacea to replace GBCAs in patients with renal
failure, there are two areas where FeOx NPs have shown clear benefits in over GBCAs,
and that is in the imaging of lymph node metastases and cell tracking. Two recent
meta-analyses looking at the performance of GBCAs329 and FeOx NPs57 in diagnosing
malignancy in lymph nodes suggest that FeOx NPs have better sensitivity and
specificity in this application. The sensitivity of FeOx NPs enhanced MRI was 0.90
(95% confidence interval: 0.88-0.91) versus 0.84 (0.70 to 0.92) for GBCAs, with
specificities of 0.96 (0.95-0.97) versus 0.82 (0.72 to 0.89) respectively. The meta-analysis
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of FeOx NPs57 addressed a valid criticism of their use, which is that it takes 24 hours
after administration of FeOx NPs before an optimal MRI scan of the lymph nodes can
be made. It was found that there was no decrease in diagnostic accuracy when a
pre-contrast scan was omitted with FeOx NPs.
Although the reported values of sensitivity for the two types of contrast agent had
overlapping confidence intervals, MRI enhanced with FeOx NPs produced an
improvement in sensitivity over unenhanced scans that reached statistical significance
whereas GBCAs enhanced scans did not. An earlier meta-analysis examining FeOx NPs
in the diagnosis of lymph node metastases330 reported similar values of sensitivity
(0.88) and specificity (0.96). The most remarkable finding from comparison of the three
studies is the improvement in specificity in images enhanced with FeOx NPs compared
to GBCAs. These differences can be partially explained by the different mechanisms of
contrast produced by FeOx NPs and GBCAs.
A side effect which has been commonly encountered with large FeOx NPs (> 100nm
such as Feridex) is the onset of severe back pain with administration. The mechanism of
the pain is unclear but was severe enough to warrant interruption or discontinuation of
the infusion in 2.5% of patients177. This problem can be ameliorated by administering
Feridex by slow infusion. Fe NPs, with their improved T2 relaxivity, could be
administered at lower doses than FeOx NPs thus decreasing the time of infusion and/or
reducing the risk of side effects.
FeOx NPs are taken up by phagocytic cells, particularly macrophages, that are
abundant in lymph nodes. As discussed in Chapter 4, normal lymph node tissue is rich
in macrophages, whereas tumour tissue has relatively fewer macrophages and decreased
relative uptake of FeOx NPs331. In contrast, GBCAs, which remain extracellular, can
detect the new blood vessels that develop within and around lymph nodes following
implantation of metastatic cells332 and demonstrate some of the abnormal
morphological characteristics of tumor tissue within the node333,334. Lymph node
enlargement associated with inflammation can also result in new blood vessel
formation335 and is in general associated with an increased infiltration of
macrophages326. Therefore, in an inflamed, non-cancerous lymph node, GBCAs could
give a false positive result by highlighting new blood vessels whilst FeOx NPs would be
taken up actively across the node and give a true negative result for cancer infiltration.
Despite these advantages of FeOx NPs over GBCAs, there are still drawbacks to FeOx
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NPs which have prevented their licensure for imaging lymph nodes by the European
Medicine Agency (EMA) or the US FDA. These were summarised in a licensing
withdrawal report of an FeOx NP agent, Sinerem, that failed to gain approval by the
EMA51. The report was based primarily on a multi-centre clinical trial which enrolled
1,777 patients. The report states that:
1. ”The pivotal study failed to demonstrate a consistent and statistically significant
benefit for Sinerem in sensitivity and failed to confirm non-inferiority with regards to
specificity.”
2. ”The lack of consistency between the three readers, both with regards to initial
assessment and post-Sinerem assessments is worrisome.”
Both of these issues could be potentially ameliorated with the use of Fe NPs instead of
FeOx NPs. In chapter 4 it was demonstrated that Fe NPs can improve both the
sensitivity and specificity of tumour diagnosis in macrophage rich organs (Figure 4-10)
and that Fe NPs can reduce the intra- and inter-observer variability of diagnosis relative
to FeOx NPs (Figure 4-11). Furthermore, the clinical need for such a contrast agent in
prostatic cancer was reported by Arnon Krongrad, one of the pioneers of
minimally-invasive prostatic surgery336, who commented in response to the Sinerem
ruling337:
”We [the industry] desperately need better tests that can be used to accurately detect
the presence of prostate cancer once it has escaped from the prostate into other organs.
It would seem all too sad if the research on (Sinerem) cannot be used as the basis for
another attempt to develop a new imaging agent with a comparable safety profile and a
slightly better effectiveness profile.”
The findings in this thesis give weight to the argument that Fe NPs could meet this
demand with their improved efficacy and similar safety profile.
One application in which the effectiveness of FeOx NPs is unrivalled by GBCAs is in
the labelling of cells for tracking with MRI. Due to the relatively low T1 contrast effects
per unit concentration (relaxivity) of GBCAs, which is reduced within cells338 and at
higher magnetic fields used for cell tracking339, combined with poor intracellular
biocompatibility340, there are relatively few examples of cell labeling applications using
Gd in the scientific literature341,342. FeOx NPs do not suffer from any of these
drawbacks and are currently the most widely used contrast agent for MRI cell tracking
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studies343. Fe NPs can improve the sensitivity of cell tracking studies beyond that of
FeOx NPs by lowering the threshold of labelled cell detection, as demonstrated in
Chapters 3 and 5. This is particularly important when sensitivity is the limiting factor
of a cell tracking application, which is often the case with 1.5 T scanners344.
In some cell tracking applications, the dose of Fe used to label cells can be the limiting
factor. Although there is evidence that FeOx NPs can be used to track stem cells
without affecting their phenotype345,346, some studies have shown that FeOx NPs can
interfere with chondrogenesis of mesenchymal stem cells347, microglial cell implantation
in the spinal cord348 and macrophage-T cell interactions349. It was also shown in
Chapter 5 that at higher doses, Fe NPs and FeOx NPs can interfere with dendritic cell
maturation (Figure 5.4). Therefore there is scope for Fe NPs to be applied at the same
doses as FeOx NPs to improve sensitivity or at reduced doses to reduce effects without
compromising sensitivity. Although cell tracking applications currently exist exclusively
in the research realm (no agents have been approved for cell tracking in the clinic), the
use of magnetic NPs for MRI cell tracking is likely to increase alongside the expanding
funding research in stem cell therapies350 and with the FDA approval of the first
cell-based vaccine351.
Beyond lymph node imaging and cell tracking, there are a multitude of clinical
applications of FeOx NPs that are being researched. These include in vivo
drug-delivery352 and drug release353, gene therapy354, molecular sensors355, cellular
mechanical manipulation356, MRI reporter genes357 and magnetic hyperthermia358.
Although these applications are beyond the scope of this thesis, it is worth noting that
Fe NPs, with their superior magnetic properties, could potentially improve many if not
all of these applications. Investigating this hypothesis would require comparative
studies with FeOx NPs, such as those performed in this thesis. A promising candidate
would the use of Fe NPs to improve magnetic hyperthermia, and it has been shown that
NPs with increased magnetisation can improve the hyperthemic effect359. Fe NPs offer
the additional benefit of improved MRI sensitivity which could result in better cancer
identification combined with MRI and treatment with magnetic hyperthermia.
The development of a non-invasive assay to detect the presence of antigen-specific
immune responses following DC/lysate vaccination is a significant contribution made by
this thesis research to the field of cancer immunotherapy. Although Fe NPs are not
strictly required for this assay, they could be administered to identify the draining
lymph node of a vaccination site in which to observe the enlargement. The
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identification of draining lymph nodes has been successfully demonstrated using FeOx
NPs360,361. Although it is more readily accessible and easier to operate, it is unlikely
that ultrasound would be used instead of MRI for conducting repeated measurements of
lymph nodes, as discussed in chapter 6. Therefore a preliminary MRI scan with Fe NPs
could be used to assess the draining lymph node and measure its baseline size, followed
by a second scan, 12-30 hours after DC vaccination.
A final aspect worth considering regards the cost of manufacturing MRI contrast
agents. Despite the fact that gadolinium is a rare-earth mineral that is substantially
more expensive as a bulk material than Fe (USD $120/kg versus 0.20/kg, respectively),
the marketed price of FeOx NPs is greater than GBCAs362. This is due in part to
difficulties in translating the synthesis of FeOx NPs to industrial scale processes able
that are able to produce large quantities of consistent quality NPs49. The patented
synthetic method of producing Fe NPs presented in this thesis requires an approximate
cost of NZD $1,382/g including labour costs363. This compares with similar size (20nm)
FeOx NPs of chemical grade that are sold for NZD $33,516/g (Sigma Aldrich).
Although challenges still remain in upscaling the synthetic method, there is a very large
margin between the current cost of manufacturing Fe NPs and the listed price of FeOx
NPs. Reduced cost could prove to be another advantage of the commercial application
of Fe NPs over FeOx NPs.
In conclusion, this thesis has argued that Fe NPs can produce more effective MRI
contrast than FeOx NPs to enhance cell detection, increase the accuracy in detecting
small tumours and improve cell tracking. The resulting improvement in MRI contrast
with Fe NPs led to the development of novel techniques that can be readily applied in
clinical vaccine trials to measure the antigen specific immune response following
DC-based vaccines. Fe NPs hold excellent potential to improve the MRI diagnosis of
lymph node metastases where FeOx NPs have failed to cross the threshold for clinical
approval. Further clinical applications of FeOx NPs, specifically stem cell tracking and
magnetic hyperthermia of cancer tissue, warrant investigation with Fe NPs to improve
their effectiveness.
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Simple Synthesis and Functionalization of Iron Nanoparticles for
Magnetic Resonance Imaging**
Soshan Cheong, Peter Ferguson, Kirk W. Feindel, Ian F. Hermans, Paul T. Callaghan,
Claire Meyer, Angela Slocombe, Chia-Hao Su, Fong-Yu Cheng, Chen-Sheng Yeh,
Bridget Ingham, Michael F. Toney, and Richard D. Tilley*
Magnetic nanoparticles (NPs) are increasingly important in
many biomedical applications, such as drug delivery, hyper-
thermia, and magnetic resonance imaging (MRI) contrast
enhancement.[1] For MRI, iron oxide NPs are the only
commercial T2 or negative contrast agents, due to their
biocompatibility and ease of synthesis[2] and research in the
area is highly active.[3] The efficacy of these contrast agents
depends mainly on the surface chemistry and magnetic
properties of the NPs.[1] Materials with larger magnetization
could induce more efficient transverse (T2) relaxation of
protons and result in greater contrast enhancement.[4] As iron
has the highest saturation magnetization at room temperature
among all elements,[5] and is biocompatible, it is an ideal
candidate for MRI contrast enhancement. Nevertheless, the
development of using iron NPs for magnetic applications has
been challenging and limited compared to those of its oxides,
due to the difficulty in preparing stable iron NPs with simple
synthesis methods and precursors.[5,6]
Under ambient conditions, iron NPs of 8 nm or smaller
oxidize completely upon exposure to air.[7] For larger NPs, an
oxide shell of 3–4 nm forms instantly on the surface, forming
iron/iron oxide core/shell NPs. Groundbreaking studies for
the synthesis of iron NPs of larger than 8 nm has largely been
achieved by decomposition of iron pentacarbonyl,
[Fe(CO)5].[6,8] Additional reports include the use of other
precursors in forming iron nanocubes.[9] However, all of these
processes are limited in terms of ease of synthesis and
scalability; [Fe(CO)5] is volatile and highly toxic,
[5] and other
processes involve precursors that are expensive and air-
sensitive,[9a] or require high decomposition temperatures.[9b]
Here, we chose an easy to handle iron organometallic
sandwich compound as the precursor and prepared single-
crystal iron NPs using a simple, low-temperature synthesis
method. The iron nanocrystals oxidized naturally to form
highly crystalline iron/iron oxide core/shell NPs. The ease of
this synthesis facilitates the larger-scale application of stabi-
lized iron NPs. To enable the use of these NPs in biological
applications, the NP surface was modified to make the NPs
water soluble. The strongly magnetic core/shell NPs are
shown to be more effective T2 contrast agents for in vivo MRI
and small tumor detection, compared to pure iron oxides. The
successful detection of small tumors in vivo demonstrated
here holds a great promise for accurate detection of early
metastases in human lymph nodes, which has a large impact
on the treatment and prognosis of a range of cancers.
The iron/iron oxide core/shell NPs were prepared by first
synthesizing iron nanocrystals by decomposition of the iron
precursor [Fe(C5H5)(C6H7)], in the presence of oleylamine
(OLA) stabilizing molecules. The non-carbonyl, sandwich
compound was chosen for its simple preparation and ease of
decomposition compared to other more stable sandwich
compounds such as ferrocene.[10] The synthesis was carried out
in a closed reaction vessel[11] under a mild hydrogen atmos-
phere, at 130 8C. The temperature required was lower than the
usual temperature range (150–300 8C) needed for decompo-
sition of other iron precursors in previous studies. Once
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synthesized, the iron nanocrystals were exposed to air to
allow oxidation of the surface, forming iron/iron oxide core/
shell NPs.
From an application point of view, the oxide layer can be
exploited for two purposes: 1) to act as a passivation shell that
prevents further oxidation;[7] and 2) to be readily functional-
ized for various biomedical applications using protocols
established for iron oxides.[2b] The stabilizing agent OLA
was exchanged with dimercaptosuccinic acid (DMSA) as a
capping agent to achieve a stable dispersion in water. DMSA
was chosen for its excellent safety profile.[12] Besides, its strong
binding of the oxygen-containing acid groups to the iron
atoms on the NP surface[13] means the OLA is easily replaced.
Upon ligand exchange, the DMSA-coated NPs were readily
dispersible in water, and the core/shell structures were stable
for at least six months (Supporting Information, Figure S1).
Figure 1a shows a transmission electron microscopy
(TEM) image of the spherical, core/shell NPs obtained. The
NPs were relatively monodisperse, with an average size of
(16! 1.5) nm (calculated from 450 NPs). The contrast of the
NPs in the image shows a darker core and a lighter shell that
reveals a core/shell structure. In high-resolution TEM
(HRTEM) images, uniform lattice fringes were observed
across the entire NP core, with spacings corresponding to a-
Fe(110). For the shell, multiple crystalline domains with
lattice spacings matching those of iron oxide were observed
(Figure 1b). The X-ray diffraction (XRD) pattern of the
sample (Figure 1c) shows diffraction peaks of bulk body-
centered cubic iron or a-Fe, and iron oxide of spinel structure,
that is, magnetite (Fe3O4) or maghemite (g-Fe2O3). The latter
is consistent with the native iron oxide film structure
previously reported.[14] Using the Scherrer equation,[15] the
average crystallite size of a-Fe was estimated from the peak
width of Fe(110) and Fe(211), to be (8.9! 0.7) nm. This value
is close to the average iron core size of (9.0! 1.0) nm
measured on TEM images. The much broader peaks of iron
oxide shows a much smaller average crystallite size, and agree
with TEM observation of a 3.2 nm, polycrystalline shell layer
of the NPs.
The magnetic hysteresis loop of the sample measured at
300 K (Figure 1d) shows that the iron/iron oxide core/shell
NPs exhibit a soft ferromagnetic behavior, with a remnant
magnetization of ca. 19 emug"1(Fe), and a coercivity of ca.
370 Oe. The magnetization values were 140 and
150 emug"1(Fe) at low (2 T) and high (6 T) fields, respectively
(1 T= 10 kOe). This magnetization value is in agreement with
other reports of NPs comprising iron core and iron oxide shell
of similar size range.[16] The presence of a single-crystal iron
core in the sample induces a far higher magnetization
compared to iron oxide NPs that typically range from 40–
70 emug"1(Fe).[2]
To compare the properties of the core/shell
NPs, DMSA-coated iron oxide NPs of similar
size, of average diameter (15! 2) nm, were
prepared using standard methods.[17] The effec-
tiveness of the NPs as contrast agents was first
assessed by measuring T2-weightedMR images of
the NPs at 9.4 T. The NPs were dispersed in agar
at different concentrations of iron (in mg-
(iron)mL"1). As shown in Figure 2a, the core/
shell NPs produced much improved negative
contrast compared to the oxide NPs at a range of
iron concentrations, from 0.5 to 10 mg(Fe)mL"1.
In addition, contrast enhancement produced by
the core/shell NPs can be detected down to a
concentration of 0.5 mg(Fe)mL"1, at which the
oxide NPs showed no noticeable difference in the
contrast compared the control.
The transverse relaxivity (r2) of the core/shell
NPs was determined for the samples and com-
pared with that of the oxide NPs. (See Figure S2
for a representative plot of T2 vs. [Fe].) The core/
shell NPs had an r2 of 324 mm"1 s"1, more than
twice that of the oxide NPs, of 145 mm"1 s"1, as
shown in Figure 2b. Contrast improvement rela-
tive to that of iron oxide NPs has been reported
for amorphous, iron-based core/shell NPs of
similar sizes.[18] However, little improvement
was observed for the r2 value indicating the
importance of the single-crystal a-Fe core in our
samples. This increase in r2 indicates a signifi-
cantly improved sensitivity of the MR signal for
iron that will enable applications of much lower
doses and produce far greater detection.
Figure 1. a) TEM image of 16 nm iron/iron oxide core/shell nanoparticles.
b) HRTEM image showing a core of single-crystal a-Fe, with {110} planes observed
across the core area, and a shell consisting of multiple domains of iron oxide, with
{220} planes observed on sections of the shell. c) XRD pattern of the nanoparticles
obtained using synchrotron radiation (l=0.775 "), with diffraction peaks indexed to
a-Fe and iron oxide of the spinel phase (*). d) Magnetization (M) of the core/shell
nanoparticles at 300 K, with inset showing the low-field region.
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To assess the clinical applicability of the NPs in vivo, the
iron/iron oxide core/shell and iron oxide NPs were adminis-
tered to mice and MRI experiments were performed at 1.5 T.
Contrast effects of the NPs were examined at the liver, spleen,
and lymph nodes. Tissues in these organs are rich in
phagocytic cells and have a strong tendency to uptake
circulating iron and iron oxide NPs.[19]
As shown in Figure 3a–c, the core/shell NPs produced
noticeably darker contrast than the oxide NPs for all three
organs (regions indicated by arrows). The contrast effects
were statistically analyzed by comparing the % reduction in
the T2 signal produced by the NPs relative to that observed for
the control mice (Figure 3d). When the core/shell NPs were
used as the contrast agents, typically twice the contrast
improvement was observed over the use of oxide NPs. With
core/shell NPs, 45, 58 and 29% reduction in the T2-weighted
signal were seen in the liver, spleen and lymph nodes,
respectively. The corresponding signal reduction with the use
of oxide NPs were 21, 29 and 17%, respectively. The fact that
contrast is improved for the mouse lymph nodes that have an
average size of 1.5 mm, is particularly significant and indicates
that the core/shell NPs could improve the detection of small
tumors.
To investigate small tumor detection in vivo, mice bearing
breast cancer cells were administered with the core/shell and
oxide NPs and T2-weighted MR images were obtained. In the
MR images of the mouse that received the core/shell NPs,
tumor of 1–3 mm could be unambiguously detected (Fig-
ure S3). In comparison, the contrast enhancement achieved
by the oxide NPs was relatively insignificant and the tumor
could not be visibly distinguished. It has been shown that the
sensitivity for detecting cancerous nodes in vivo decreases to
below 50% when the tumor is smaller than 5 mm.[20] The
improved tumor detection demonstrated here by the core/
shell NPs holds the potential to a more effective detection of
early lymph node metastases, which has a large impact on the
treatment of a range of cancers.
In this study, the doses of contrast agents used are much
lower than the maximum safe limit reported for mice,[21] and
we found no evidence of overt toxicity or failure to thrive in
any mice for up to three months after nanoparticle admin-
istration.
Figure 2. a) T2-weighted MR images at 9.4 T comparing the T2 contrast
(darkening effect) from the iron/iron oxide core/shell nanoparticles
and iron oxide nanoparticles in agar with Fe concentration of 0
(control), 0.5, 1.0, 2.0, 5.0, and 10.0 mg(Fe)mL"1. b) Relaxivity (r2) of
the core/shell and oxide nanoparticles determined from the same
samples.
Figure 3. T2-weighted MR images of a control mouse and mice 24 h
after injection of iron oxide and iron/iron oxide core/shell nanoparti-
cles; arrows indicate the regions of interest, where T2 contrast was
analyzed: a) coronal images with arrows indicating the liver; b) axial
images at the level of spleen; c) coronal images enlarged at the left
inguinal region. d) Bar graph comparing the % reduction of T2 relative
to that of control caused by the presence of oxide and core/shell
nanoparticles in the liver (a), spleen (b), and lymph nodes (c).
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In summary, single-crystal iron NPs were synthesized
through a straightforward solution-phase route, which
involved low temperatures and without the use of highly
toxic chemicals. Natural oxidation of the iron nanocrystals
subsequently yielded highly crystalline iron/iron oxide core/
shell NPs. These NPs are demonstrated to exhibit highly
effectiveMR contrast enhancement in multiple organs, and to
enable unambiguous detection of small tumors of 1–3 mm in
vivo at 1.5 T. The improvements in MR contrast will contrib-
ute to further development and advancement of various
diagnostic and therapeutic medical applications.
Experimental Section
The iron precursor [Fe(C5H5)(C6H7)] was prepared according to a
previously describedmethod.[22] For the synthesis of iron nanocrystals,
the iron precursor (0.4 g), OLA (2 mL, Aldrich, 98%), and mesity-
lene (8 mL, Aldrich, 98%) were added to a closed reaction vessel,
which was then flushed three times with hydrogen gas (H2) before
being filled with 100 kPaH2, and sealed. The bottle was placed into an
oven heated at 130 8C and remained for 2 days. The reaction was
allowed to cool to room temperature naturally before the reaction
vessel was opened to air. Ligand exchange to replace OLA with
DMSA was carried out based on known methods.[23] Each synthesis
typically produced 60 mg Fe, which gave approximately 50% yield.
The TEM images were taken on a JEOL 2010, operated at an
acceleration voltage of 200 keV. Powder XRD measurements were
conducted at the Stanford Synchrotron Radiation Lightsource at
beam line 7–2, using radiation of l= 0.775!. Magnetization meas-
urements were performed on a Quantum Design SQUID magneto-
meter, of model MPMS-XL. MRI of NPs was performed at 9.4 T,
using a Bruker Instruments AVANCE400 NMR spectrometer,
equipped with a Bruker Micro 2.5 imaging module. In vivo MRI of
mice was performed using a clinical 1.5-T MR scanner (Philips
Medical Systems), equipped with a wrist solenoid coil.
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Experimental Section 
Preparation of water dispersible iron/iron oxide core/shell nanoparticles: All reagents were used as 
received without further purification. The iron precursor Fe(C5H5)(C6H7) was prepared according to a 
previously described method.[1] For the synthesis of iron nanocrystals, the iron precursor (0.4 g, ~2 mmol), 
oleylamine (2 mL, ~6 mmol, Aldrich, 98%) and mesitylene (8 mL, Aldrich, 98%) were added to a closed 
reaction vessel (Fischer-Porter bottle), which was then flushed three times with hydrogen gas (H2) before 
being filled with 100 kPa H2, and sealed. The bottle was placed into an oven heated at 130 °C and 
remained for 2 days. The reaction was allowed to cool to room temperature naturally before the reaction 
vessel was opened to air. Ligand exchange to replace oleylamine (OLA) with meso-2,3-
dimercaptosuccinic acid (DMSA) was carried out based on known methods.[2] The as-synthesized 
nanoparticle solution was sonicated briefly and divided into four equal portions. For each aliquot, the 
solution was dried in vacuum overnight to leave a powder, which was then dispersed in 20 mL of 
degassed and deionized (DDI) water. Separately, DMSA (20 mg, Aldrich, 98%) was added to 20 mL of 
DDI water. The pH of both solutions was adjusted to 3.0 with HCl, prior to mixing the solutions. After 
adding the DMSA solution to the nanoparticle solution the pH was again adjusted to 3.0 with HCl under 
vigorous stirring and constant nitrogen bubbling, and remained for 30 minutes. The resulting mixture was 
centrifuged at 3500 rpm for 10 minutes, to give a black precipitate, which was redispersed in 20 mL DI 
water. The supernatant, comprising aqueous and oil (OLA) layers, was discarded. The pH of the product 
dispersion was adjusted with NaOH to 9.25-9.5 under constant stirring and was maintained for 30 
minutes before lowering the pH to 7.4 with HCl. The resulting solution was centrifuged at 3500 rpm for 
10 minutes. The supernatant was discarded, and the nanoparticles were dispersed in water or sterile 
phosphate-buffered saline (PBS), which was sterile filtered. The dispersion in PBS was used as stock 
solution and was stored at 4 °C. The iron content of each stock solution was determined by atomic 
absorption spectrometry. Each synthesis typically produced 60 mg Fe, which gave ~50% yield. 
 
Preparation of iron oxide nanoparticles: The nanoparticles were synthesized following a commonly 
adopted method.[3,4] Briefly, under vigorous stirring, two solutions, (i) FeCl3 (5.406 g, Aldrich, 99%) in 
20 mL deionized (DI) water, and (ii) FeCl2 (1.988 g, Aldrich, 98%) in 5 mL of HCl (2 M), were added to 
100 mL DI water, to which 120 mL of ammonia solution (2 M) was added, and remained under stirring 
for 5 minutes. Black precipitate was purified by centrifugation at 3500 rpm for 20 minutes, and 
redispersed in DI water. The same purification process was repeated 4 additional times and the resulting 
precipitate was redispersed in 35 mL DI water. DMSA coating was applied using the same ligand 
exchange procedure for the core/shell nanoparticles. 
 
Physical measurements: The TEM images and electron diffraction patterns were taken on a JEOL 2010, 
operated at an acceleration voltage of 200 keV. TEM samples were prepared by dipping a carbon-coated 
TEM grid into the nanoparticle dispersion and allowing the solvent to evaporate under ambient conditions. 
Powder XRD measurements were conducted at the Stanford Synchrotron Radiation Lightsource at beam 
line 7-2, using radiation of O  cZLWKDSRLQWGHWHFWRUJHRPHWU\XVLQJPUDG§6ROOHU
slits. Diffractogram was recorded between 2T values of 7° and 47°. The sample was prepared by placing 
the nanoparticle dispersion on a silicon wafer and was allowed to evaporate under ambient conditions. 
Magnetization measurements were carried out on a dried powder, pressed and secured in a cylindrical 
gelatin holder. The measurements were performed at 300 K, on a Quantum Design SQUID magnetometer, 
of model MPMS-XL. 
 
Preparation of nanoparticle dispersion in agar: 2% agar was used. A stock solution was diluted with 
PBS to give concentrations of 1, 2, 3, 4, 10 and 20 Pg mL-1 of Fe in PBS. To 100 PL of each of the 
dilutions, 100 PL of 2% agar was added to give concentrations of 0.5, 1.0, 1.5, 2.0, 5.0 and 10.0 PgFe 
mL-1 in 1% agar. The control was prepared by adding 100 PL of 2% agar to 100 PL PBS.  
MRI of nanoparticles: MRI was performed using a Bruker Instruments AVANCE400 nuclear magnetic 
resonance (NMR) spectrometer, equipped with a Bruker Micro 2.5 imaging module. MR images were 
acquired at 9.4 T using a 2D multi-slice spin-echo sequence, at room temperature, with the following 
parameters: echo time (TE) = 8 ms, repetition time (TR) = 2000 ms, pixel size = 100 Pm x 100 Pm, slice 
thickness = 0.5 mm, number of echoes = 64, 4 averages, total experiment time = 16 min. Measurements 
were repeated on four separate samples for each iron concentration for consistency. 
 
Determination of transverse relaxivity (r2): Paravision software (Bruker) was used for MR image 
reconstruction and analysis. A region of interest was manually selected within the axial image of each 
nanoparticle dispersion in agar. A plot of the signal intensity against the echo time was fitted with an 
exponential function: I(t) = I0 exp(-t/T2); where I(t) = signal intensity at time t, I0 = signal intensity at 0 s, 
and the transverse time T2 was then calculated. The plot of 1/T2(sample) - 1/T2(control) against iron 
concentration ([Fe], in mM) (see Supplementary Figure S3) was fitted with a linear function: 
1/T2(sample) ± 1/T2(control) = r2 x [Fe]; where the relaxivity r2 was determined as the slope of the fit. 
This procedure was repeated four times for the core/shell and the oxide nanoparticle dispersions to 
determine the average and the standard error of the mean (s.e.m.). 
 
In vivo studies: All mice were handled in accordance with the Animal Ethics Policy approved by the 
Animal Ethics Committee of Victoria University of Wellington. Nanoparticles dispersed in PBS (200 PL) 
were administered either intravenously through the tail vein or subcutaneously into the hind limb of 6 
week-old C57BL/6 mice. A control mouse was injected with the same volume of PBS, without the 
presence of nanoparticles. 24 hours after injection the mice were anaesthetized by intraperitoneal (IP) 
injection of a ketamine/xylazine mixture in PBS (100/10 mg/kg) and MRI was performed. For the tumor 
studies, 6 week-old BALB/c mice were anaesthetized by IP injection as described above. 10 and 5 mm 
incisions were made through the skin in the left hypochondrium and the peritoneum, respectively. The 
spleen was exposed and injected with 1 million 4T1 breast cancer cells. The peritoneum and skin were 
closed with sutures and the mice were given buprenorphine (0.1 mg/kg single dose) and carprofen (5 
mg/kg, 2 doses 12 hours apart) subcutaneously for analgesia. 72 hours after the cancer cell implantation 
the mice were anaesthetized by IP injection and MRI was performed. Nanoparticles dispersed in PBS 
were then administered intravenously and MRI was performed 8 hours after injection. Doses of 3 Pmol 
Fe kg-1 were employed for imaging the liver and 120 Pmol Fe kg-1 for the spleen and lymph nodes. 
In vivo MRI was performed using a clinical 1.5-T MR scanner (Philips Medical Systems), equipped with 
a wrist solenoid coil. The mice were positioned in the centre of the wrist coil and the same protocols were 
used for all images. T2-weighted spin-echo images were acquired with the following parameters: TE = 54 
ms, TR = 2000 ms, pixel size = 300 Pm x 300 Pm, thickness = 1 mm, number of echoes = 8, 3 averages, 
total experiment time = 4 min. 24 s. Images were analyzed with ImageJ (National Institutes of Health) by 
manually selecting regions of interest (ROIs) corresponding to the liver, spleen or inguinal lymph nodes 
and integrating the signal intensity of each ROI. 
Supplementary F igures 
 
 
F igure S1. a) Photo shows dispersion of nanoparticles in hexane and in water, before and after ligand 
exchange, respectively. TEM images of iron/iron oxide core/shell nanoparticles dispersed in a) hexane 








F igure S3. T2-weighted MR images of a mouse implanted with 4T1 breast cancer cells a,c) pre-injection 
and b,d) 8 hours post-injection of iron/iron oxide core/shell nanoparticles. (a) and (b) are the coronal 
images, whereas (c) and (d) show the axial images at the level of spleen. e,f) Enlargements at the spleen 
region, as boxed in (b) and (d), respectively. After injection of the core/shell nanoparticles, dark contrast 
is observed at the spleen region and the tumors appear relatively bright and can be readily identified 
(arrows). 
The mice were sacrificed after post-injection imaging and the spleens were examined. 1-3 mm tumors 
were present in all mice, although only the tumors in the mice that had received the core/shell 
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